{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "77b759ab",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/speech/nency/miniconda3/envs/BERTTopic/lib/python3.8/site-packages/tqdm/auto.py:22: TqdmWarning: IProgress not found. Please update jupyter and ipywidgets. See https://ipywidgets.readthedocs.io/en/stable/user_install.html\n",
      "  from .autonotebook import tqdm as notebook_tqdm\n",
      "2023-09-01 15:45:13.814138: W tensorflow/compiler/xla/stream_executor/platform/default/dso_loader.cc:64] Could not load dynamic library 'libnvinfer.so.7'; dlerror: libnvinfer.so.7: cannot open shared object file: No such file or directory\n",
      "2023-09-01 15:45:13.814310: W tensorflow/compiler/xla/stream_executor/platform/default/dso_loader.cc:64] Could not load dynamic library 'libnvinfer_plugin.so.7'; dlerror: libnvinfer_plugin.so.7: cannot open shared object file: No such file or directory\n",
      "2023-09-01 15:45:13.814331: W tensorflow/compiler/tf2tensorrt/utils/py_utils.cc:38] TF-TRT Warning: Cannot dlopen some TensorRT libraries. If you would like to use Nvidia GPU with TensorRT, please make sure the missing libraries mentioned above are installed properly.\n"
     ]
    }
   ],
   "source": [
    "import nlpaug.augmenter.char as nac\n",
    "import nlpaug.augmenter.word as naw\n",
    "import nlpaug.augmenter.sentence as nas\n",
    "import re"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "id": "1c5cc5fc",
   "metadata": {},
   "outputs": [],
   "source": [
    "#This cell contains code to augment data using NLP augmentation libraries\n",
    "\n",
    "def augment_title(line):\n",
    "    augmented_title = []\n",
    "    splitted_text = line.split(\"|\")\n",
    "    pmid = splitted_text[0]\n",
    "    aug = naw.SynonymAug()\n",
    "    aug_title = aug.augment(splitted_text[2], n=1)\n",
    "    new_title = pmid + \"|t|\" + aug_title[0]\n",
    "    augmented_title.append(new_title)\n",
    "    \n",
    "#     aug = naw.SpellingAug()\n",
    "#     aug_title = aug.augment(splitted_text[2], n=1)\n",
    "#     new_title = pmid + \"|t|\" + aug_title[0]\n",
    "#     augmented_title.append(new_title)\n",
    "\n",
    "    aug = naw.ContextualWordEmbsAug()\n",
    "    aug_title = aug.augment(splitted_text[2], n=1)\n",
    "    new_title = pmid + \"|t|\" + aug_title[0]\n",
    "    augmented_title.append(new_title)\n",
    "    return augmented_title\n",
    "\n",
    "def augment_abstract(line):\n",
    "    augmented_abstract = []\n",
    "    splitted_text = line.split(\"|\")\n",
    "    pmid = splitted_text[0]\n",
    "    aug = naw.SynonymAug()\n",
    "    aug_abstract = aug.augment(splitted_text[2], n=1)\n",
    "    new_abstract = pmid + \"|a|\" + aug_abstract[0]\n",
    "    augmented_abstract.append(new_abstract)\n",
    "    \n",
    "#     aug = naw.SpellingAug()\n",
    "#     aug_abstract = aug.augment(splitted_text[2], n=1)\n",
    "#     new_abstract = pmid + \"|a|\" + aug_abstract[0]\n",
    "#     augmented_abstract.append(new_abstract)\n",
    "\n",
    "    aug = naw.ContextualWordEmbsAug()\n",
    "    aug_abstract = aug.augment(splitted_text[2], n=1)\n",
    "    new_abstract = pmid + \"|a|\" + aug_abstract[0]\n",
    "    augmented_abstract.append(new_abstract)\n",
    "    return augmented_abstract\n",
    "    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "id": "23ace692",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "32172939|t|CFTR gene variants, epidemiology and molecular pathology.\n",
      "\n",
      "30245141|t|The genetic landscape of Parkinson's disease.\n",
      "\n",
      "15082523|t|Androgen receptor in prostate cancer.\n",
      "\n",
      "28966576|t|Modifications and Trafficking of APP in the Pathogenesis of Alzheimer's Disease.\n",
      "\n",
      "29173173|t|AR Copy Number and AR Signaling-directed Therapies in Castrationresistant Prostate Cancer.\n",
      "\n",
      "28920889|t|Therapies targeting DNA and RNA in Huntington's disease.\n",
      "\n",
      "34098113|t|Gene targeting techniques for Huntington's disease.\n",
      "\n",
      "34934215|t|Cystic fibrosis: current concepts.\n",
      "\n",
      "24631642|t|Genetics of cystic fibrosis: CFTR mutation classifications toward genotype-based CF therapies.\n",
      "\n",
      "30798813|t|Hemochromatosis: Hereditary hemochromatosis and HFE gene.\n",
      "\n",
      "34090606|t|Cystic fibrosis.\n",
      "\n",
      "31904117|t|SCN1A-related phenotypes: Epilepsy and beyond.\n",
      "\n",
      "31407125|t|Serum amyloid A1 is involved in amyloid plaque aggregation and memory decline in amyloid beta abundant condition.\n",
      "\n",
      "33132897|t|Interleukin-17A: The Key Cytokine in Neurodegenerative Diseases.\n",
      "\n",
      "35935951|t|Th17 cells and inflammation in neurological disorders: Possible mechanisms of action.\n",
      "\n",
      "30081688|t|IL-17A and IL-23: plausible risk factors to induce age-associated inflammation in Alzheimer's disease.\n",
      "\n",
      "26684655|t|Novel Therapeutic Targets and Drug Candidates for Modifying Disease Progression in Adrenoleukodystrophy.\n",
      "\n",
      "22353463|t|Oxidative stress underlying axonal degeneration in adrenoleukodystrophy: a paradigm for multifactorial neurodegenerative diseases?\n",
      "\n",
      "18854420|t|A key role for the peroxisomal ABCD2 transporter in fatty acid homeostasis.\n",
      "\n",
      "29441009|t|Autophagy and Alzheimer's Disease: From Molecular Mechanisms to Therapeutic Implications.\n",
      "\n",
      "24777780|t|The genetic contributions of SNCA and LRRK2 genes to Lewy Body pathology in Alzheimer's disease.\n",
      "\n",
      "15717024|t|Genetics of Parkinson disease.\n",
      "\n",
      "23727323|t|SOD2 in mitochondrial dysfunction and neurodegeneration.\n",
      "\n",
      "17713121|t|[Pathology of familial Parkinson's disease].\n",
      "\n",
      "23814539|t|Genetics and Pathophysiology of Neurodegeneration with Brain Iron Accumulation (NBIA).\n",
      "\n",
      "30245141|t|The genetic landscape of Parkinson's disease.\n",
      "\n",
      "33229544|t|ATP13A2-mediated endo-lysosomal polyamine export counters mitochondrial oxidative stress.\n",
      "\n",
      "28894968|t|Lysosomal defects in ATP13A2 and GBA associated familial Parkinson's disease.\n",
      "\n",
      "19019493|t|Differential cerebral deposition of IDE and NEP in sporadic and familial Alzheimer's disease.\n",
      "\n",
      "29547664|t|Overlapping expression patterns and functions of three paralogous P5B ATPases in Caenorhabditis elegans.\n",
      "\n",
      "27486710|t|Genetics of Parkinson's disease: a review of SNCA and LRRK2.\n",
      "\n",
      "31773362|t|CRISPR System: A High-throughput Toolbox for Research and Treatment of Parkinson's Disease.\n",
      "\n",
      "34626793|t|Molecular chaperones and Parkinson's disease.\n",
      "\n",
      "36039535|t|DJ-1 is an essential downstream mediator in PINK1/parkin-dependent mitophagy.\n",
      "\n",
      "35063084|t|Tau interactome maps synaptic and mitochondrial processes associated with neurodegeneration.\n",
      "\n",
      "34612485|t|Managing risky assets - mitophagy in vivo.\n",
      "\n",
      "36282767|t|PINK1-PRKN mediated mitophagy: differences between in vitro and in vivo models.\n",
      "\n",
      "18322368|t|Etiology and pathophysiology of frontotemporal dementia, Parkinson disease and Alzheimer disease: lessons from genetic studies.\n",
      "\n",
      "31218162|t|Microglia express GPNMB in the brains of Alzheimer's disease and Nasu-Hakola disease.\n",
      "\n",
      "36362324|t|Neurodegenerative Disorder Risk in Krabbe Disease Carriers.\n",
      "\n",
      "34857772|t|Mapping the serum proteome to neurological diseases using whole genome sequencing.\n",
      "\n",
      "28738127|t|Early-Onset Alzheimer Disease and Candidate Risk Genes Involved in Endolysosomal Transport.\n",
      "\n",
      "36759259|t|Prioritization of Drug Targets for Neurodegenerative Diseases by Integrating Genetic and Proteomic Data From Brain and Blood.\n",
      "\n",
      "12464229|t|Turner syndrome in childhood and adolescence.\n",
      "\n",
      "32688058|t|Two novel intragenic variants in the FMR1 gene in patients with suspect clinical diagnosis of Fragile X syndrome and no CGG repeat expansion.\n",
      "\n",
      "23666967|t|Prepubertal girls with Turner syndrome and children with isolated SHOX deficiency have similar bone geometry at the radius.\n",
      "\n",
      "26191517|t|Turner syndrome presented with tall stature due to overdosage of the SHOX gene.\n",
      "\n",
      "20542038|t|Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment.\n",
      "\n",
      "25064704|t|Diagnostic evaluation of hereditary hemochromatosis (HFE and non-HFE).\n",
      "\n",
      "30374284|t|Fighting the Cause of Alzheimer's and GNE Myopathy.\n",
      "\n",
      "34369389|t|Antisense oligonucleotide treatment rescues UBE3A expression and multiple phenotypes of an Angelman syndrome mouse model.\n",
      "\n",
      "32654068|t|The RNA-binding fragile-X mental retardation protein and its role beyond the brain.\n",
      "\n",
      "27345143|t|Hippocampal dysfunction and cognitive impairment in Fragile-X Syndrome.\n",
      "\n",
      "17166801|t|Fragile-X syndrome and fragile X-associated tremor/ataxia syndrome: two faces of FMR1.\n",
      "\n",
      "27037841|t|Aberrant O-GlcNAcylation disrupts GNE enzyme activity in GNE myopathy.\n",
      "\n",
      "30283027|t|The intellectual disability gene PQBP1 rescues Alzheimer's disease pathology.\n"
     ]
    }
   ],
   "source": [
    "# this code is collecting augmented title, augmented abstracts and all annotations in pmid_mesh nested dictionary. \n",
    "# pmid_mesh structure is {pmid:{mes_id}}\n",
    "# mesh_id structure is {entity_name:[entity_name, meahid]}\n",
    "\n",
    "#causal_abstracts_with_ner is created in bertgt_results_analysis\n",
    "\n",
    "import re\n",
    "with open(\"latest_cau_train_file.txt\", \"r\", encoding=\"utf-8\") as file:\n",
    "    augmented_titles = []\n",
    "    augmented_abstracts = []\n",
    "    pmids = []\n",
    "    mesh_id={}\n",
    "    pmid_mesh = {}\n",
    "    pmid = 0\n",
    "    causal_relations = []\n",
    "    for line in file:\n",
    "        line = line.rstrip()\n",
    "        p_title = re.compile('^([0-9]+)\\|t\\|(.*)$')\n",
    "        p_abstract = re.compile('^([0-9]+)\\|a\\|(.*)$')\n",
    "        p_annotation = re.compile('^([0-9]+)\t([0-9]+)\t([0-9]+)\t([^\\t]+)\t([^\\t]+)(.*)')\n",
    "        if p_title.search(line):\n",
    "            print(line)\n",
    "            pmid_mesh[pmid] = mesh_id \n",
    "            mesh_id = {}\n",
    "            augmented_titles.append(augment_title(line))\n",
    "            m = p_title.match(line)\n",
    "            pmid = m.group(1)\n",
    "            \n",
    "        elif p_abstract.search(line):\n",
    "            m = p_abstract.match(line)\n",
    "            pmid = m.group(1)\n",
    "            augmented_abstracts.append(augment_abstract(line))\n",
    "\n",
    "        elif p_annotation.search(line):  # annotation\n",
    "            m = p_annotation.match(line)\n",
    "            pmid = m.group(1)\n",
    "            start = m.group(2)\n",
    "            last = m.group(3)\n",
    "            mention = m.group(4)\n",
    "            type = m.group(5)\n",
    "            id = m.group(6)\n",
    "            mesh_id[mention]=[type,id]\n",
    "        elif \"GCD\" in line:\n",
    "            causal_relations.append(line)\n",
    "        else:\n",
    "            print(line)\n",
    "        pmids.append(pmid)\n",
    "    pmid_mesh[pmid] = mesh_id "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "id": "88d37a8d",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "cftr gene variants, epidemiology and molecular pathology. pathogenic variants of the cftr gene are responsible for a across the board phenotypic spectrum characterized by malfunction of some exocrine tissues, with an autosomal recessive mode of inheritance. more than 2, 000 variants, distributed throughout the cftr gene, have been identified, with different effects on the gene and protein expression and function. genotype - phenotype coefficient of correlation studies have associated severe var. with a typical multi - organ form of cystic fibrosis, while mild variants are involved in monosymptomatic or grownup - onset diseases, called cftr - related disorders. however, the interpretation of rare variants remains challenging. this review presents an overview of the epidemiology of cftr variants worldwide and in france and describes the functional classification. finally, some frequent cystic fibrosis - causing and mild cftr variants are used as example to depict the molecular pathology of the cftr locus. finally, we give the recommendations concerning nomenclature and classification that are useful for appropriate genetic counseling. 2020 french society of pediatrics. published by elsevier masson sas. all rights reserved.\n",
      "cftr [0, 85, 312, 643, 791, 932, 1007]\n",
      "cystic fibrosis [538, 897]\n",
      "cftr genetic variants, genetics and disease evolution. pathogenic variants of the cftr locus are stable for a broad phenotypic spectrum characterized by malfunction of some exocrine tissues, with an autosomal recessive mode of inheritance. more than 2, 000 variants, distributed throughout the cftr gene, have been identified, with different effects on the gene and protein organization and function. genotype - phenotype correlation studies have associated severe variants with a typical multi - organ form termed cystic fibrosis, while mild variants are involved in monosymptomatic or adult - onset diseases, often cftr - related disorders. however, the interpretation involving rare variants remains evolving. this review presents an overview of the epidemiology of cftr variants worldwide and in france and describes the functional classification. finally, some frequent cystic fibrosis - causing and unknown cftr variants are studied as example to depict the molecular pathology of the cftr locus. finally, we have the recommendations concerning nomenclature and classification that are useful for appropriate genetic counseling. 2020 french society of pediatrics. published by elsevier masson sas. all rights reserved.\n",
      "cftr [0, 82, 294, 617, 769, 913, 991]\n",
      "cystic fibrosis [515, 875]\n",
      "the genetic landscape of james parkinson ' s disease. the cause of parkinson ' s disease (pd) remains unknown in most patients. since 1997, with the first genetic mutation known to cause pd described in snca gene, many other genes with mendelian inheritance have been discover. we summarize genetic, clinical and neuropathological findings relate to the 27 genes reported in the literature since 1997, associated either with autosomal dominant (ad ): lrrk2, snca, vps35, gch1, atxn2, dnajc13, tmem230, gigyf2, htra2, ric3, eif4g1, uchl1, chchd2, and gba; or autosomal recessive (ar) inheritance: prkn, pink1, dj1, atp13a2, pla2g6, fbxo7, dnajc6, synj1, spg11, vps13c, podxl, and ptrhd1; or an x - linked transmission: rab39b. clinical and neuropathological variability among genes is great. lrrk2 mutation carriers present a phenotype similar to those with idiopathic pd whereas, depending on the snca mutations, the phenotype ranges from early onset typical pd to dementia with lewy bodies, let in many other atypical forms. dnajc6 nonsense mutations lead to a very severe phenotype whereas dnajc6 missense mutations cause a more typical form. prkn, pink1 and dj1 cases present with typical early onset pd with slow progression, whereas other are genes present severe atypical parkinsonism. rab39b is responsible for a typical phenotype in women and a variable phenotype in men. gba is a major pd risk factor often associated with dementia. a growing number of reported genes described as causal genes (dnajc13, tmem230, gigyf2, htra2, ric3, eif4g1, uchl1, and chchd2) are still awaiting replication or indeed have not been retroflex, thus raising questions as to their pathogenicity. phenotypic data collection and next generation sequencing of large numbers of cases and controls are needed to differentiate pathogenic dominant mutations with incomplete penetrance from rare, non - pathogenic variants. although known genes cause a minority of pd cases, their identification will lead to a better understanding their pathological mechanisms, and may contribute to patient care, genetic counselling, prognosis determination and finding new therapeutic targets.\n",
      "parkinson's disease []\n",
      "pd [90, 187, 868, 959, 1204, 1395, 1947]\n",
      "snca [203, 458, 897]\n",
      "lrrk2 [451, 791]\n",
      "vps35 [464]\n",
      "gch1 [471]\n",
      "atxn2 [477]\n",
      "dnajc13 [484, 1504]\n",
      "tmem230 [493, 1513]\n",
      "gigyf2 [502, 1522]\n",
      "htra2 [510, 1530]\n",
      "ric3 [517, 1537]\n",
      "eif4g1 [523, 1543]\n",
      "uchl1 [531, 1551]\n",
      "chchd2 [538, 1562]\n",
      "gba [550, 1380]\n",
      "prkn [596, 1145]\n",
      "pink1 [602, 1151]\n",
      "dj1 [609, 1161]\n",
      "atp13a2 [614]\n",
      "pla2g6 [623]\n",
      "fbxo7 [631]\n",
      "dnajc6 [638, 1026, 1092]\n",
      "synj1 [646]\n",
      "spg11 [653]\n",
      "vps13c [660]\n",
      "podxl [668]\n",
      "ptrhd1 [679]\n",
      "rab39b [718, 1292]\n",
      "dementia [965, 1432]\n",
      "parkinsonism [1278]\n",
      "several neural foundations of parkinson's disease. the cause of parkinson's disease ( pd ) remains unknown in most patients. since 1997, with the first human mutation known to cause pd occur in snca gene, many other genes with mendelian inheritance have been identified. we summarize genetic, clinical and neuropathological findings related to the 27 genes reported in the literature since 1997, associated either with autosomal dominant ( ad ) : lrrk2, snca, vps35, gch1, atxn2, dnajc13, tmem230, gigyf2, htra2, ric3, eif4g1, uchl1, chchd2, and gba ; or autosomal recessive ( ar ) inheritance : prkn, pink1, dj1, atp13a2, pla2g6, fbxo7, dnajc6, synj1, spg11, vps13c, podxl, and ptrhd1 ; or an x - fi transmission : rab39b. clinical and neuropathological variability among genes is great. lrrk2 mutation carriers present a phenotype similar to people with idiopathic pd where, depending on the snca mutations, the phenotype ranges from early onset typical pd to dementia with lewy bodies, including many other atypical forms. dnajc6 mutant mutations lead to a very severe depression whereas dnajc6 missense mutations cause a more typical form. prkn, pink1 and dj1 cases present with typical early onset pd with slow progression, whereas other ar genes present severe atypical parkinsonism. rab39b is responsible for a typical phenotype in women and a variable phenotype in men. gba is a major pd risk factor often associated with dementia. a growing number of reported genes described as causal genes ( dnajc13, tmem230, gigyf2, htra2, eta, eif4g1, uchl1, and chchd2 ) are still awaiting replication or indeed have not been replicated, thus raising questions as to their pathogenicity. phenotypic data collection and next generation sequencing of large numbers of cases with controls are needed to differentiate from dominant mutations with incomplete penetrance from rare, non - pathogenic variants. although known genes cause a minority of pd cases, their identification will lead to a better understanding their pathological mechanisms, and may contribute to patient care, genetic counselling, prognosis determination and finding new therapeutic targets.\n",
      "parkinson's disease [30, 64]\n",
      "pd [86, 182, 867, 956, 1203, 1393, 1942]\n",
      "snca [194, 454, 894]\n",
      "lrrk2 [447, 789]\n",
      "vps35 [460]\n",
      "gch1 [467]\n",
      "atxn2 [473]\n",
      "dnajc13 [480, 1503]\n",
      "tmem230 [489, 1512]\n",
      "gigyf2 [498, 1521]\n",
      "htra2 [506, 1529]\n",
      "ric3 [513]\n",
      "eif4g1 [519, 1541]\n",
      "uchl1 [527, 1549]\n",
      "chchd2 [534, 1560]\n",
      "gba [546, 1378]\n",
      "prkn [596, 1144]\n",
      "pink1 [602, 1150]\n",
      "dj1 [609, 1160]\n",
      "atp13a2 [614]\n",
      "pla2g6 [623]\n",
      "fbxo7 [631]\n",
      "dnajc6 [638, 1026, 1091]\n",
      "synj1 [646]\n",
      "spg11 [653]\n",
      "vps13c [660]\n",
      "podxl [668]\n",
      "ptrhd1 [679]\n",
      "rab39b [716, 1290]\n",
      "dementia [962, 1430]\n",
      "parkinsonism [1276]\n",
      "androgen receptor in prostate gland crab. the normal development and maintenance of the prostate is dependent on androgenic hormone acting through the androgenic hormone sensory receptor (ar ). ar remains important in the development and progression of prostate cancer. ar expression is maintained throughout prostate cancer progression, and the majority of androgen - independent or hormone refractory prostate cancers express ar. sport of ar, specially mutations that result in a relaxation of ar ligand specificity, may contribute to the progression of prostate cancer and the failure of endocrine therapy by allowing ar transcriptional activation in response to antiandrogens or early endogenous hormones. similarly, alterations in the relative expression of ar coregulators have been found to occur with prostate cancer progression and english hawthorn contribute to differences in ar ligand specificity or transcriptional activity. prostate cancer progression is also associated with increased growth factor production and an altered reply to growth factors by prostate cancer cells. the kinase signal transduction cascades initiated by mitogenic growth factors modulate the transcriptional activity of ar and the interaction between ar and ar coactivators. the inhibition of ar activity through mechanisms in addition to androgen ablation, such as modulation of signal transduction pathways, may delay prostate cancer progression.\n",
      "androgen receptor [0]\n",
      "prostate cancer [253, 309, 403, 556, 809, 938, 1067, 1409]\n",
      "androgen receptor [0]\n",
      "ar [188, 194, 270, 428, 441, 496, 621, 684, 715, 763, 887, 1209, 1240, 1247, 1282]\n",
      "refractory prostate cancers [392]\n",
      "prostate cancer [253, 309, 403, 556, 809, 938, 1067, 1409]\n",
      "delay prostate cancer [1403]\n",
      "prostate receptor during prostate development. the normal development and maintenance of the prostate is dependent on androgen acting through the androgen receptor ( ar ). ar remains constant in the development and progression of prostate cancer. ar expression is maintained through prostate cancer progression, and the majority of androgen - independent or hormone sensitive prostate cancers express ar. mutation of ar, especially mutations that result in partial relaxation of ar ligand specificity, may contribute to the progression of prostate cancer by the failure of endocrine therapy further allowing ar transcriptional activation and response to antiandrogens or other endogenous hormones. similarly, alterations in the relative expression of ar coregulators have been found to occur with prostate orchid progression and may contribute to differences in ar ligand specificity or transcriptional activity. prostate cancer progression is also associated with increased growth factor production and an altered response to growth factors by prostate cancer cells. the kinase signal transduction cascades initiated by mitogenic growth factors modulate the transcriptional activity of ar through the interaction between ar and ar coactivators. the inhibition of ser activity through mechanisms in addition to androgen ablation, such as modulation of signal transduction pathways, may delay prostate cancer progression.\n",
      "androgen receptor [146]\n",
      "prostate cancer [230, 283, 376, 539, 913, 1045, 1392]\n",
      "androgen receptor [146]\n",
      "ar [166, 172, 247, 401, 417, 458, 479, 608, 703, 751, 862, 1187, 1222, 1229]\n",
      "refractory prostate cancers []\n",
      "prostate cancer [230, 283, 376, 539, 913, 1045, 1392]\n",
      "delay prostate cancer [1386]\n",
      "modification and trafficking of app in the pathogenesis of alzheimer ' s disease. alzheimer ' s disease (ad ), the most common neurodegenerative disorder, is the leading cause of dementedness. neuritic plaque, one of the major characteristics of ad neuropathology, mainly consists of amyloid beta (abeta) protein. abeta is derived from amyloid precursor protein (app) by sequential cleavages of beta - and gamma - secretase. although app upregulation can promote advertizement pathogenesis by facilitating abeta production, maturate evidence indicates that aberrant post - translational modification and trafficking of app play a pivotal purpose in ad pathogenesis by dysregulating app processing and abeta generation. in this study, we reviewed the current knowledge of app modifications and trafficking as easily as their role in app processing. more importantly, we discussed the effect of aberrant app modifications and trafficking on abeta generation and the underlying chemical mechanism, which may provide novel strategies for drug development in ad.\n",
      "alzheimer's disease []\n",
      "alzheimer's disease []\n",
      "ad [105, 164, 246, 463, 649, 1054]\n",
      "neurodegenerative disorder [127]\n",
      "dementia []\n",
      "abeta [298, 314, 506, 701, 939]\n",
      "amyloid precursor protein [336]\n",
      "storage and trafficking of molecules in the environment in alzheimer'e disease. alzheimer's disease ( ad ), the most common neurodegenerative disorder, is the leading cause of dementia. neuritic plaque, one of the major characteristics of ad neuropathology, mainly consists the amyloid beta ( abeta ) protein. abeta is derived from amyloid type i ( app ) by sequential cleavages of beta - and gamma - secretase. although app upregulation can promote ad pathogenesis by stimulating abeta production, growing evidence indicates that aberrant post - mature modifications and trafficking of app play a pivotal role in ad pathogenesis by dysregulating app processing and abeta formation. in this regard, we reviewed the current knowledge of app modifications and simulation as well of their role in app processing. more importantly, we discussed the effect of aberrant app modifications and trafficking on abeta generation and suggested underlying mechanisms, which may provide novel strategies for drug development in ad.\n",
      "alzheimer's disease [80]\n",
      "alzheimer's disease [80]\n",
      "ad [102, 161, 239, 450, 614, 1014]\n",
      "neurodegenerative disorder [124]\n",
      "dementia [176]\n",
      "abeta [293, 310, 481, 666, 901]\n",
      "amyloid precursor protein []\n",
      "land of opportunity transcript number and ar signaling - directed therapies in castrationresistant prostate cancer. background: adaptive upregulation of androgen receptor (ar) is the most common event involved in the progression from hormone sensitive to castration - resistant prostate gland cancer (crpc ). ar signaling remains the main target of new ar signalling - directed therapies such as abiraterone and enzalutamide in crpc patients. objective: in this review, we discuss general mechanisms of resistance to ar - targeted therapies, with a focus on the role of ar copy number (cn ). we reported methods and clinical applications of ar cn evaluation in tissue and liquid biopsy, thus to have a complete information regarding its role as predictive and prognostic biomarker. determination: outcomes of crpc patients are reported to be highly variable as the consequence of tumor heterogeneity. ar cn could contribute to patient selection and neoplasm monitoring in crpc treated with novel anti - cancer treatment as abiraterone and enzalutamide. further studies to look into ar cn effect to these agents and its potential combination with other prognostic or predictive clinical factors are necessary in the context of harmonized clinical trial design.\n",
      "prostate cancer [99]\n",
      "androgen receptor [153]\n",
      "-resistant prostate cancer []\n",
      "tumor [880]\n",
      "cancer [108, 293, 1003]\n",
      "ar copy number suggests several protein - directed therapies for advanced breast cancer. background : adaptive upregulation of androgen receptor ( ar ) is the relatively common event involved in the progression from hormone sensitive to castration - resistant prostate cancer ( crpc ). ar signaling remains the main target of new ar signalling - directed therapies such as abiraterone and enzalutamide in crpc patients. objective : after this review, we discuss general mechanisms of resistance to ar - targeted therapies, with a discussion on the role of ar copy number ( cn ). we reported methods and clinical applications of ar cn evaluation in tissue and liquid biopsy, thus i have a complete information regarding its role as predictive and prognostic biomarker. conclusion : outcomes across crpc patients are reported to be highly variable as the consequence of tumor therapy. ar cn could contribute to patient selection and tumor monitoring in patients treated with new anti - ar treatment as abiraterone and enzalutamide. further studies to investigate what cn effect to these agents and its potential combination with other prognostic yet predictive clinical factors are necessary in the context of harmonized clinical trial design.\n",
      "prostate cancer [260]\n",
      "androgen receptor [127]\n",
      "-resistant prostate cancer []\n",
      "tumor [868, 931]\n",
      "cancer [81, 269]\n",
      "therapy targeting dna and ribonucleic acid in huntington ' s disease. no disease - slowing treatment exists for samuel huntington ' s disease, merely its monogenic inheritance establish it an appealing candidate for the development of therapies targeting processes close to its genetic cause. huntington ' s disease be caused by cag repeat expansions in the htt gene, which encodes the huntingtin protein; development of therapies to target htt transcription and the translation of its mrna is therefore an area of intense investigation. huntingtin - lowering strategies include antisense oligonucleotides and rna interference targeting mrna, and zinc finger transcriptional repressors and crispr - cas9 methods aiming to reduce transcription by targeting dna. an intrathecally delivered antisense oligonucleotide that aims to lower huntingtin is now well into its first human clinical trial, with other antisense oligonucleotides expected to enter trials in the next 1 - 2 years and virally delivered rna interference and zinc finger transcriptional repressors in advanced testing in fleshly modelling. recent advances in the design and delivery of therapies to target htt rna and dna are expected to improve their efficacy, safety, tolerability, and duration of event in future studies.\n",
      "huntington's disease []\n",
      "htt [358, 441, 1170]\n",
      "huntingtin [386, 538, 833]\n",
      "huntingtin [386, 538, 833]\n",
      "therapies target structure and rna repair huntington'h disease. no disease - slowing treatment exists for huntington's disease, but its monogenic inheritance makes it an appealing candidate for the development of therapies targeting processes close to its genetic cause. huntington's disease is caused by cag repeat expansions in the htt gene, which encodes the huntingtin motif ; development of therapies to target htt genes and the translation of its mrna is therefore an area of intense investigation. huntingtin - lowering attempts include antisense oligonucleotides and rna interference targeting mrna, and zinc finger transcriptional repressors and crispr - cas9 methods aiming to reduce transcription by targeting dna. an intrathecally delivered antisense oligonucleotide that aims to lower huntingtin is now well into its first human clinical trial, with other antisense oligonucleotides planning to attend trials in the next 1 - three years and virally delivered rna interference and zinc wrist transcriptional repressors through vitro testing in animal models. recent progress in the design and delivery of therapies to target htt rna and dna are expected to improve their efficacy, safety, tolerability, and duration of effect in future studies.\n",
      "huntington's disease [106, 271]\n",
      "htt [334, 416, 1137]\n",
      "huntingtin [362, 505, 798]\n",
      "huntingtin [362, 505, 798]\n",
      "gene aim techniques for collis potter huntington ' s disease. huntington ' s disease (hd) is an autosomal neurodegenerative disorder caused by extended trinucleotide cag repetition in the htt gene. wild - type huntingtin protein (htt) constitute essential, involved in a variety of crucial cellular functions such as vesicle transportation, cell division, transcription regulation, autophagy, and tissue maintenance. the mutant htt (mhtt) proteins in the body interfere with htt ' s normal cellular functions and cause additional detrimental effects. in this review, we discuss multiple approaches targeting dna and rna to reduce mhtt expression. these approaches are categorise into non - allele - specific silencing and allele - specific - silencing using single nucleotide polymorphisms (snps) and haplogroup analysis. additionally, this review discusses a potential application of recent crispr prime editing technology in targeting hd.\n",
      "huntington's disease []\n",
      "hd [86, 937]\n",
      "autosomal neurodegenerative disorder [96]\n",
      "htt [188, 230, 428, 434, 475, 631]\n",
      "huntingtin [210]\n",
      "mhtt [433, 630]\n",
      "gene targeting programs for maxwell's clock. huntington's disease ( hd ) is the autosomal neurodegenerative disorder caused by extended trinucleotide cag repetition in the htt gene. g - type huntingtin a ( htt ) is essential, involved in wide variety of crucial cellular functions essential as vesicle growth, cell division, transcription regulation, autophagy, and memory maintenance. the mutant htt ( mhtt ) proteins in the body interfere with htt's normal cellular functions and cause additional detrimental effects. in this review, we discuss multiple approaches targeting dna and rna to reduce mhtt expression. these approaches are categorized into non - allele - specific silencing and allele - specific - identification using single nucleotide polymorphisms ( snps ) and haplogroup analysis. additionally, this review discusses a potential application by recent crispr genome editing technology in targeting hd.\n",
      "huntington's disease [45]\n",
      "hd [68, 915]\n",
      "autosomal neurodegenerative disorder [80]\n",
      "htt [172, 206, 397, 404, 446, 600]\n",
      "huntingtin [191]\n",
      "mhtt [403, 599]\n",
      "cystic fibrosis: current concepts. cystic fibrosis is an autosomal recessive genetic disease, mainly in caucasian children and young adults. it is caused by pathogenic variants in the cftr (cystic fibrosis transmembrane conductance regulator) gene, which results in increased viscosity and difficult mucus clearance. the main organ affected is the lung, the pancreas, sweat glands, intestine, liver, nasal mucosa, salivary glands, and generative tract. the clinical manifestations vary, ranging from the most frequent pulmonary symptoms of obstructive disease to gastrointestinal manifestations relatection of pathogenic variants in the cftr gene leave the diagnosis to be integrated. cystic fibrosis management consists of three main strategies: firstly, to keep the airway free of secretion; secondly, to keep the airway free of infection; and finally, to maintain an optimal nutritional status. therapies that seek to redress alterations in the cystic fibrosis transport regulator gene are focused on avoiding a pathogenic nonsense variant, correcting folding, increasing trafficking to the plasma tissue layer, or increasing the function of the cftr channel. other therapies still under development include cistron therapy, genome editing, and antisense oligonucleotides to modify the expression of this gene.\n",
      "cystic fibrosis [0, 35, 190, 685, 948]\n",
      "autosomal recessive genetic disease [57]\n",
      "cftr [184, 637, 1149]\n",
      "cystic fibrosis transmembrane conductance regulator [190]\n",
      "pulmonary symptoms of obstructive disease [518]\n",
      "infection [831]\n",
      "cystic people : the work. cystic fibrosis is an autosomal recessive genetic disease, mainly in caucasian children and young adults. it is caused by pathogenic variants in the cftr ( cystic fibrosis with conductance regulator ) gene, which results in increased mobility and difficult mucus clearance. other main organ affected is the lung, the pancreas, sweat glands, intestine, liver, nasal mucosa, salivary glands, upper reproductive tract. the clinical manifestations vary, ranging from acute most frequent pulmonary symptoms of obstructive disease to gastrointestinal manifestations relatection of pathogenic variants into the cftr gene allow the diagnosis to be integrated. cystic fibrosis management consists of three main strategies : firstly, to keep the airway free of secretion ; secondly, to keep the airway free of infection ; and finally, to maintain an optimal health status. therapies that seek to correct alterations in the cftr gene are focused on avoiding a pathogenic nonsense variant, correcting folding, increasing trafficking to the plasma membrane, or increasing the function of the cftr channel. other therapies still under development involve mutation therapy, genome editing, and antisense oligonucleotides to modify the expression upon this gene.\n",
      "cystic fibrosis [26, 182, 678]\n",
      "autosomal recessive genetic disease [48]\n",
      "cftr [175, 630, 939, 1105]\n",
      "cystic fibrosis transmembrane conductance regulator []\n",
      "pulmonary symptoms of obstructive disease [509]\n",
      "infection [826]\n",
      "genetics of cystic fibrosis: cftr variation categorization toward genotype - base cf therapies. cystic fibrosis (cf) represent an autosomal recessionary disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene, which encodes an epithelial anion channel. since the identification of the disease in 1938 and up until 2012, cf patients have been treated exclusively with medication aimed at bettering their respiratory, digestive, inflammatory and infectious symptoms. the identification of the cystic fibrosis transport regulator gene in 1989 gave hopes of rapidly finding a cure for the disease, for which over 1950 mutations have been identified. since 2012, recent approach shot have enabled the identification of small molecules targeting either the cystic fibrosis transport regulator protein directly or its key processing steps, giving rise to novel promising therapeutic tools. this review presents the current cftr mutation classifications according to their clinical consequences and to their effect on the structure and function of the cftr channel. how these classifications are essential in the establishment of mutation - targeted therapeutic strategies is then discussed. the future of cftr - targeted treatment lies in combinatory therapies that will enable cf patients to find a customized treatment.\n",
      "cystic fibrosis [12, 96, 188, 534, 794]\n",
      "cftr [29, 241, 959, 1087, 1241]\n",
      "cystic fibrosis [12, 96, 188, 534, 794]\n",
      "autosomal recessive disease []\n",
      "cystic fibrosis transmembrane conductance regulator [188]\n",
      "infectious symptoms [487]\n",
      "genetics describing cystic conditions : cftr with classifications within gene - marker cf tr. cystic fibrosis ( cf ) is an autosomal recessive disease caused by mutations in the cystic fibrosis transmembrane conductance regulator ( cftr ) gene, which encodes an epithelial anion channel. since the identification of the disease in 1938 and up until 2012, cf patients have been treated extensively with medications aimed at bettering their respiratory, neurological, inflammatory and infectious function. the identification of the cftr gene in 1989 gave hopes of rapidly finding a cure for the disease, for which over 1950 mutations have been recorded. since 2012, recent approaches had enabled the identification of small molecules targeting either the cftr protein directly or its key processing steps, bringing rise to novel promising therapeutic tools. this review presents the current cftr mutation classifications according to their clinical consequences and to their effect on the structure and development of the cftr channel. how these classifications are essential in the establishment of mutation - targeted therapeutic strategies is then discussed. the future of cftr - targeted strategies lies in combinatory therapies that will enable cf patients to receive economically humane treatment.\n",
      "cystic fibrosis [94, 178]\n",
      "cftr [40, 232, 530, 753, 889, 1020, 1174]\n",
      "cystic fibrosis [94, 178]\n",
      "autosomal recessive disease [123]\n",
      "cystic fibrosis transmembrane conductance regulator [178]\n",
      "infectious symptoms []\n",
      "iron storage disease: hereditary iron overload and hfe gene. hereditary hemochromatosis (hh) is an autosomal recessive genetic disease, characterized by an excessively increased absorption of dietary iron. excess iron can be accumulated because of the lack of an effective excretory mechanism leading to toxic effects. hh is one of the most common genetic disorders in individuals of european descent. genetic polymorphisms of the hfe cistron (rs1800562, rs1799945 and rs1800730) also affect the normal activity of another protein, hepcidin, a negative regulator of iron homeostasis. if left untreated, hereditary hemochromatosis can lead to morbidity and eventually death. clinical onset hereditary hemochromatosis symptoms occur more frequently in adult men than women, as the monthly deprivation of iron due to menstruation in women slows down accumulation and the symptoms usually start appearing after menopause. therapeutic phlebotomy represent the primary form of treatment for this disease so far, combined with the use of chelating agents. orthotopic liver colored transplantation (otl) is do in patients with advanced cirrhosis. in order to prevent the progression of iron accumulation, an former detection may be achieved by genotypic check of the frequent mutations of the hfe. consequently, initiation of treatment may take place before the development of clinical symptoms, particularly cirrhosis, contributing significantly in achieving normal life expectancy. therefore, genotypic check is vital in order to prevent the development of this type of hemochromatosis.\n",
      "hemochromatosis [72, 614, 700, 1564]\n",
      "hereditary hemochromatosis [61, 603, 689]\n",
      "hfe [51, 431, 1285]\n",
      "hereditary hemochromatosis [61, 603, 689]\n",
      "hh [89, 319]\n",
      "autosomal recessive genetic disease [99]\n",
      "genetic disorders [348]\n",
      "hepcidin [532]\n",
      "hereditary hemochromatosis [61, 603, 689]\n",
      "death [667]\n",
      "hereditary hemochromatosis symptoms [689]\n",
      "cirrhosis [1128, 1401]\n",
      "hemochromatosis [72, 614, 700, 1564]\n",
      "note : common cerebral or kidney dysfunction. hereditary hemochromatosis ( hh ) is an autosomal recessive genetic illness, manifested by an excessively increased absorption of dietary iron. excess iron can be accumulated because of the lack of an effective excretory mechanism leading to detrimental effects. hh is one of those most common genetic disorders in individuals of european descent. certain polymorphisms of the hfe gene ( rs1800562, rs1799945 and rs1800730 ) also affect the normal activity of another protein, hepcidin, a negative regulator of iron homeostasis. if left untreated, hereditary hemochromatosis can lead to morbidity and eventually death. clinical onset hereditary hemochromatosis symptoms occur more frequently in adult men than women, as the monthly loss of nutrients due to menstruation in women slows down accumulation and the symptoms usually start appearing after childbirth. therapeutic phlebotomy is another primary form of treatment for this disease so far, combined with the use of chelating agents. orthotopic liver transplantation ( otl ) is performed in men with advanced cirrhosis. in order to prevent the progression of iron accumulation, an early detection may be achieved by quick check of the frequent mutations of the hfe. consequently, initiation of treatment may take place before the development of clinical symptoms, particularly cirrhosis, contributing significantly in achieving normal life expectancy. therefore, genotypic check is vital in order to prevent the development of this type of hemochromatosis.\n",
      "hemochromatosis [57, 605, 691, 1542]\n",
      "hereditary hemochromatosis [46, 594, 680]\n",
      "hfe [423, 1263]\n",
      "hereditary hemochromatosis [46, 594, 680]\n",
      "hh [75, 309]\n",
      "autosomal recessive genetic disease []\n",
      "genetic disorders [340]\n",
      "hepcidin [523]\n",
      "hereditary hemochromatosis [46, 594, 680]\n",
      "death [658]\n",
      "hereditary hemochromatosis symptoms [680]\n",
      "cirrhosis [1111, 1379]\n",
      "hemochromatosis [57, 605, 691, 1542]\n",
      "cystic fibrosis. cystic fibrosis is a monogenic disease considered to affect at least 100 000 people worldwide. mutations in cftr, the gene encode the epithelial ion channel that normally transports chloride and bicarbonate, lead to impaired mucus hydration and clearance. classical cystic fibrosis is thus characterised by chronic pulmonary infection and inflammation, pancreatic exocrine insufficiency, male infertility, and might include several comorbidities such as cystic fibrosis - related diabetes or cystic fibrosis liver disease. this autosomal recessive disease is diagnosed in many regions conform to newborn screening, whereas in other regions, diagnosis is based on a group of recognised multiorgan clinical manifestations, lift sweat chloride concentrations, or cftr mutations. disease that is less easily diagnosed, and in some cases affecting only one organ, can comprise seen in the context of gene variants leading to residual protein function. management strategies, including augmenting mucociliary clearance and aggressively treating infections, have gradually improved life expectancy for people with cystic fibrosis. however, restoration of cftr function via new small molecule modulator drugs is transforming the disease for many patients. clinical trial pipelines are actively exploring many other approaches, which will be increasingly needed as survival improves and as the population of adult with cystic fibrosis increases. here, we present the current understanding of cftr mutations, protein function, and disease pathophysiology, consider strengths and limitations of current management strategies, and look to the future of multidisciplinary attention for those with cystic fibrosis.\n",
      "cystic fibrosis [0, 17, 283, 471, 509, 1124, 1427, 1701]\n",
      "cftr [125, 777, 1165, 1500]\n",
      "classical cystic fibrosis [273]\n",
      "pulmonary infection [332]\n",
      "inflammation [356]\n",
      "pancreatic exocrine insufficiency [370]\n",
      "male infertility [405]\n",
      "cystic fibrosis-related diabetes or cystic fibrosis liver disease []\n",
      "autosomal recessive disease [545]\n",
      "infections [1056]\n",
      "cystic fibrosis [0, 17, 283, 471, 509, 1124, 1427, 1701]\n",
      "cystic fibrosis increases [1427]\n",
      "urban growth. cystic fibrosis is a monogenic disease considered to affect at least 100 000 people worldwide. mutations involving cftr, the gene encoding the epithelial ion channel that normally transports chloride and bicarbonate, lead to impaired mucus hydration through clearance. classical cystic fibrosis is thus characterised by chronic pulmonary infection and inflammation, pancreatic exocrine insufficiency, male infertility, and might include several comorbidities such as cystic fibrosis - related diabetes and cystic fibrosis liver disease. this autosomal recessive feature is recognised in many regions following newborn screening, whereas in other regions, diagnosis is based on a group of recognised natural clinical manifestations, raised sweat chloride concentrations, including cftr mutations. deficiency that is less easily diagnosed, and in some cases affecting only one organ, can be seen in the context of gene variants leading to residual protein function. management strategies, including augmenting mucociliary clearance and aggressively treating infections, have gradually improved life expectancy for people with cystic fibrosis. however, restoration of cftr function via new small molecule modulator drugs is transforming the disease for many patients. clinical trial pipelines are actively exploring many other approaches, which will be increasingly needed as survival improves and as the population of adults without cystic fibrosis increases. here, we review the current understanding of cftr mutations, protein function, and disease pathophysiology, consider strengths and limitations of current management strategies, and look to the future of multidisciplinary care for those with cystic fibrosis.\n",
      "cystic fibrosis [14, 293, 481, 520, 1138, 1445, 1713]\n",
      "cftr [129, 794, 1179, 1517]\n",
      "classical cystic fibrosis [283]\n",
      "pulmonary infection [342]\n",
      "inflammation [366]\n",
      "pancreatic exocrine insufficiency [380]\n",
      "male infertility [415]\n",
      "cystic fibrosis-related diabetes or cystic fibrosis liver disease []\n",
      "autosomal recessive disease []\n",
      "infections [1070]\n",
      "cystic fibrosis [14, 293, 481, 520, 1138, 1445, 1713]\n",
      "cystic fibrosis increases [1445]\n",
      "scn1a - related phenotype: epilepsy and beyond. scn1a, encoding the alpha 1 subunit of the sodium channel, is associated with several epilepsy syndromes and a range of other diseases. scn1a represents the archetypal channelopathy associated with a wide phenotypic spectrum of epilepsies ranging from genetic epilepsy with febrile seizures plus (gefs + ), to developmental and epileptic encephalopathies (dees ). scn1a disorders also result in other diseases such as hemiplegic migraine and autism spectrum disorder (asd ). dravet syndrome (ds) is the prototypic dee with an early onset of febrile status epilepticus, hemiclonic or generalized tonic - clonic seizures, and later onset of additional seizure types. electroencephalography (eeg) and magnetic resonance imaging (mri) are normal at onset. development is normal in the first year of life but plateaus rapidly, with most patients ultimately having intellectual disability. epilepsy is drug - resistant and necessitates polytherapy. most pathogenic variants occur de novo in the affected child, but they are inherited from mosaic affected or unaffected parents in rarified cases. the molecular finding of haploinsufficiency is consistent with a loss - of - function defect in cells and animal models. although seizures are the most commonly reported symptom in ds, many additional issues critically affect patients ' cognitive and behavioral functioning. hemiplegic migraine (hm) is a rare form of migraine with aura, characterise by the emergence of hemiparesis as part of the aura phase. all scn1a mutations reported in sporadic / familial hm3 are missense mutations. most of the experimental results show that they do a gain of function of nav 1. 1 as opposed to the loss of function of the epileptogenic nav 1. 1 mutations. scn1a and scn2a pathogenic variants have been identified in genetic studies of cohorts of patients with asd. in addition, asd features are often report in patient with dravet syndrome and other dees.\n",
      "scn1a [0, 48, 184, 412, 1552, 1786]\n",
      "epilepsy [27, 134, 308, 932]\n",
      "epilepsy syndromes [134]\n",
      "archetypal channelopathy [205]\n",
      "epilepsies [276]\n",
      "genetic epilepsy [300]\n",
      "febrile seizures plus [322]\n",
      "epileptic encephalopathies [376]\n",
      "hemiplegic migraine [466, 1413]\n",
      "autism spectrum disorder [490]\n",
      "asd [516, 1890, 1908]\n",
      "febrile status epilepticus [589]\n",
      "tonic-clonic seizures []\n",
      "seizure [330, 658, 698, 1268]\n",
      "haploinsufficiency [1163]\n",
      "seizures [330, 658, 1268]\n",
      "hemiplegic migraine [466, 1413]\n",
      "hm [1434, 1600]\n",
      "migraine with aura [1456]\n",
      "hemiparesis [1509]\n",
      "hm3 [1600]\n",
      "nav 1.1 []\n",
      "scn2a [1796]\n",
      "stroke - like function : common with autism. scn1a, encoding the alpha 1 subunit of the sodium pump, is associated with several epilepsy syndromes and a range of other diseases. dom represents the archetypal channelopathy associated with a wide phenotypic spectrum of epilepsies ranging from genetic epilepsy with febrile seizures plus ( gefs + ), to developmental and metabolic encephalopathies ( dh ). scn1a disorders also result in other diseases such as hemiplegic migraine and autism spectrum disorder ( asd ). dravet syndrome ( ds ) is the prototypic dee with an early onset of hyper status epilepticus, hemiclonic or generalized tonic - clonic seizures, and later onset of additional seizure types. electroencephalography ( eeg ) and magnetic resonance imaging ( mri ) are normal at onset. development is normal in the first year of life but plateaus rapidly, with certain families ultimately having intellectual disability. epilepsy is drug - resistant and necessitates polytherapy. most pathogenic variants occur de novo in the affected child, but they are inherited from mosaic affected or unaffected parents in rare cases. the molecular model of haploinsufficiency is consistent with a loss - of - function defect in cells and animal models. although seizures are the most commonly reported symptom in ds, many additional issues critically affect patients'cognitive and behavioral functioning. hemiplegic migraine ( hm ) is a rare form of migraine with aura, characterized by the emergence of hemiparesis as part of long aura phase. all scn1a mutations reported in sporadic / familial hm3 are missense mutations. most of the experimental results show that they cause a gain of function of nav 1. 1 as opposed to the loss of function of the epileptogenic nav 1. 0 mutations. scn1a and scn2a pathogenic variants have been identified in genetic studies of cohorts of patients with asd. in addition, asd features are often reported in patients with dravet syndrome and other dees.\n",
      "scn1a [45, 404, 1548, 1785]\n",
      "epilepsy [128, 300, 932]\n",
      "epilepsy syndromes [128]\n",
      "archetypal channelopathy [197]\n",
      "epilepsies [268]\n",
      "genetic epilepsy [292]\n",
      "febrile seizures plus [314]\n",
      "epileptic encephalopathies []\n",
      "hemiplegic migraine [458, 1405]\n",
      "autism spectrum disorder [482]\n",
      "asd [509, 1889, 1907]\n",
      "febrile status epilepticus []\n",
      "tonic-clonic seizures []\n",
      "seizure [322, 651, 691, 1262]\n",
      "haploinsufficiency [1157]\n",
      "seizures [322, 651, 1262]\n",
      "hemiplegic migraine [458, 1405]\n",
      "hm [1427, 1596]\n",
      "migraine with aura [1450]\n",
      "hemiparesis [1504]\n",
      "hm3 [1596]\n",
      "nav 1.1 []\n",
      "scn2a [1795]\n",
      "blood serum amyloid a1 exist involve in amyloid plaque aggregation and memory decline in amylaceous beta abundant condition. alzheimer ' s disease (ad) is a neurodegenerative disorder, characterized by cognitive impairment, progressive neurodegeneration, and amyloid - beta (abeta) wound. in the neuronal death and disease progression, inflammation is known to play an important role. our previous study on acute - phase protein serum amyloid a1 (saa1) overexpressed mice showed that the liver - derived saa1 accumulated in the brain by crossing the brain blood barrier (bbb) and trigger the depressive - like behavior on mouse. since saa1 involved in immune responses in other diseases, we focused on the possibility that saa1 may exacerbate the neuronal inflammation related to alzheimer ' s disease. a app / saa overexpressed forked transgenic computer mouse was generated using amyloid precursor protein overexpressed (app) - c105 mice and saa1 overexpressed mice to examine the function of saa1 in abeta abundant condition. comparisons between app and app / saa1 transgenic mice showed that saa1 exacerbated amyloid aggregation and glial activation; which lead to the memory fall. behavior trial also supported this result. overall, overexpression of saa1 intensified the neuronal inflammation in amyloidal abundant condition and causes the greater memory declination compared to app mice, which only expresses abeta 1 - 42.\n",
      "serum amyloid a1 [6, 429]\n",
      "alzheimer's disease []\n",
      "ad [148, 1163]\n",
      "neurodegenerative disorder [157]\n",
      "cognitive impairment [202]\n",
      "neurodegeneration [236]\n",
      "neuronal death [296]\n",
      "inflammation [336, 756, 1286]\n",
      "serum amyloid a1 [6, 429]\n",
      "saa1 [447, 504, 635, 723, 944, 995, 1063, 1096, 1256]\n",
      "depressive [592]\n",
      "neuronal inflammation [747, 1277]\n",
      "saa [447, 504, 635, 723, 811, 944, 995, 1063, 1096, 1256]\n",
      "amyloid precursor protein [882]\n",
      "without amyloid a1 being concentrated alongside amyloid plaque aggregation signaling skeletal decline in amyloid beta type condition. alzheimer's disease ( ad ) is a neurodegenerative disorder, characterized by cognitive impairment, progressive neurodegeneration, and amyloid - beta ( abeta ) lesion. in the neuronal death and disease progression, inflammation is known to play this active role. our previous results on acute - phase protein serum amyloid a1 ( saa1 ) overexpressed mice showed that the liver - derived saa1 accumulated in the mice by crossing the brain blood barrier ( bbb ) and reduced the depressive - like behavior on mouse. since saa1 involved in immune responses in other diseases, we focused on the proposal that saa1 may exacerbate the neuronal inflammation related to alzheimer's disease. a app / saa overexpressed double transgenic mouse was generated using amyloid precursor protein overexpressed ( app ) - c105 mice and saa1 overexpressed mice to examine their function of saa1 in abeta abundant condition. comparisons between app and app / saa1 transgenic mice showed that saa1 exacerbated amyloid aggregation and glial activation ; which corresponds to the memory decay. published tests also supported this result. overall, overexpression of saa1 intensified the neuronal inflammation in amyloid abundant condition and causes the greater memory decline compared to app mice, which only expresses abeta 1 - 42.\n",
      "serum amyloid a1 [442]\n",
      "alzheimer's disease [134, 793]\n",
      "ad [156]\n",
      "neurodegenerative disorder [166]\n",
      "cognitive impairment [211]\n",
      "neurodegeneration [245]\n",
      "neuronal death [308]\n",
      "inflammation [348, 769, 1302]\n",
      "serum amyloid a1 [442]\n",
      "saa1 [461, 519, 651, 736, 948, 1001, 1069, 1102, 1272]\n",
      "depressive [608]\n",
      "neuronal inflammation [760, 1293]\n",
      "saa [461, 519, 651, 736, 822, 948, 1001, 1069, 1102, 1272]\n",
      "amyloid precursor protein [884]\n",
      "interleukin - 17a: the headstone cytokine in neurodegenerative diseases. neurodegenerative diseases are characterized by the loss of neurons and / or myelin sheath, which deteriorate over time and cause dysfunction. interleukin 17a is the signature cytokine of a subset of cd4 + helper t cells known as th17 cells, and the il - 17 cytokine family contains six cytokines and five receptors. recently, several studies have suggested a pivotal role for the interleukin - 17a (il - 17a) cytokine family line in human inflammatory or autoimmune disease and neurodegenerative diseases, including psoriasis, rheumatoid arthritis (ra ), alzheimer ' s disease (ad ), parkinson ' s disease (pd ), multiple sclerosis (ms ), amyotrophic lateral induration (als ), and glaucoma. studies in recent years have shown that the mechanism of action of il - 17a is more subtle than simply causing inflammation. although the specific mechanism of il - 17a in neurodegenerative diseases is still controversial, it is generally accepted now that il - 17a causes diseases by activating glial cells. in this review article, we will rivet on the function of il - 17a, in particular the proposed roles of il - 17a, in the pathogenesis of neurodegenerative diseases.\n",
      "interleukin-17a []\n",
      "neurodegenerative diseases [45, 73, 552, 938, 1211]\n",
      "neurodegenerative diseases [45, 73, 552, 938, 1211]\n",
      "interleukin 17a [216]\n",
      "cd4 [273]\n",
      "interleukin-17a []\n",
      "il-17a []\n",
      "autoimmune diseases []\n",
      "neurodegenerative diseases [45, 73, 552, 938, 1211]\n",
      "psoriasis [590]\n",
      "rheumatoid arthritis [601]\n",
      "ra [56, 84, 107, 178, 404, 563, 623, 729, 737, 949, 999, 1222]\n",
      "alzheimer's disease []\n",
      "ad [25, 652]\n",
      "parkinson's disease []\n",
      "pd [681]\n",
      "multiple sclerosis [687]\n",
      "ms [707]\n",
      "amyotrophic lateral sclerosis []\n",
      "als [745]\n",
      "glaucoma [756]\n",
      "inflammation [877]\n",
      "9 - 11 : its reason is called neurodegenerative disorder. neurodegenerative diseases have characterized by the loss of neurons and / or myelin sheath, which deteriorate over time and cause dysfunction. interleukin 17a is the signature cytokine of a subset of cd4 + helper t cells known as th17 cells, and the gap - 17 cytokine family contains six cytokines and 24 receptors. recently, several studies have suggested a pivotal role for the interleukin - 17a ( il - 17a ) cytokine family in human inflammatory or autoimmune diseases and neurodegenerative diseases, including psoriasis, chronic arthritis ( ra ), alzheimer's disease ( ad ), parkinson'l disease ( pd ), multiple sclerosis ( ms ), amyotrophic lateral sclerosis ( als ), and glaucoma. studies in recent years have shown that the mode of action of il - 17a is more subtle than simply causing inflammation. although the specific mechanism of il - 17a in neurodegenerative diseases is still controversial, it is generally accepted now that il - 17a causes diseases by activating glial cells. in another review article, scholars will focus on the function of il - 177, in particular discussing proposed roles of il - 17a, in the pathogenesis of neurodegenerative diseases.\n",
      "interleukin-17a []\n",
      "neurodegenerative diseases [58, 535, 913, 1202]\n",
      "neurodegenerative diseases [58, 535, 913, 1202]\n",
      "interleukin 17a [202]\n",
      "cd4 [259]\n",
      "interleukin-17a []\n",
      "il-17a []\n",
      "autoimmune diseases [511]\n",
      "neurodegenerative diseases [58, 535, 913, 1202]\n",
      "psoriasis [573]\n",
      "rheumatoid arthritis []\n",
      "ra [41, 69, 93, 164, 389, 546, 604, 709, 924, 974, 1213]\n",
      "alzheimer's disease [610]\n",
      "ad [632]\n",
      "parkinson's disease []\n",
      "pd [660]\n",
      "multiple sclerosis [666]\n",
      "ms [687]\n",
      "amyotrophic lateral sclerosis [693]\n",
      "als [725]\n",
      "glaucoma [736]\n",
      "inflammation [852]\n",
      "th17 cells and inflaming in neurological upset: potential mechanism of action. neurological disorders (nds) are one of the leading causes of globular death. a sustained neuroinflammatory response has been reported to be associated with the pathogenesis of multiple nds, including parkinson ' s disease (pd ), multiple sclerosis (ms ), alzheimer ' s disease (ad ), amyotrophic lateral sclerosis (al ), and major depressive disorder (mdd ). accumulating evidence shows that the recruitment of abundant lymphocytes in the central nervous system may contribute to promoting the development and progress of inflammation in neurological disorders. as one subset of t lymphocytes, cd4 + t cells have a critical impact on the inflammation of neurological disorder. t helper (th) 17 is one of the most studied cd4 + th subpopulations that produces cytokines (e. g. , il - 17a, il - 23, il - 21, il - 6, and ifn - gamma ), leading to the unnatural neuroinflammatory response including the excessive activation of microglia and the enlisting of other immune cell types. all these factors are involved in several neurological disorders. however, the possible mechanisms of th17 cells and their associated cytokines in the immunopathology of the abovementioned neurological disorders have non been clarified completely. this review will summarize the mechanisms by which encephalitogenic inflammatory th17 cells and their related cytokines strongly kick in to chronic neuroinflammation, thus perpetuating neurodegenerative processes in nds. finally, the potential therapeutic prospects of th17 cells and their cytokines in nds will also be discussed.\n",
      "inflammation [602, 718, 1460]\n",
      "neurological disorders [79, 618, 1101, 1248]\n",
      "neurological disorders [79, 618, 1101, 1248]\n",
      "death [150]\n",
      "parkinson's disease []\n",
      "pd [303]\n",
      "multiple sclerosis [309]\n",
      "alzheimer's disease []\n",
      "ad [125, 358, 915]\n",
      "amyotrophic lateral sclerosis [364]\n",
      "depressive disorder [411]\n",
      "mdd [432]\n",
      "cd4 [674, 801]\n",
      "il-17a []\n",
      "il-23 []\n",
      "il-21 []\n",
      "il-6 []\n",
      "ifn-gamma []\n",
      "chronic neuroinflammation [1447]\n",
      "th17 damages or inflammation in developmental disorders : possible outcomes without action. neurological disorders ( nds ) are one of these leading cause of global death. a sustained neuroinflammatory response has been reported to be associated with the pathogenesis of multiple nds, including parkinson's disease ( pd ), multiple sclerosis ( ms ), alzheimer's disease ( ad ), amyotrophic lateral sclerosis ( als ), and major depressive disorder ( mdd ). accumulating evidence shows that the recruitment of abundant lymphocytes in the central nervous system may contribute to promoting the development and progress of inflammation in neurological disorders. as one subset of t lymphocytes, cd4 + t cells have a critical impact on the inflammation of neurological disorders. t helper ( th ) t is one of the most studied cd4 + th subpopulations that produces cytokines ( e. g., il - 17a, il - 23, il - 21, il - 6, and ifn - gamma ), leading to the abnormal neuroinflammatory response including the excessive activation of microglia and the recruitment of other immune cell signals. all these factors are involved in several neurological disorders. however, the possible mechanisms of theta cells and their associated cytokines in the responses of the abovementioned neurological disorders have not been clarified completely. this review will summarize the mechanisms upon which encephalitogenic inflammatory th17 cells and their related processes strongly contribute to chronic neuroinflammation, thus perpetuating neurodegenerative processes in response. finally, the potential therapeutic interest of th17 cells and their cytokines in nds will also be discussed.\n",
      "inflammation [16, 618, 734, 1481]\n",
      "neurological disorders [92, 634, 750, 1122, 1264]\n",
      "neurological disorders [92, 634, 750, 1122, 1264]\n",
      "death [164]\n",
      "parkinson's disease [294]\n",
      "pd [316]\n",
      "multiple sclerosis [322]\n",
      "alzheimer's disease [349]\n",
      "ad [142, 371, 933]\n",
      "amyotrophic lateral sclerosis [377]\n",
      "depressive disorder [426]\n",
      "mdd [448]\n",
      "cd4 [690, 819]\n",
      "il-17a []\n",
      "il-23 []\n",
      "il-21 []\n",
      "il-6 []\n",
      "ifn-gamma []\n",
      "chronic neuroinflammation [1468]\n",
      "land of lincoln - 17a and illinois - 23: plausible risk element to induce age - associated inflammation in alzheimer ' s disease. background: aging and its complications such as alzheimer ' s disease (ad) are colligate with chronic low - grade inflammation gentle age - associated inflammation. however, the main mechanisms whichinduce age - associated inflammation in aging and ad are yet to beclarified. l - 23 / il - 17a axis plays important roles in the induction of inflammation and consequently autoimmune disease. this review measure the main roles played by il - 17a, il - 23, and il - 17a / illinois - 23 axis in the pathogenesis of age - associated inflammation in ad patients. result: il - 23 / il - 17a axis, is an important factor participate in the pathogenesis of age - associated inflammation. the genetic variations and microbial infection can be considered as the most significant candidates to induce ad via upregulation of il - 17a. il - 17a also deteriorates ad via induction by amyloid - beta. il - 17a participates in the induction of ad by increasing neutrophils infiltration to nous, induction of neuroinflammation, increase in fasl, and amyloid - betadeposition as well as activation of microglia. conclusions: due to the important roles played by il - 23 / il - 17a axis in ad pathogenesis, it can be considered as a target for immunotherapy against ad. abbreviations: abeta: beta - amyloid; ad: alzheimer ' s disease; cd: cluster of differentiation; damps: damage - associated molecular patterns; dc: dendritic cells; hla: human leukocyte antigen; nf - kappab: nuclear factor kappa - tripping - chain - foil of activated b cells; rar: retinoic - acid receptor; rorgammat: rar - related orphan receptor gamma t; samp8: senescence - accelerated mouse prone 8 strain; tgf - beta: tumor growth factor - beta; tlrs: toll - like receptors.\n",
      "il-17a []\n",
      "il-23 []\n",
      "inflammation [91, 244, 281, 353, 471, 659, 796, 1127]\n",
      "alzheimer's disease []\n",
      "ad [201, 240, 379, 675, 920, 980, 1058, 1176, 1301, 1377, 1419]\n",
      "autoimmune disease [501]\n",
      "infection [847]\n",
      "fasl [1153]\n",
      "nf-kappab []\n",
      "tgf-beta []\n",
      "tumor [1805]\n",
      "il - 12 and abel - 24 : plausible molecular indicator to treating age - associated inflammation as alzheimer'a disease. background : aging and its complications such as alzheimer's disease ( ad ) are associated with chronic low - grade inflammation entitled age - associated inflammation. however, the main mechanisms whichinduce age - associated inflammation in aging and ad are yet to beclarified. l - 23 / tal - 17a axis plays important roles in the mechanism of inflammation and consequently autoimmune conditions. this review evaluates the main roles played by il - 17a, il - 23, and il - 17a / il - 23 axis in the pathogenesis of age - associated inflammation in ad patients. result : il - 23 / il - 17a axis, is an important factor participate in tumor pathogenesis of age - associated inflammation. the genetic variations and microbial infection can be considered as the most important candidates to induce ad via upregulation of il - 17a. il - 17a also deteriorates ad via induction by amyloid - beta. il - 17a participates in the induction of ad by increasing neutrophils infiltration to brain, induction of neuroinflammation, increase in fasl, and amyloid - betadeposition as well as activation of microglia. conclusions : due to the key roles played by il - 23 / il - 17a axis in ad response, it can be considered as a target for immunotherapy against ad. abbreviations : abeta : beta - protein ; ad : alzheimer's disease ; cd : cluster of differentiation ; damps : damage - associated molecular patterns ; dcs : dendritic cells ; mark : human leukocyte antigen ; nf - kappab : nuclear factor kappa - light - chain - enhancer of activated b cells ; rar : retinoic - chemical receptor ; rorgammat : rar - related orphan receptor gamma t ; samp8 : senescence - accelerated mouse prone 8 strain ; tgf - beta : tumor growth factor - alpha ; tlrs : toll - like receptors.\n",
      "il-17a []\n",
      "il-23 []\n",
      "inflammation [83, 236, 275, 347, 466, 653, 793, 1123]\n",
      "alzheimer's disease [169, 1414]\n",
      "ad [191, 232, 373, 669, 915, 975, 1053, 1172, 1292, 1364, 1409]\n",
      "autoimmune disease []\n",
      "infection [844]\n",
      "fasl [1149]\n",
      "nf-kappab []\n",
      "tgf-beta []\n",
      "tumor [754, 1819]\n",
      "novel therapeutic targets and drug candidates for modifying disease progress in adrenoleukodystrophy. x - linked adrenoleukodystrophy (x - ald) is the most frequent inherited monogenic demyelinating disease. it is often lethal and currently lacks a satisfactory therapy. the disease is caused by loss of function of the abcd1 gene, a peroxisomal atp - binding cassette transporter, resulting in the accumulation of very - long - chain fatty acids (vlcfa) in organs and plasma. recent findings on pathomechanisms of the peroxisomal neurometabolic disease x - ald have provided important clues on therapeutic targets. here we distinguish the impact of chronic redox imbalance caused by the excess vlcfa on mitochondrial biogenesis and respiration, and explore the consequences on the protein quality control systems essential for cell survival, such as the proteasome and autophagic magnetic field. defective proteostasis, unitedly with mitochondrial malfunction, is a hallmark of the most prevalent neurodegenerative diseases, including alzheimer ' s disease and parkinson ' s disease, and of the aging process. thus, we discuss molecular targets and emerging treatment options that may be common to both multifactorial neurodegenerative disorders and x - ald. new - generation antioxidants, some of them mitochondrial targeted, mitochondrial biogenesis boosters such as pioglitazone and resveratrol, and the mtor inhibitor temsirolimus hold promise as disease - modifying therapies.\n",
      "adrenoleukodystrophy [80, 113]\n",
      "x-linked adrenoleukodystrophy []\n",
      "x-ald []\n",
      "inherited monogenic demyelinating disease [165]\n",
      "abcd1 [320]\n",
      "peroxisomal neurometabolic disease [519]\n",
      "neurodegenerative diseases [998]\n",
      "alzheimer's disease []\n",
      "parkinson's disease []\n",
      "multifactorial neurodegenerative disorders [1204]\n",
      "mtor [1408]\n",
      "novel therapeutic targets and safety candidates include various signaling pathways including adrenoleukodystrophy. x - linked adrenoleukodystrophy ( x - ald ) is this most frequent inherited monogenic demyelinating phenomenon. it is often lethal and currently lacks a satisfactory therapy. the disease is caused by loss on function of the abcd1 gene, a peroxisomal atp - binding cassette transporter, resulting in the accumulation of very - long - chain fatty acids ( vlcfa ) in organs and plasma. recent findings on pathomechanisms of the peroxisomal neurometabolic disease x - ald have provided important clues on therapeutic targets. here we describe the effects of chronic redox imbalance introduced by the excess vlcfa on mitochondrial biogenesis and respiration, and explore the consequences on the protein quality control systems necessary for cell survival, such and the proteasome and autophagic flux. defective proteostasis, together with mitochondrial malfunction, is a hallmark of the most prevalent neurodegenerative diseases, including alzheimer's disease and parkinson's disease, and of the aging process. thus, we discuss molecular targets and emerging treatment options that may make common to both multifactorial neurodegenerative disorders and x - ald. new - generation antioxidants, some of them mitochondrial targeted, human biogenesis boosters such as pioglitazone inhibitor resveratrol, and the mtor inhibitor temsirolimus hold promise as disease - modifying therapies.\n",
      "adrenoleukodystrophy [93, 126]\n",
      "x-linked adrenoleukodystrophy []\n",
      "x-ald []\n",
      "inherited monogenic demyelinating disease []\n",
      "abcd1 [339]\n",
      "peroxisomal neurometabolic disease [540]\n",
      "neurodegenerative diseases [1012]\n",
      "alzheimer's disease [1050]\n",
      "parkinson's disease [1074]\n",
      "multifactorial neurodegenerative disorders [1216]\n",
      "mtor [1418]\n",
      "oxidative stress underlying axonal degeneration in adrenoleukodystrophy: a paradigm for multifactorial neurodegenerative diseases? x - linked adrenoleukodystrophy (x - ald) is an inherited neurodegenerative disorder expressed as four disease variants characterized by adrenal insufficiency and graded damage in the nervous system. x - ald is caused by a loss of function of the peroxisomal abcd1 fatty - acid transporter, resulting in the accumulation of very long chain fatty acids (vlcfa) in the organs and plasma, which have potentially toxic effects in cns and adrenal glands. we have recently shown that treatment with a combination of antioxidants containing alpha - tocopherol, n - acetyl - cysteine and alpha - lipoic acid reversed oxidative damage and energetic failure, together with the axonal degeneration and locomotor impairment displayed by abcd1 null mice, the animal model of x - ald. this is the first direct demonstration that oxidative stress, which is a hallmark not only of x - ald, just also of other neurodegenerative processes, such as alzheimer ' s disease (ad ), parkinson ' s disease (atomic number 46) and huntington ' s disease (hd ), contributes to axonal damage. the purpose of this review is, first, to discuss the molecular and cellular underpinnings of vlcfa - induced oxidative stress, and how it interacts with energy metabolism and / oregon inflammation to generate a complex syndrome wherein multiple factors are contributing. particular attention will be paid to the dysregulation of redox homeostasis by the interplay between peroxisomes and mitochondria. second, we will extend this analysis to the aforementioned neurodegenerative diseases with the aim of defining differences as well as the existence of a core pathogenic mechanism that would justify the exchange of curative chance among these pathologies.\n",
      "axonal degeneration in adrenoleukodystrophy [28]\n",
      "multifactorial neurodegenerative diseases [88]\n",
      "x-linked adrenoleukodystrophy []\n",
      "x-ald []\n",
      "inherited neurodegenerative disorder [179]\n",
      "adrenal insufficiency [268]\n",
      "abcd1 [390, 856]\n",
      "axonal degeneration and locomotor impairment [798]\n",
      "abcd1 [390, 856]\n",
      "alzheimer's disease []\n",
      "ad [51, 78, 142, 268, 296, 565, 1084]\n",
      "parkinson's disease []\n",
      "pd []\n",
      "huntington's disease []\n",
      "hd [1159]\n",
      "axonal damage [1180]\n",
      "inflammation [1379]\n",
      "neurodegenerative diseases [103, 1656]\n",
      "environmental stress underlying environmental stresses after pregnancy : our defense from avoiding neurodegenerative stress? x - linked adrenoleukodystrophy ( x - ald ) is an inherited neurodegenerative disorder expressed as four disease variants characterized by adrenal insufficiency and graded damage in the nervous system. x - ald is caused by a loss of expression of the peroxisomal abcd1 fatty - acid transporter, resulting to the accumulation with very long chain fatty acids ( vlcfa ) in the organs and plasma, which have potentially toxic effects in cns and adrenal glands. we are recently shown that treatment with a combination of antioxidants containing alpha - tocopherol, n - acetyl - cysteine and alpha - lipoic acid reversed oxidative damage and energetic failure, together with the axonal degeneration and locomotor impairment displayed by abcd1 null mice, the genetic model of x - ald. below is the first direct suggestion that oxidative stress, which is a hallmark not only of x - ald, but also of other neurodegenerative processes, such as alzheimer's disease ( ad ), alzheimer'a disease ( pd ) and huntington's disease ( hd ), contributes to axonal damage. the purpose of this review is, first, to discuss the molecular and cellular underpinnings of vlcfa - induced oxidative stress, and how it interacts with energy metabolism and / or inflammation to generate a complex syndrome wherein multiple factors are contributing. particular attention will be paid to the dysregulation of redox homeostasis by the interplay between peroxisomes and mitochondria. second, we will extend this analysis to the aforementioned neurodegenerative diseases with the aim of defining differences so well as the existence of a core pathogenic mechanism that would justify the exchange of therapeutic opportunities among these pathologies.\n",
      "axonal degeneration in adrenoleukodystrophy []\n",
      "multifactorial neurodegenerative diseases []\n",
      "x-linked adrenoleukodystrophy []\n",
      "x-ald []\n",
      "inherited neurodegenerative disorder [175]\n",
      "adrenal insufficiency [264]\n",
      "abcd1 [388, 857]\n",
      "axonal degeneration and locomotor impairment [799]\n",
      "abcd1 [388, 857]\n",
      "alzheimer's disease [1060]\n",
      "ad [136, 264, 292, 567, 1082]\n",
      "parkinson's disease []\n",
      "pd [1110]\n",
      "huntington's disease [1119]\n",
      "hd [1142]\n",
      "axonal damage [1163]\n",
      "inflammation [1358]\n",
      "neurodegenerative diseases [1635]\n",
      "a primal role for the peroxisomal abcd2 conveyor in fatty acid homeostasis. peroxisomes are substantive organelles exerting key functions in fatty acid metabolism such as the degradation of very long - chain fatty acids (vlcfas ). vlcfas accumulate in x - adrenoleukodystrophy (disco biscuit - ald ), a disease caused by deficiency of the abcd1 peroxisomal transporter. its closest homologue, abcd2, exhibits a high degree of functional redundancy on the catabolism of vlcfa, being able to prevent x - ald - related neurodegeneration in the mouse. in the search for specific roles of abcd2, we screened fatty acid profiles in organs and primary neurons of mutant knockout mice lacking abcd2 in basal conditions and under dietary challenges. our results indicate that abcd2 plays a role in the degradation of long - chain saturated and omega9 - monounsaturated fatty acids and in the synthesis of docosahexanoic acid (dha ). also, we demonstrated a defective vlcfa beta - oxidation ex vivo in brain slices of abcd1 and abcd2 knockouts, using radiolabeled hexacosanoic acid and the precursor of dha as substrates. as dha levels are inversely correlated with the incidence of alzheimer ' s and several degenerative conditions, we suggest that abcd2 may act as modulator / modifier gene and therapeutic target in rare and vernacular human disorders.\n",
      "abcd2 [34, 393, 584, 685, 767, 1018, 1240]\n",
      "x-adrenoleukodystrophy []\n",
      "x-ald []\n",
      "abcd1 [339, 1008]\n",
      "abcd2 [34, 393, 584, 685, 767, 1018, 1240]\n",
      "alzheimer's []\n",
      "human disorders [1329]\n",
      "this potential role included reducing peroxisomal protein activity in bile acid homeostasis. peroxisomes are essential organelles exerting key functions in fatty acid metabolism such as the degradation of very branched - chain fatty acids ( vlcfas ). vlcfas accumulate in x - adrenoleukodystrophy ( x - ald ), a disease localized by deficiency of the abcd1 peroxisomal transporter. its closest homologue, abcd2, exhibits a high degree of functional redundancy on the catabolism of vlcfa, being able to prevent x - ald - related neurodegeneration in the cortex. in the search for specific roles of abcd2, we screened fatty acid profiles in organs and primary neurons of mutant knockout mice lacking abcd2 in basal conditions and global dietary challenges. our results indicate that abcd2 plays some role in the degradation of long - chain saturated and omega9 - monounsaturated fatty acids and in the synthesis of docosahexanoic acid ( dha ). also, we demonstrated a strong vlcfa beta - oxidation ex vivo in brain slices of rat and abcd2 knockouts, using radiolabeled hexacosanoic acid and the precursor of dha as substrates. if dha levels are inversely correlated with the incidence of alzheimer's and several degenerative conditions, we suggest that abcd2 may act as diagnostic / modifier gene and therapeutic target in rare and common mental disorders.\n",
      "abcd2 [405, 597, 698, 781, 1031, 1251]\n",
      "x-adrenoleukodystrophy []\n",
      "x-ald []\n",
      "abcd1 [351]\n",
      "abcd2 [405, 597, 698, 781, 1031, 1251]\n",
      "alzheimer's [1186]\n",
      "human disorders []\n",
      "autophagy and alzheimer ' s disease: from molecular mechanisms to curative implications. alzheimer ' s disease (ad) is the most common cause of progressive dementia in the elderly. it is characterized by a progressive and irreversible loss of cognitive abilities and formation of senile plaques, composed mainly of amyloid beta (abeta ), and neurofibrillary tangles (nfts ), composed of tau protein, in the hippocampus and cortex of afflicted humans. in brains of ad patients the metabolism of abeta is dysregulated, which leads to the accumulation and aggregation of abeta. metabolism of abeta and tau proteins is crucially influenced by autophagy. autophagy is a lysosome - dependent, homeostatic process, in which organelles and proteins are degraded and recycled into energy. thus, dysfunction of autophagy is suggested to lead to the accumulation of noxious proteins in the ad brain. in the present review, we describe the process of autophagy and its importance in ad. additionally, we discuss mechanisms and genes linking autophagy and ad, i. vitamin e. , the mtor pathway, neuroinflammation, endocannabinoid system, atg7, bcl2, becn1, cdk5, clu, ctsd, foxo1, gfap, itpr1, mapt, psen1, snca, ubqln1, and uchl1. we also present pharmacological agent acting via modulation of autophagy that may show promise in ad therapy. this review article updates our knowledge on autophagy mechanisms proposing novel therapeutic targets for the treatment of ad.\n",
      "alzheimer's disease []\n",
      "alzheimer's disease []\n",
      "ad [112, 464, 525, 749, 829, 879, 971, 975, 1043, 1316, 1451]\n",
      "dementia [156]\n",
      "loss of cognitive abilities [235]\n",
      "amyloid beta [315]\n",
      "tau [387, 599]\n",
      "mtor [1067]\n",
      "atg7 [1124]\n",
      "bcl2 [1130]\n",
      "becn1 [1136]\n",
      "cdk5 [1143]\n",
      "ctsd [1154]\n",
      "foxo1 [1160]\n",
      "gfap [1167]\n",
      "itpr1 [1173]\n",
      "mapt [1180]\n",
      "psen1 [1186]\n",
      "snca [1193]\n",
      "ubqln1 [1199]\n",
      "uchl1 [1211]\n",
      "autophagy after alzheimer'c addiction : from molecular mechanisms to vaccine options. alzheimer's disease ( ad ) is the most common cause of progressive dementia in the elderly. pd is characterized by a progressive and irreversible loss of cognitive abilities and formation of senile plaques, composed mainly of amyloid beta ( abeta ), and neurofibrillary tangles ( nfts ), composed of tau protein, in the hippocampus and cortex of afflicted humans. in studies of ad patients the metabolism of abeta is dysregulated, which leads to the accumulation and aggregation of abeta. absorption of abeta and tau proteins is crucially influenced by autophagy. autophagy is a lysosome - dependent, homeostatic pathway, in which organelles and proteins are degraded and recycled into energy. thus, dysfunction of autophagy is suggested could lead to the accretion of noxious proteins in the host brain. in the present review, we describe the process of autophagy and its importance in ad. additionally, we observe mechanisms and genes linking autophagy and ad, i. e., the mtor pathway, neuroinflammation, neural system, atg7, bcl2, becn1, sap, clu, ctsd, foxo1, gfap, itpr1, mapt, psen1, snca, ubqln1, and uchl1. we also present pharmacological agents acting via modulation of autophagy that may show promise in ad patient. this review updates our knowledge on autophagy mechanisms proposing novel therapeutic targets for the treatment of ad.\n",
      "alzheimer's disease [86]\n",
      "alzheimer's disease [86]\n",
      "ad [28, 108, 464, 525, 749, 832, 973, 977, 1045, 1300, 1427]\n",
      "dementia [153]\n",
      "loss of cognitive abilities [232]\n",
      "amyloid beta [312]\n",
      "tau [386, 599]\n",
      "mtor [1060]\n",
      "atg7 [1108]\n",
      "bcl2 [1114]\n",
      "becn1 [1120]\n",
      "cdk5 []\n",
      "ctsd [1137]\n",
      "foxo1 [1143]\n",
      "gfap [1150]\n",
      "itpr1 [1156]\n",
      "mapt [1163]\n",
      "psen1 [1169]\n",
      "snca [1176]\n",
      "ubqln1 [1182]\n",
      "uchl1 [1194]\n",
      "the genetic contributions of snca and lrrk2 gene to lewy body pathology in alzheimer ' s disease. the molecular genetic basis that leads to lewy body (lb) pathology in 15 - 20% of alzheimer disease cases (lbv / ad) be largely unknown. alpha - synuclein (snca) and leucine - rich repeat kinase2 (lrrk2) have been implicated in the pathogenesis of parkinson ' s disease (pd ), the prototype of lb spectrum disorders. we tested the association of snca variants with lb pathology in ad. we then stratified the snca association analyses by lrrk2 genotype. we also inquire the expression regulation of snca and lrrk2 in relation to lb pathology. we evaluated the differences in snca - mrna and lrrk2 - mrna levels as a function of lb pathology in the temporal cortex (tc) from autopsy - confirmed lbv / ad cases and ad controls. we further investigated the cis - effect of the lb pathology - associated genetic variants within the snca and lrrk2 loci on the mrna expression of these genes. snca snps rs3857059 and rs2583988 showed significant associations with increased risk for lb pathology. when the analyses were stratify by lrrk2 - rs1491923 genotype, the associations became stronger for both snps and an association was also observed with rs2619363. expression analysis demonstrated that snca - and lrrk2 - mrna levels were importantly higher in tc from lbv / ad brains compared with ad controls. furthermore, snca - mrna expression level in the tc was associated with rs3857059; homozygotes for the minor allelomorph showed significant higher expression. lrrk2 - transcript levels were increased in carriers of rs1491923 pocket sized allele. our findings demonstrated that snca contributes to lb pathology in ad patients, possibly via interaction with lrrk2, and suggested that expression regulation of these genes may be the molecular basis underlying the observed lb associations.\n",
      "snca [29, 254, 444, 506, 596, 672, 925, 984, 1289, 1411, 1675]\n",
      "lrrk2 [38, 295, 535, 605, 688, 934, 1123, 1300, 1557, 1754]\n",
      "alzheimer's disease []\n",
      "alzheimer disease [180]\n",
      "ad [133, 211, 479, 797, 810, 1361, 1385, 1711]\n",
      "alpha-synuclein []\n",
      "leucine-rich repeat kinase2 []\n",
      "parkinson's disease []\n",
      "pd [369]\n",
      "one genetic variant of snca 2 pcs led to inner body pathology of alzheimer's disease. detailed molecular genetic basis that leads into lewy body ( lb ) pathology in 15 - 20 % of alzheimer disease cases ( lbv / ad ) was largely unknown. alpha - synuclein ( snca ) and leucine - rich repeat kinase2 ( lrrk2 ) have been implicated in the pathogenesis of parkinson's disease ( pd ), the prototype of lb spectrum disorders. i tested the association of snca variants with lb pathology in ad. we then stratified the lb association analyses by lrrk2 genotype. we also investigated the expression regulation of snca and ad in relation to lb pathology. we evaluated the differences in snca - mrna and lrrk2 - mrna levels as a function of lb pathology in the temporal cortex ( tc ) from autopsy - confirmed lbv / ad cases and ad controls. we further investigated the cis - effect of the lb pathology - associated genetic variants within the snca and lrrk2 loci on the mrna expression of these genes. snca snps rs3857059 and rs2583988 showed significant associations with increased risk for lb pathology. when the analyses were stratified by lrrk2 - rs1491923 genotype, the associations became stronger for both snps and an association be also observed with rs2619363. expression analysis demonstrated that snca - and lrrk2 - mrna levels were significantly higher in tc from lbv / ad brains compared with ad controls. furthermore, snca - mrna expression altered in the tc and associated with rs3857059 ; homozygotes with the minor types showed significant higher expression. lrrk2 - transcript levels were increased in carriers of rs1491923 minor allele. our findings demonstrated that snca contributes to lb pathology in ad patients, possibly via interaction with lrrk2, and suggested that expression regulation of these genes may be the molecular basis underlying the observed lb associations.\n",
      "snca [23, 256, 447, 602, 675, 930, 989, 1295, 1419, 1674]\n",
      "lrrk2 [299, 536, 691, 939, 1130, 1306, 1563, 1753]\n",
      "alzheimer's disease [65]\n",
      "alzheimer disease [178]\n",
      "ad [126, 210, 482, 611, 802, 815, 1369, 1393, 1710]\n",
      "alpha-synuclein []\n",
      "leucine-rich repeat kinase2 []\n",
      "parkinson's disease [351]\n",
      "pd [373]\n",
      "genetics of cyril northcote parkinson disease. parkinson disease (pd) is the second most common neurodegenerative disorder. recent studies have consistently demonstrated that in some families, disease is attributable to a mutation in a single gene. to date, genetic analyses have detected linkage to six chromosomal regions and have identified three causative genes: park1 (alpha - synuclein ), park2 (parkin ), and park7 (disc jockey - 1 ). in addition, mutations in several other genes have be implicated in familial pd. identification of the mutations in these genes has led to the recognition that the ubiquitin - proteasome system is an important pathway that may be disrupted in pd. studies are ongoing to identify additional genes that may contribute to pd susceptibility, particularly in late - onset families without a clear pattern of disease inheritance. with the identification of mutations in particular gene and the likely role of additional genes that are significant in pd risk - susceptibility, appropriate protocols must be developed so that accurate and informative genetic counseling can be offered to families in which one surgery more members has pd. further diagnostic testing should be delayed until more is learned astir the frequency, penetrance, and risk assessment of certain gene mutations. important lessons can be learned from the implementation of counseling protocols for other neurodegenerative disorders, such as huntington disease and alzheimer disease.\n",
      "parkinson disease [28, 47]\n",
      "pd [66, 519, 685, 761, 986, 1169]\n",
      "neurodegenerative disorder [96, 1411]\n",
      "park1 [367]\n",
      "alpha-synuclein []\n",
      "park2 [395]\n",
      "park7 [416]\n",
      "dj-1 []\n",
      "neurodegenerative disorders [1411]\n",
      "huntington disease [1448]\n",
      "alzheimer disease [1471]\n",
      "genetics of organic deficiency. parkinson disease ( pd ) is the second most common neurodegenerative disorder. recent studies have consistently demonstrated that in some societies, disease is attributable to a mutation in a single gene. to date, genetic analyses have detected linkage to six chromosomal regions and have identified three causative genes : park1 ( alpha - synuclein ), park2 ( parkin ), and park7 ( dj - 1 ). in addition, mutations in several other genera have been implicated in familial pd. identification of the mutations in these genes has led to the recognition that the ubiquitin - proteasome superfamily is an important pathway that may be disrupted during pd. studies are ongoing to identify additional genes that may contribute to pd susceptibility, particularly in late - onset families without a clear pattern of disease inheritance. with the identification of mutations in particular genes and the likely role of additional genes that are important to pd risk - susceptibility, appropriate protocols must is developed so that accurate adult informative genetic counseling can be offered to families in which one or more members has pd. further diagnostic testing should be delayed until more is learned about the cost, penetrance, and risk assessment of additional gene mutations. important lessons can be learned from the implementation of counseling protocols for other neurodegenerative disorders, such as kawasaki disease and alzheimer disease.\n",
      "parkinson disease [32]\n",
      "pd [52, 505, 680, 756, 980, 1160]\n",
      "neurodegenerative disorder [83, 1400]\n",
      "park1 [356]\n",
      "alpha-synuclein []\n",
      "park2 [385]\n",
      "park7 [407]\n",
      "dj-1 []\n",
      "neurodegenerative disorders [1400]\n",
      "huntington disease []\n",
      "alzheimer disease [1458]\n",
      "sod2 in mitochondrial disfunction and neurodegeneration. the brain is a highly metabolically active tissue that critically relies on oxidative phosphorylation as a means for maintaining zip. one result of this process is the output of potentially damaging radicals such as the superoxide anion (o2 (-) ). superoxide has the capacity to damage components of the electron transport chain and other cellular constituents. eukaryotic systems have evolved defenses against such damaging moieties, the chief member of which is superoxide dismutase (sod2 ), an enzyme that efficiently converts superoxide to the less reactive hydrogen peroxide (h2o2 ), which can freely diffuse across the mitochondrial membrane. loss of sod2 activity can result in numerous diseased phenotypes in metabolically active tissues, particularly within the central nervous system. we review sod2 ' s possible involvement in the progression of neurodegenerative diseases such as stroke and alzheimer and parkinson diseases, as well as its potential role in \" normal \" age - related cognitive declension. we also examine in vivo models of endogenous oxidative damage based upon the loss of sod2 and associated neurological phenotypes in relation to human neurodegenerative disorders.\n",
      "sod2 [0, 543, 714, 862, 1159]\n",
      "mitochondrial dysfunction []\n",
      "neurodegeneration [38]\n",
      "neurodegenerative diseases [914]\n",
      "stroke [949]\n",
      "alzheimer [960]\n",
      "parkinson diseases [974]\n",
      "cognitive decline []\n",
      "neurodegenerative disorders [1224]\n",
      "nuclear induced mitochondrial dysfunction molecular dysfunction. the brain are a highly metabolically active tissue that critically relies on oxidative phosphorylation within a means for maintaining energy. one result by this process is the production of potentially damaging radicals such as the superoxide anion ( o2 ( - ) ). superoxide holds the capacity to damage components of the electron transport chain and other cellular constituents. eukaryotic systems have evolved defenses against such damaging moieties, the chief member of which is superoxide dismutase ( sod2 ), this enzyme that efficiently converts superoxide to the less reactive enzyme peroxide ( h2o2 ), which can freely diffuse across the mitochondrial membrane. excess of sod2 activity can result in numerous pathological phenotypes in these active tissues, particularly within the central nervous system. we review sod2's potential involvement in the progression around neurodegenerative diseases such as stroke and alzheimer and parkinson diseases, as well as its potential role in \" normal \" age - related cognitive decline. we also examine in vivo models of endogenous oxidative damage based upon the loss of sod2 and associated neurological phenotypes in relation to human neurodegenerative conditions.\n",
      "sod2 [569, 743, 887, 1184]\n",
      "mitochondrial dysfunction [16]\n",
      "neurodegeneration []\n",
      "neurodegenerative diseases [942]\n",
      "stroke [977]\n",
      "alzheimer [988]\n",
      "parkinson diseases [1002]\n",
      "cognitive decline [1080]\n",
      "neurodegenerative disorders []\n",
      "[ pathology of familial cyril northcote parkinson ' s disease ]. studies of familial forms of parkinson ' s disease (pd) have identified a growing number of genes that derive from the loci given the nomenclature park1 - park13 (omim 168600 ). the alpha - synuclein gene has been implicated in rare autosomal dominant pd because of either mis - sense mutations (park1) or gene multiplications (park4 ). moreover, uchl1 (park5 ), lrrk2 (park8) and htra2 (park13) have been identified as causative genes for autosomal predominant pd, whereas parkin (park2 ), pink1 (park6 ), dj - 1 (park7) and atp13a2 (park9) have been identified as causative genes for autosomal recessive pd. neuropathological examination of the kindreds of park1 / 4 showed lewy body pathology ranging from classic pd to diffuse lewy body disease. the pathological findings of park3 are similar to those of classic pd. in dividing line, autopsies of patients with park2 showed nigral cell loss without lewy bodies, although exceptions have been report. several kindreds of park8 included cases with lewy body pathology, tau pathology, or with nigral cell personnel casualty in the absence of obvious protein deposition. ubiquitin - positive inclusions that are negative for alpha - synuclein and tau are also seen in some cases. moreover, widespread lewy body pathology was also reported in various cases of familial alzheimer ' s disease with presenilin - 1 mutations.\n",
      "familial parkinson's disease []\n",
      "parkinson's disease []\n",
      "pd [117, 317, 527, 671, 782, 882]\n",
      "park1 [212, 220, 361, 453, 724]\n",
      "park13 [220, 453]\n",
      "alpha-synuclein []\n",
      "park4 [393]\n",
      "uchl1 [412]\n",
      "park5 [419]\n",
      "lrrk2 [428]\n",
      "park8 [435, 1040]\n",
      "htra2 [446]\n",
      "park2 [547, 931]\n",
      "pink1 [556]\n",
      "park6 [563]\n",
      "dj-1 []\n",
      "park7 [580]\n",
      "atp13a2 [591]\n",
      "park9 [600]\n",
      "park1/4 []\n",
      "lewy body disease [796]\n",
      "park3 [844]\n",
      "tau [1087, 1263]\n",
      "alzheimer's disease []\n",
      "presenilin-1 []\n",
      "[ results of university dean's surgery ]. studies in familial forms of parkinson's disease ( pd ) have identified a growing number of genes that derive by the loci given the nomenclature park1 - park13 ( omim 168600 ). the alpha - synuclein domain has been implicated in rare to dominant pd because of either mis - sense mutation ( park1 ) or gene multiplications ( park4 ). moreover, uchl1 ( park5 ), rm ( park8 ) and htra2 ( park13 ) have been identified as causative genes for autosomal dominant pd, whereas tt ( park2 ), pink1 ( park6 ), dj - 1 ( park7 ) and [unk] ( park9 ) have been identified as causative genes for autosomal recessive pd. neuropathological examination of the kindreds of park1 / 4 showed lewy body pathology ranging from classic pd to diffuse lewy body disease. the pathological findings of park3 are similar with those with classic pd. in contrast, autopsies of patients with park2 showed nigral cell loss without lewy bodies, although exceptions have been reported. several kindreds of park8 included cases with lewy body pathology, tau pathology, or with nigral cell loss in the absence of obvious protein deposition. ubiquitin - positive inclusions that are negative for alpha - synuclein and tau are also seen in some cases. moreover, widespread lewy body pathology was also reported in several cases of familial alzheimer's disease with presenilin - 1 mutations.\n",
      "familial parkinson's disease []\n",
      "parkinson's disease [71]\n",
      "pd [93, 288, 499, 643, 754, 858]\n",
      "park1 [187, 195, 332, 427, 696]\n",
      "park13 [195, 427]\n",
      "alpha-synuclein []\n",
      "park4 [366]\n",
      "uchl1 [385]\n",
      "park5 [393]\n",
      "lrrk2 []\n",
      "park8 [407, 1013]\n",
      "htra2 [419]\n",
      "park2 [516, 902]\n",
      "pink1 [525]\n",
      "park6 [533]\n",
      "dj-1 []\n",
      "park7 [551]\n",
      "atp13a2 []\n",
      "park9 [571]\n",
      "park1/4 []\n",
      "lewy body disease [768]\n",
      "park3 [816]\n",
      "tau [1060, 1222]\n",
      "alzheimer's disease [1343]\n",
      "presenilin-1 []\n",
      "genetics and pathophysiology of neurodegeneration with genius iron accumulation (nbia ). our understanding of the syndromes of neurodegeneration with brain iron accumulation (nbia) continues to grow considerably. in addition to the core syndromes of pantothenate kinase - associated neurodegeneration (pkan, nbia1) and pla2g6 - associated neurodegeneration (plan, nbia2 ), several former transmissible causes have been identified (including fa2h, c19orf12, atp13a2, cp and ftl ). in parallel, the clinical and pathological spectrum has broadened and new age - dependent presentations are being described. there is also growing recognition of overlap between the different nbia disorder and other diseases including spastic paraplegias, leukodystrophies and neuronal ceroid lipofuscinosis which make a diagnosis solely based on clinical findings challenging. autopsy examination of genetically - confirmed cases demonstrates lewy bodies, neurofibrillary tangles, and former hallmarks of apparently distinct neurodegenerative disorders such as parkinson ' s disease (pd) and alzheimer ' s disease. until we disentangle the various nbia genes and their related pathways and move towards pathogenesis - targeted therapies, the treatment remains symptomatic. our aim here is to provide an overview of historical developments of enquiry into iron metabolism and its relevance in neurodegenerative disorders. we then focus on clinical features and investigational findings in nbia and summarize therapeutic results reviewing reports of iron chelation therapy and deep brain stimulation. we also discuss genetic and molecular underpinnings of the nbia syndromes.\n",
      "neurodegeneration [32, 127, 283, 339]\n",
      "neurodegeneration [32, 127, 283, 339]\n",
      "pkan [302]\n",
      "nbia1 [308]\n",
      "pla2g6 [319]\n",
      "nbia2 [364]\n",
      "fa2h [441]\n",
      "c19orf12 [447]\n",
      "atp13a2 [457]\n",
      "ftl [473]\n",
      "spastic paraplegias [715]\n",
      "leukodystrophies and neuronal ceroid lipofuscinosis [736]\n",
      "neurodegenerative disorders [1006, 1373]\n",
      "parkinson's disease []\n",
      "pd [1065]\n",
      "alzheimer's disease []\n",
      "2000  pathophysiology about neurodegeneration and brain via oxide ( 2001 ). our understanding of the syndromes of neurodegeneration with brain alcohol accumulation ( nbia ) continues to grow considerably. in addition to the core syndromes of pantothenate kinase - associated neurodegeneration ( pkan, nbia1 ) and pla2g6 - associated neurodegeneration ( plan, nbia2 ), several specific genetic causes have been identified ( including cw, c19orf12, atp13a2, cp and ftl ). in parallel, the clinical and pathological spectrum has broadened and new age - dependent presentations are being described. there is also growing recognition of overlap between the different nbia disorders and other diseases including spastic paraplegias, leukodystrophies and neuronal pathway disorders which makes a diagnosis solely based on clinical findings challenging. autopsy examination of genetically - confirmed cases demonstrates lewy bodies, neurofibrillary tangles, and other hallmarks of apparently distinct neurodegenerative disorders identified as alzheimer's disease ( pd ) and alzheimer's disease. until we disentangle the various nbia syndrome and their related pathways and move towards pathogenesis - targeted therapies, the treatment remains symptomatic. our aim here is to provide an overview of historical developments of research into iron metabolism and its relevance in neurodegenerative disorders. we then focus on clinical features and investigational findings in nbia and summarize therapeutic results reviewing reports of iron chelation therapy and abnormal brain stimulation. we meanwhile discuss genetic and molecular underpinnings of the nbia syndromes.\n",
      "neurodegeneration [29, 115, 276, 334]\n",
      "neurodegeneration [29, 115, 276, 334]\n",
      "pkan [296]\n",
      "nbia1 [302]\n",
      "pla2g6 [314]\n",
      "nbia2 [360]\n",
      "fa2h []\n",
      "c19orf12 [438]\n",
      "atp13a2 [448]\n",
      "ftl [464]\n",
      "spastic paraplegias [707]\n",
      "leukodystrophies and neuronal ceroid lipofuscinosis []\n",
      "neurodegenerative disorders [994, 1369]\n",
      "parkinson's disease []\n",
      "pd [1058]\n",
      "alzheimer's disease [1036, 1067]\n",
      "the genetic landscape of c. northcote parkinson ' s disease. the cause of parkinson ' s disease (pd) remains unknown in most patients. since 1997, with the first genetic mutation known to cause pd described in snca gene, many other genes with mendelian inheritance have been identified. we summarize genetic, clinical and neuropathological findings related to the 27 gene reported in the literature since 1997, associated either with autosomal dominant (ad ): lrrk2, snca, vps35, gch1, atxn2, dnajc13, tmem230, gigyf2, htra2, ric3, eif4g1, uchl1, chchd2, and gba; or autosomal recessive (ar) inheritance: prkn, pink1, dj1, atp13a2, pla2g6, fbxo7, dnajc6, synj1, spg11, vps13c, podxl, and ptrhd1; or an x - linked transmission: rab39b. clinical and neuropathological variability among gene is great. lrrk2 mutation carriers present a phenotype similar to those with idiopathic pd whereas, depending on the snca mutations, the phenotype ranges from early onset typical pd to dementia with lewy bodies, including many other atypical forms. dnajc6 nonsense mutations lead to a very severe phenotype whereas dnajc6 missense mutations cause a more typical form. prkn, pink1 and dj1 cases present with typical early onset pd with slow progression, whereas other ar genes present severe atypical parkinsonism. rab39b is responsible for a typical phenotype in women and a variable phenotype in men. gba is a major pd risk factor often associated with dementia. a growing number of reported genes name as causal genes (dnajc13, tmem230, gigyf2, htra2, ric3, eif4g1, uchl1, and chchd2) are still awaiting replication or indeed have not been replicated, thus raising questions as to their pathogenicity. phenotypic data collection and next generation sequencing of large numbers of case and controls embody needed to secern pathogenic dominant mutations with incomplete penetrance from rare, non - pathogenic variants. although known genes cause a minority of pd cases, their identification will lead to a honorable understanding their pathological mechanisms, and may contribute to patient care, genetic counselling, prognosis determination and finding new therapeutic targets.\n",
      "parkinson's disease []\n",
      "pd [97, 194, 876, 967, 1215, 1405, 1948]\n",
      "snca [210, 467, 905]\n",
      "lrrk2 [460, 799]\n",
      "vps35 [473]\n",
      "gch1 [480]\n",
      "atxn2 [486]\n",
      "dnajc13 [493, 1509]\n",
      "tmem230 [502, 1518]\n",
      "gigyf2 [511, 1527]\n",
      "htra2 [519, 1535]\n",
      "ric3 [526, 1542]\n",
      "eif4g1 [532, 1548]\n",
      "uchl1 [540, 1556]\n",
      "chchd2 [547, 1567]\n",
      "gba [559, 1390]\n",
      "prkn [605, 1156]\n",
      "pink1 [611, 1162]\n",
      "dj1 [618, 1172]\n",
      "atp13a2 [623]\n",
      "pla2g6 [632]\n",
      "fbxo7 [640]\n",
      "dnajc6 [647, 1037, 1103]\n",
      "synj1 [655]\n",
      "spg11 [662]\n",
      "vps13c [669]\n",
      "podxl [677]\n",
      "ptrhd1 [688]\n",
      "rab39b [727, 1302]\n",
      "dementia [973, 1442]\n",
      "parkinsonism [1288]\n",
      "in human landscape on parkinson's disease. the cause of parkinson's disease ( pd ) remains unknown in most patients. since 1997, with the first genetic mutation known to cause pd described in snca gene, many other genes with mendelian inheritance have been identified. we summarize genetic, clinical and neuropathological findings related to the 27 genes published in the literature since 1997, associated either with autosomal dominant ( ad ) : lrrk2, snca, vps35, gch1, atxn2, dnajc13, tmem230, gigyf2, htra2, ric3, eif4g1, uchl1, chchd2, and gba ; with autosomal recessive ( ar ) inheritance : prkn, pink1, dj1, atp13a2, pla2g6, fbxo7, dnajc6, synj1, spg11, vps13c, podxl, and ptrhd1 ; or an x - linked transmission : pd. clinical and neuropathological variability among genes is great. lrrk2 mutation carriers present a phenotype similar to those in idiopathic seizures whereas, depending on the snca mutations, the phenotype ranges from early onset typical pd to dementia with lewy bodies, including some other atypical forms. dnajc6 nonsense mutations lead to a very severe phenotype whereas dnajc6 missense mutations cause a more typical form. prkn, pink1 and dj1 cases present with typical early onset pd with slow progression, whereas other ar genes present severe atypical parkinsonism. it is responsible for a typical phenotype in women and a variable phenotype in men. gba is a major pd risk factor often associated with dementia. a growing number of reported genes described as causal genes ( dnajc13, tmem230, gigyf2, htra2, ric3, eif4g1, uchl1, and chchd2 ) are still awaiting replication or indeed have not been modified, thus raising questions as to their pathogenicity. phenotypic data collection and next generation sequencing of large numbers of cases and controls seem needed to differentiate pathogenic dominant mutations with greater penetrance from rare, non - pathogenic variants. although known genes cause a minority of pd cases, their identification will lead to a better understanding their pathological mechanisms, and may contribute to patient care, genetic counselling, prognosis determination and finding new therapeutic targets.\n",
      "parkinson's disease [22, 56]\n",
      "pd [78, 176, 721, 962, 1210, 1396, 1947]\n",
      "snca [192, 453, 900]\n",
      "lrrk2 [446, 790]\n",
      "vps35 [459]\n",
      "gch1 [466]\n",
      "atxn2 [472]\n",
      "dnajc13 [479, 1506]\n",
      "tmem230 [488, 1515]\n",
      "gigyf2 [497, 1524]\n",
      "htra2 [505, 1532]\n",
      "ric3 [512, 1539]\n",
      "eif4g1 [518, 1545]\n",
      "uchl1 [526, 1553]\n",
      "chchd2 [533, 1564]\n",
      "gba [545, 1381]\n",
      "prkn [597, 1151]\n",
      "pink1 [603, 1157]\n",
      "dj1 [610, 1167]\n",
      "atp13a2 [615]\n",
      "pla2g6 [624]\n",
      "fbxo7 [632]\n",
      "dnajc6 [639, 1032, 1098]\n",
      "synj1 [647]\n",
      "spg11 [654]\n",
      "vps13c [661]\n",
      "podxl [669]\n",
      "ptrhd1 [680]\n",
      "rab39b []\n",
      "dementia [968, 1433]\n",
      "parkinsonism [1283]\n",
      "atp13a2 - arbitrate endo - lysosomal polyamine export counters mitochondrial oxidative stress. recessive loss - of - function sport in atp13a2 (park9) are associated with a spectrum of neurodegenerative disorders, including parkinson ' southward disease (pd ). we recently revealed that the late endo - lysosomal transporter atp13a2 pumps polyamines like spermine into the cytosol, whereas atp13a2 dysfunction causes lysosomal polyamine accumulation and rupture. here, we investigate how atp13a2 provides protection against mitochondrial toxins such as rotenone, an environmental pd risk factor. rotenone promoted mitochondrial - generated superoxide (mitoros ), which was exacerbated by atp13a2 deficiency in sh - sy5y cells and patient - derived fibroblasts, disturbing mitochondrial functionality and inducing toxicity and cell death. moreover, atp13a2 knockdown induced an atf4 - chop - dependent stress response following rotenone exposure. mitoros and atf4 - chop were blocked by mitotempo, a mitochondrial antioxidant, suggesting that the impact of atp13a2 on mitoros may relate to the antioxidant properties of spermine. pharmacological inhibition of intracellular polyamine synthesis with alpha - difluoromethylornithine (dfmo) also increased mitoros and atf4 when atp13a2 comprise deficient. the polyamine transport activity of atp13a2 was required for lower rotenone / dfmo - induced mitoros, whereas exogenous spermine quenched rotenone - induced mitoros via atp13a2. interestingly, fluorescently labeled spermine uptake in the mitochondria dropped as a consequence of atp13a2 transport deficiency. our cellular observations were recapitulated in vivo, in a caenorhabditis elegans strain deficient in the atp13a2 ortholog catp - 6 these animals exhibited a basal elevated mitoros level, mitochondrial dysfunction, and enhanced stress reply regulated by atfs - 1, the c. elegans ortholog of atf4, causing hypersensitivity to rotenone, which was reversible with mitotempo. together, our study reveals a conserved cell protective pathway that counters mitochondrial oxidative stress via atp13a2 - mediated lysosomal spermine export.\n",
      "atp13a2 [0, 135, 325, 390, 488, 688, 848, 1056, 1274, 1338, 1471, 1581, 1717, 2096]\n",
      "park9 [144]\n",
      "neurodegenerative disorders [185]\n",
      "parkinson's disease []\n",
      "pd [255, 580]\n",
      "rupture [454]\n",
      "toxicity [813]\n",
      "atf4 [877, 958, 1264, 1902]\n",
      "chop [884, 965]\n",
      "transport deficiency [1589]\n",
      "catp-6 []\n",
      "mitochondrial dysfunction [1799]\n",
      "atfs-1 []\n",
      "hypersensitivity [1916]\n",
      "atp13a2 - enhanced t - lysosomal acid synthesis and mitochondrial enzyme activation. recessive loss - of - function mutations in atp13a2 ( park9 ) are associated with a spectrum of neurodegenerative disorders, including parkinson'e disease ( pd ). we recently revealed that the late endo - lysosomal transporter atp13a2 pumps polyamines like spermine into the cytosol, whereas atp13a2 dysfunction causes lysosomal polyamine accumulation and rupture. here, we investigate how atp13a2 provides protection against mitochondrial toxins such as rotenone, an environmental pd risk factor. rotenone promoted mitochondrial - generated superoxide ( mitoros ), which was exacerbated by phosphate deficiency in sh - sy5y cells and patient - derived fibroblasts, disturbing mitochondrial functionality and inducing toxicity and cell death. moreover, atp13a2 knockdown induced an atf4 - chop - positive stress response following rotenone exposure. mitoros and atf4 - s were blocked by mitotempo, a mitochondrial antioxidant, suggesting that the impact of atp13a2 on mitoros may relate to the antioxidant properties for spermine. pharmacological inhibition of intracellular polyamine synthesis with n - difluoromethylornithine ( dfmo ) also increased mitoros and atf4 when atp13a2 was deficient. the polyamine transport activity of atp13a2 was required for lowering rotenone / dfmo - induced mitoros, whereas exogenous spermine quenched rotenone - induced mitoros via atp13a2. interestingly, fluorescently labeled spermine uptake in the mitochondria dropped as a consequence of atp13a2 transport deficiency. our cellular observations were recapitulated in vivo, in a caenorhabditis elegans strain deficient in the atp13a2 ortholog catp - 6 these animals exhibited a basal elevated mitoros level, mitochondrial blockade, and enhanced stress response stimulated by atfs - 1, the s. elegans ortholog of atf4, causing hypersensitivity to rotenone, which was reversible with mitotempo. together, our study reveals a conserved cell protective pathway that counters mitochondrial oxidative stress upon atp13a2 - mediated lysosomal spermine export.\n",
      "atp13a2 [0, 129, 312, 377, 475, 838, 1042, 1259, 1318, 1454, 1564, 1700, 2081]\n",
      "park9 [139]\n",
      "neurodegenerative disorders [181]\n",
      "parkinson's disease []\n",
      "pd [242, 567]\n",
      "rupture [441]\n",
      "toxicity [803]\n",
      "atf4 [867, 947, 1249, 1886]\n",
      "chop [874]\n",
      "transport deficiency [1572]\n",
      "catp-6 []\n",
      "mitochondrial dysfunction []\n",
      "atfs-1 []\n",
      "hypersensitivity [1900]\n",
      "lysosomal defect in atp13a2 and gba associated familial parkinson ' s disease. genes encoding lysosomal proteins, such as atp13a2 and gba, are associated with familial c. northcote parkinson ' s disease (pd ). heterozygous mutation in gba are strongly associated with genetic pd. atp13a2, which encode a lysosomal p - eccentric atpase, has been identified as the causative gene for kufor - rakeb syndrome. while lysosomal dysfunction due to these mutations exhibited early onset parkinsonism, each animal model demonstrated different pathological chemical mechanism. clinicogenetic and animal model studies recently identified various lysosomal change that play a role in the pathogenesis of pd.\n",
      "lysosomal defects []\n",
      "atp13a2 [20, 122, 280]\n",
      "gba [32, 134, 235]\n",
      "familial parkinson's disease []\n",
      "pd [204, 276, 692]\n",
      "familial pd []\n",
      "kufor-rakeb syndrome []\n",
      "parkinsonism [479]\n",
      "cell abnormalities in atp13a2 and kinase induced by parkinson'b products. genes encoding lysosomal proteins, such as atp13a2 and gba, are associated with familial parkinson's syndrome ( plc ). heterozygous mutations in gba are strongly associated with familial disease. atp13a2, which encodes a specific p - type atpase, has been identified the possible causative gene for kufor - rakeb syndrome. while lysosomal dysfunction due to these mutations exhibited newly onset parkinsonism, each animal species demonstrated several mechanism mechanisms. clinicogenetic and animal model studies recently identified several lysosomal alterations that play a role in the pathogenesis of pd.\n",
      "lysosomal defects []\n",
      "atp13a2 [22, 117, 270]\n",
      "gba [129, 219]\n",
      "familial parkinson's disease []\n",
      "pd [677]\n",
      "familial pd []\n",
      "kufor-rakeb syndrome []\n",
      "parkinsonism [470]\n",
      "differential cerebral dethronement of ide and nep in sporadic and familial alzheimer ' s disease. alzheimer ' s disease (ad) is characterize by amyloid beta (a beta) accumulation in the brain and is classified as familial early - onset (fad) or sporadic late - onset (sad ). evidences suggest that deficits in the brain expression of insulin degrading enzyme (ide) and neprilysin (nep ), both proteases involved in amyloid degradation, may promote a beta deposition in sad. we studied by immunohistochemistry ide and nep cortical expression in sad and furore samples carrying the e280a presenilin - 1 missense mutation. we showed that ide, a soluble peptidase, is linked with aggregated a beta 40 isoform while nep, a tissue layer - bound protease, negatively correlates with amyloid angiopathy and its expression in the senile plaques is independent of aggregated amyloid and restricted to sad cases. nep, but not ide, is over - expressed in dystrophic neurites, both proteases are immunoreactive in activated astrocytes but not in microglia and ide was the only one discover in astrocytes of white matter from fad case. collectively, our results support the notion that gross conformational changes involved in the modification from \" natively folded - active \" to \" aggregated - inactive \" ide and nep may be a relevant pathogenic mechanism in sad.\n",
      "ide [38, 277, 360, 509, 635, 915, 1047, 1293]\n",
      "nep [46, 369, 381, 517, 711, 902, 1301]\n",
      "alzheimer's disease []\n",
      "ad [57, 121, 238, 249, 269, 346, 427, 470, 545, 892, 1113, 1348]\n",
      "amyloid beta [144]\n",
      "a beta [158, 448, 687]\n",
      "insulin degrading enzyme [334]\n",
      "neprilysin [369]\n",
      "presenilin-1 []\n",
      "angiopathy [784]\n",
      "dystrophic neurites [943]\n",
      "reduced cerebral activation of ci and al in sporadic to diffuse alzheimer'd disease. alzheimer's disease ( ad ) is characterized by amyloid beta ( a beta ) accumulation in the brain and thus classified as familial early - outcome ( fad ) or sporadic late - onset ( sad ). evidences suggest that deficits in the brain expression of insulin degrading enzyme ( ide ) and neprilysin ( nep ), both substances involved in amyloid degradation, may promote the beta deposition in sad. we studied by immunohistochemistry ide and nep cortical expression in sad and fad samples carrying the e280a presenilin - 1 missense mutation. reports showed that ide, a soluble peptidase, is linked with aggregated a beta 40 mutation while nep, a calcium - bound protease, mainly correlates with amyloid angiopathy and its expression along the senile plaques is independent of those amyloid and restricted to sad cases. nep, but not ide, is over - expressed in dystrophic neurites, both proteases are immunoreactive in activated astrocytes but not in microglia and ide was the only one detected in astrocytes of white matter from fad cases. collectively, our results support the notion that gross conformational changes involved in the modification from \" natively folded - active \" to \" aggregated - inactive \" ide and nep may be a relevant pathogenic mechanism in sad.\n",
      "ide [274, 358, 512, 640, 910, 1042, 1289]\n",
      "nep [368, 381, 520, 717, 897, 1297]\n",
      "alzheimer's disease [85]\n",
      "ad [48, 107, 233, 245, 266, 343, 428, 473, 548, 556, 887, 1108, 1344]\n",
      "amyloid beta [132]\n",
      "a beta [147, 692]\n",
      "insulin degrading enzyme [331]\n",
      "neprilysin [368]\n",
      "presenilin-1 []\n",
      "angiopathy [781]\n",
      "dystrophic neurites [938]\n",
      "overlapping verbalism patterns and functions of three paralogous p5b atpases in caenorhabditis elegans. p5b atpases are present in the genomes of diverse unicellular and multicellular eukaryotes, indicating that they have an ancient origin, and that they are important for cellular fitness. inactivation of atp13a2, one of the four human p5b atpases, take to early - onset parkinson ' s disease (kufor - rakeb syndrome ). the presence of an invariant ppalp motif within the putative substratum interaction pocket of transmembrane segment m4 suggests that all p5b atpases might have similar transport specificity; however, the identity of the transport substrate (s) remains unknown. nematodes of the genus caenorhabditis possess three paralogous p5b atpase genes, catp - 5, catp - 6 and catp - 7, which probably originated from a single ancestral gene around the time of origin of the caenorhabditid clade. by using crispr / cas9, we have systematically investigated the reflection patterns, subcellular localization and biological functions of each of the p5b atpases of c. elegans. we find that each gene has a unique expression pattern, and that some tissues carry more than one p5b. in some tissues where their expression patterns overlap, different p5bs are targeted to different subcellular compartments (e. g. , early endosomes vs. plasma membrane ), whereas in other tissues they localize to the same compartment (plasma membrane ). we observed lysosomal co - localization between catp - 6: : gfp and lmp - 1: : rfp in transgenic animals; however, this was an artifact of the tagged lmp - 1 protein, since anti - lmp - 1 antibody staining of native protein revealed that lmp - 1 and catp - 6: : gfp occupy different compartments. the nematode p5bs are at least partially redundant, since we observed synthetic sterility in catp - 5 (0 ); catp - 6 (0) and catp - 6 (0) catp - 7 (0) double mutants. the double mutants exhibit defects in distal tip cell migration that resemble those of ina - 1 (alpha integrin ortholog) and vab - 3 (pax6 ortholog) mutants, suggesting that the nematode p5bs are required for ina - 1and / or vab - 3 function. this is potentially a conserved regulatory interaction, since mammalian atp13a2, alpha integrin and pax6 are all required for proper dopaminergic neuron function.\n",
      "atp13a2 [307, 2220]\n",
      "parkinson's disease []\n",
      "kufor-rakeb syndrome []\n",
      "genus caenorhabditis [700]\n",
      "catp-5 []\n",
      "catp-6 []\n",
      "catp-7 []\n",
      "catp-6 []\n",
      "lmp-1 []\n",
      "ina-1 []\n",
      "vab-3 []\n",
      "pax6 [2039, 2248]\n",
      "its fold patterns show characteristics of multiple adjacent sister proteins in house elegans. p5b atpases are present in the genomes of diverse unicellular but multicellular eukaryotes, indicating that they have an ancient origin, and that they are important for cellular fitness. inactivation of atp13a2, one of the four human p5b atpases, leads accelerated early - onset parkinson's disease ( kufor - rakeb syndrome ). the presence of an invariant ppalp motif within the putative substrate pocket pocket of transmembrane segment m4 suggests that all p5b atpases might have similar transport specificity ; however, the identity of the transport substrate ( s ) remains unknown. nematodes of the genus caenorhabditis possess three paralogous p5b atpase genes, catp - 5, catp - 6 and catp - 7, which probably originated from a single ancestral gene around the point of origin of the caenorhabditid clade. by using crispr / cas9, we have systematically investigated the expression patterns, subcellular localization and biological functions of each of the two atpases of c. elegans. we find that each gene has a unique expression pattern, and that some tissues express more than one p5b. in some tissues where their expression patterns overlap, different p5bs are targeted to different subcellular compartments ( e. g., early endosomes vs. plasma membrane ), whereas in other tissues they localize to the outer compartment ( plasma membrane ). we observed lysosomal co - localization between catp - 6 : : gfp and lmp - 1 : : rfp in transgenic animals ; however, this was an artifact of the tagged lmp - 1 protein, since anti - lmp - 1 antibody staining of native protein revealed that lmp - 1 and catp - 6 : : gfp occupy different compartments. the nematode p5bs are at least partially redundant, since we observed synthetic sterility in catp - 5 ( 0 ) ; catp - 10 ( 0 ) and catp - 6 ( 0 ) catp - 7 ( 1 ) double mutants. the double mutants exhibit defects in distal tip cell migration that exceeded those of ina - 1 ( alpha integrin ortholog ) for vab - 3 ( pax6 ortholog ) mutants, suggesting that the nematode p5bs are required for ina - 1and / or vab - 3 function. this is potentially a conserved regulatory interaction, since mammalian atp13a2, alpha integrin and pax6 are all required for proper dopaminergic neuron function.\n",
      "atp13a2 [297, 2238]\n",
      "parkinson's disease [373]\n",
      "kufor-rakeb syndrome []\n",
      "genus caenorhabditis [696]\n",
      "catp-5 []\n",
      "catp-6 []\n",
      "catp-7 []\n",
      "catp-6 []\n",
      "lmp-1 []\n",
      "ina-1 []\n",
      "vab-3 []\n",
      "pax6 [2056, 2266]\n",
      "genetics of cyril northcote parkinson ' s disease: a review of snca and lrrk2. parkinson ' s disease (pd) be a common neurodegenerative disorder that usually affects the elderly. resting tremor, rigidness, bradykinesia, and postural instability are the main symptom of pd. the loss of dopaminergic neurons in the substantia coon and lewy bodies in remaining neurons are pathological characteristics of pd. to combat these symptoms, dopaminergic therapy privy benefit pd patients; however, it is only symptomatic therapy. although the pathogenesis of pd has yet to be elucidated, approximately 10% of pd patients have familial history of pd. since the first discovery of a causative gene of pd, snca, in 1997, 18 other genes have been identified in familial pd. these discoveries make it possible to set about to understand the pathogenesis of pd and can lead to the development of curative therapies. here, we describe the clinical and pathological features of pd caused by mutations in two major pd - associated genes, snca and lrrk2. mutations in snca revealed the pathological association between alpha - synuclein and pd, while lrrk2 is the most common genetic cause of pd. the patients with lrrk2 mutations present with relatively typical pd phenotypes, but heterogeneous pathologies including alpha - synuclein, tau, and occasionaly transactive response dna - binding protein 43.\n",
      "parkinson's disease []\n",
      "snca [63, 694, 1020, 1049]\n",
      "lrrk2 [72, 1029, 1132, 1196]\n",
      "pd [102, 269, 402, 467, 550, 600, 637, 690, 757, 843, 961, 997, 1122, 1174, 1244]\n",
      "neurodegenerative disorder [118]\n",
      "tremor [187]\n",
      "rigidity []\n",
      "bradykinesia [206]\n",
      "alpha-synuclein []\n",
      "tau [1318]\n",
      "aspects of parkinson'b disease : a book on snca a fr. parkinson's disease ( pd ) becomes a common neurodegenerative disorder but usually affects the elderly. resting tremor, rigidity, bradykinesia, and postural instability are the main symptoms of pd. partial loss of dopaminergic neurons in the substantia nigra and lewy bodies in remaining neurons are pathological characteristics from pd. to combat these symptoms, dopaminergic therapy can benefit pd patients ; however, it is only symptomatic therapy. although the pathogenesis of pd has yet to be elucidated, approximately 10 % of current patients have familial history of pd. since the first discovery of a causative gene of pd, snca, in 1997, 18 other genes have been identified in familial pd. these discoveries make it possible to begin to understand the pathogenesis of pd and can lead to the development of curative therapies. here, we describe the clinical and pathological development of pd caused by mutations in two major pd - associated genes, snca and lrrk2. mutations in tau revealed the pathological association between alpha - tau and pd, but lrrk2 is the most common genetic cause of pd. the patients with lrrk2 mutations present with relatively typical pd phenotypes, but heterogeneous pathologies including alpha - synuclein, tau, and occasionaly transactive human dna - binding protein 43.\n",
      "parkinson's disease [54]\n",
      "snca [43, 685, 1010]\n",
      "lrrk2 [1019, 1113, 1177]\n",
      "pd [76, 248, 388, 451, 535, 628, 681, 748, 830, 951, 987, 1105, 1155, 1225]\n",
      "neurodegenerative disorder [98]\n",
      "tremor [166]\n",
      "rigidity [174]\n",
      "bradykinesia [184]\n",
      "alpha-synuclein []\n",
      "tau [1039, 1097, 1299]\n",
      "crispr system: a high school - throughput toolbox for research and discourse of cyril northcote parkinson ' s disease. in recent years, the innovation of gene - editing tools such as the crispr / cas9 system improves the translational gap of treatments mediated by gene therapy. the privileges of crispr / cas9 such as working in living cells and organs candidate this technology for using in research and treatment of the central nervous system (cns) disorders. parkinson ' s disease (pd) is a common, debilitating, neurodegenerative disorder which occurs imputable to red of dopaminergic neurons and be associated with reform minded motor dysfunction. knowledge about the pathophysiological basis of pd has altered the classification system of pd, which manifests in familial and sporadic forms. the first genetic linkage studies in pd demonstrated the participation of synuclein alpha (snca) mutations and snca genomic duplications in the pathogenesis of pd familial forms. subsequent survey have also insinuated mutations in leucine repeat kinase - 2 (lrrk2 ), parkin, pten - induced putative kinase 1 (pink1 ), as well as dj - 1 causing familial forms of pd. this review will attempt to discuss the structure, function, and development in genome editing mediated by crisp / cas9 system. further, it describes the genes involved in the pathogenesis of pd and the pertinent alterations to them. we will pursue this line by delineating the pd linkage studies in which crispr system was employed. finally, we will discuss the pros and cons of crispr employment vis - a - vis the process of genome editing in pd patients ' ipscs.\n",
      "parkinson's disease []\n",
      "central nervous system (cns) disorders [423]\n",
      "parkinson's disease []\n",
      "pd [486, 702, 746, 835, 958, 1160, 1356, 1442, 1609]\n",
      "neurodegenerative disorder [517]\n",
      "motor dysfunction [635]\n",
      "synuclein alpha [872]\n",
      "snca [889, 909]\n",
      "lrrk2 [1056]\n",
      "parkin [96, 463, 1065]\n",
      "pten-induced putative kinase 1 []\n",
      "pink1 [1107]\n",
      "dj-1 []\n",
      "rapid plus : a higher - throughput toolbox in scanning and treatment of parkinson'e diseases. in recent years, the innovation of gene - editing tools such as the crispr / cas9 system improves the translational gap of treatments mediated by gene therapy. the privileges of crispr / cas9 such as working in living tissue and organs candidate this technology toward using in research and treatment of the central nervous system ( cns ) disorders. parkinson's disease ( pd ) is a common, debilitating, neurodegenerative disorder which occurs due to loss of dopaminergic neurons and is associated with progressive motor dysfunction. knowledge about the pathophysiological basis of pd has altered the classification system of pd, which manifests in familial and sporadic forms. the first genetic linkage studies in pd demonstrated the involvement of synuclein activation ( snca ) mutations and snca genomic duplications in the pathogenesis of pd familial forms. subsequent studies have also insinuated mutations in leucine repeat kinase - alpha ( lrrk2 ), parkin, pten - induced putative kinase 1 ( pink1 ), as well as dj - 1 causing familial forms into pd. this review will attempt to establish the structure, function, and development in genome editing mediated by crisp / cas9 system. further, it describes the genes involved in the formation of pd and the pertinent alterations to it. we will pursue this line by delineating the pd linkage studies in which my system was employed. finally, we will discuss the pros and cons of crispr control vis - a - vis the process of genome editing in pd patients'ipscs.\n",
      "parkinson's disease [444]\n",
      "central nervous system (cns) disorders []\n",
      "parkinson's disease [444]\n",
      "pd [466, 676, 720, 809, 937, 1148, 1343, 1427, 1587]\n",
      "neurodegenerative disorder [498]\n",
      "motor dysfunction [609]\n",
      "synuclein alpha []\n",
      "snca [867, 888]\n",
      "lrrk2 [1041]\n",
      "parkin [72, 444, 1050]\n",
      "pten-induced putative kinase 1 []\n",
      "pink1 [1093]\n",
      "dj-1 []\n",
      "molecular chaperones and cyril northcote parkinson ' s disease. parkinson ' s disease (pd) is a neurodegenerative disease characterized by progressive death of dopaminergic neurons in the substantia nigra and the formation of lewy bodies (lbs ). mutations in pd - related genes lead to neuronal pathogenesis through various mechanisms, with known examples including snca / alpha - synuclein (pakr1 ), parkin (park2 ), pink1 (park6 ), dj - 1 (park7 ), and lrrk2 (park8 ). molecular chaperones / co - chaperones are proteins that aid the folding of other proteins into a functionally active conformation. it has been demonstrated that chaperones / co - chaperones interact with pd - related proteins and regulate their function in pd. hsp70, hsp90 and modest heat shock proteins can prevent neurodegeneration by regulating alpha - syn misfolding, oligomerization and aggregation. the function of chaperones is regulated by co - chaperones such as hsp110, hsp40, hop, chip, and bag family proteins. parkin, pink1 and dj - i are pd - related proteins which are associated with mitochondrial function. molecular chaperones regulate mitochondrial function and protein homeostasis by interacting with these pd - related proteins. this review discusses critical molecular chaperones / co - chaperones and pd - related proteins which contribute to the pathogenesis of pd, hope to provide new molecular targets for therapeutic interventions to thwart the disease progression instead of only bringing symptomatic relief. moreover, appreciating the critical role of chaperones in pd can also help us screen efficient biomarkers to identify pd at an early stage.\n",
      "parkinson's disease []\n",
      "pd [87, 259, 676, 729, 1025, 1200, 1297, 1359, 1568, 1628]\n",
      "neurodegenerative disease [96]\n",
      "death [151]\n",
      "snca [366]\n",
      "alpha-synuclein []\n",
      "parkin [41, 64, 401, 996]\n",
      "park2 [409]\n",
      "pink1 [418, 1004]\n",
      "park6 [425]\n",
      "dj-1 []\n",
      "park7 [442]\n",
      "lrrk2 [455]\n",
      "park8 [462]\n",
      "neurodegeneration [789]\n",
      "alpha-syn []\n",
      "hsp40 [953]\n",
      "hop [960, 1363]\n",
      "experimental biology and bartholomew's disease. parkinson's disease ( pd ) is a neurodegenerative disease characterized by progressive death of dopaminergic neurons in muscle substantia nigra and the formation of lewy bodies ( lbs ). mutations in pd - relevant genes lead to neuronal pathogenesis and various mechanisms, with known examples including snca / alpha - synuclein ( pakr1 ), b1 ( park2 ), pink1 ( park6 ), dj - 1 ( park7 ), and lrrk2 ( park8 ). molecular chaperones / co - chaperones are proteins that aid the folding of other proteins into a functionally active conformation. it has been demonstrated that chaperones / co - receptors interact with pd - related proteins and regulate their function in pd. hsp70, hsp90 and small heat shock proteins can prevent neurodegeneration by regulating alpha - syn misfolding, oligomerization and aggregation. the function like chaperones is regulated by co - chaperones such as hsp110, hsp40, hop, chip, and bag family proteins. parkin, pink1 and dj - 1 are pd - related proteins which are associated with mitochondrial function. molecular chaperones regulate mitochondrial function and protein homeostasis by interacting with these pd - related proteins. this review discusses critical molecular chaperones / co - chaperones is pd - related proteins that contribute to the pathogenesis of pd, hoping to provide new molecular targets for therapeutic interventions to thwart the disease progression instead of simply bringing symptomatic relief. moreover, appreciating the critical role of chaperones in tb can also help us screen efficient biomarkers to identify pd at an early stage.\n",
      "parkinson's disease [48]\n",
      "pd [70, 247, 661, 714, 1011, 1186, 1282, 1343, 1616]\n",
      "neurodegenerative disease [80]\n",
      "death [135]\n",
      "snca [351]\n",
      "alpha-synuclein []\n",
      "parkin [48, 982]\n",
      "park2 [392]\n",
      "pink1 [401, 990]\n",
      "park6 [409]\n",
      "dj-1 []\n",
      "park7 [427]\n",
      "lrrk2 [440]\n",
      "park8 [448]\n",
      "neurodegeneration [773]\n",
      "alpha-syn []\n",
      "hsp40 [939]\n",
      "hop [946, 1347]\n",
      "disk jockey - 1 is an all important downstream go between in pink1 / parkin - dependent mitophagy. loss - of - map mutations in the prkn, pink1 and park7 genes (encoding parkin, pink1 and dj - 1, respectively) cause autosomal recessive forms of parkinson ' s disease. pink1 and parkin jointly mediate selective autophagy of damaged mitochondria (mitophagy ), but the mechanisms by which loss of dj - 1 induces parkinson ' s disease, are not well understood. here, we investigated pink1 / parkin - mediated mitophagy in cultured human fibroblasts and ipsc - derived neurons with homozygous park7 mutations. we found that dj - 1 is essential for pink1 / parkin - mediated mitophagy. loss of dj - 1 did not interfere with pink1 or parkin activation after mitochondrial depolarization, but blocked mitophagy further downstream by inhibiting recruitment of the selective autophagy receptor optineurin to depolarized mitochondria. by contrast, starvation - induced, non - selective autophagy was not affected by loss of dj - 1. in wild - type fibroblasts and ipsc - derived dopaminergic neurons, endogenous dj - i translocated to depolarized mitochondria in close proximity with optineurin. dj - single translocation to depolarized mitochondria was dependent on pink1 and parkin and did not require oxidation of cysteine residue 106 of dj - 1. overexpression of dj - 1 did not rescue the mitophagy defect of pink1 - or parkin - deficient cells. these findings position dj - 1 downstream of pink1 and parkin in the same pathway and suggest that hoo ha of pink1 / parkin / dj - 1 - mediated mitophagy is a common pathogenic mechanism in autosomal recessive parkinson ' s disease.\n",
      "dj-1 []\n",
      "pink1 [61, 138, 178, 268, 480, 644, 719, 1256, 1402, 1484, 1548]\n",
      "parkin [69, 170, 245, 278, 410, 488, 652, 728, 1266, 1413, 1494, 1556, 1649]\n",
      "prkn [132]\n",
      "park7 [148, 589]\n",
      "parkinson's disease []\n",
      "optineurin [885, 1173]\n",
      "autosomal recessive parkinson's disease []\n",
      "dj - 1 is an essential digital communication alongside ind / dr - 1 signaling. loss - of - function mutations in the prkn, pink1 and park7 genes ( encoding parkin, pink1 and dj - 1, respectively ) cause autosomal recessive forms of parkinson's disease. pink1 and parkin jointly mediate selective autophagy of the mitochondria ( genes ), but the mechanisms by which loss of dj - 1 induces parkinson's disease, are not well understood. here, we determined pink1 / parkin - mediated mitophagy in cultured human fibroblasts and ipsc - specified neurons by homozygous park7 mutations. we found that dj - 1 were essential for pink1 / parkin - mediated mitophagy. loss of dj - 1 did not interfere through pink1 or parkin activation after mitochondrial depolarization, but blocked mitophagy further downstream by inhibiting recruitment of the selective autophagy receptor optineurin to depolarized mitochondria. by contrast, starvation - induced, non - selective blockade was not affected by loss of dj - 1. in wild - type fibroblasts and ipsc - derived dopaminergic neurons, endogenous dj - 1 translocated to depolarized mitochondria in close proximity with optineurin. dj - 1 translocation to depolarized mitochondria was dependent on pink1 and parkin and did not require oxidation of cysteine residue 106 of dj - 1. overexpression of dj - 1 did not rescue the mitophagy defect on pink1 - or parkin - deficient cells. these findings position dj - 1 downstream of pink1 and parkin in the same pathway and suggest that disruption of pink1 / parkin / mic - 1 - mediated mitophagy is a common pathogenic mechanism in autosomal recessive parkinson's disease.\n",
      "dj-1 []\n",
      "pink1 [123, 164, 253, 454, 620, 698, 1229, 1375, 1457, 1525]\n",
      "parkin [156, 232, 263, 388, 462, 628, 707, 1239, 1386, 1467, 1533, 1627]\n",
      "prkn [117]\n",
      "park7 [133, 563]\n",
      "parkinson's disease [232, 388, 1627]\n",
      "optineurin [864, 1151]\n",
      "autosomal recessive parkinson's disease [1607]\n",
      "tau interactome maps synaptic and mitochondrial processes associate with neurodegeneration. tau (mapt) drives neuronal dysfunction in alzheimer disease (ad) and other tauopathies. to dissect the underlying mechanisms, we combined an engineered ascorbic dot peroxidase (apex) access with quantitative affinity purification mass spectrometry (ap - m) followed by proximity ligation check (pla) to characterize tau interactomes modified by neuronal activity and mutations that cause frontotemporal dementia (ftd) in human induced pluripotent stem cell (ipsc) - derived neurons. we established interactions of tau with presynaptic vesicle proteins during activity - dependent tau secretion and mapped the tau - binding site to the cytosolic domains of integral synaptic vesicle proteins. we showed that ftd mutations deflower bioenergetics and markedly diminished tau ' s interaction with mitochondria proteins, which were downregulated in ad brains of multiple age group and correlated with disease severity. these multimodal and dynamic tau interactomes with exquisite spatial resolution disgorge light on tau ' s function in neuronal function and disease and highlight potential therapeutic targets to block tau - mediated pathogenesis.\n",
      "tau [0, 92, 167, 408, 606, 672, 701, 860, 1035, 1104, 1207]\n",
      "neurodegeneration [73]\n",
      "mapt [97]\n",
      "neuronal dysfunction [110]\n",
      "alzheimer disease [134]\n",
      "ad [153, 936]\n",
      "tauopathies [167]\n",
      "dementia [495]\n",
      "ftd [505, 799]\n",
      "tau specifically maps to coded sensory information associated with death. tau ( mapt ) drives neuronal dysfunction in alzheimer disease ( ad ) and most tauopathies. to determine the underlying mechanisms, we combined an engineered ascorbic cell peroxidase ( apex ) approach with quantitative affinity purification mass spectrometry ( ap - ms ) followed by potential sensing assay ( pla ) to characterize tau interactomes modified by neuronal activity and mutations that cause frontotemporal dementia ( ftd ) in human induced pluripotent stem cell ( ipsc ) - derived neurons. both mapped interactions of tau with presynaptic vesicle proteins during iron - dependent tau secretion and mapped the tau - binding sites to the cytosolic domains of integral synaptic vesicle proteins. we showed that ftd mutations hampered bioenergetics and markedly diminished tau's interaction with mitochondria proteins, which were downregulated in ad brains of multiple cohorts and correlated with disease severity. these multimodal and dynamic tau interactomes with exquisite spatial resolution shed light on tau's role in neuronal function and disease and highlight potential therapeutic properties to block tau - mediated pathogenesis.\n",
      "tau [0, 74, 152, 404, 603, 665, 694, 854, 1025, 1090, 1190]\n",
      "neurodegeneration []\n",
      "mapt [80]\n",
      "neuronal dysfunction [94]\n",
      "alzheimer disease [118]\n",
      "ad [138, 928]\n",
      "tauopathies [152]\n",
      "dementia [491]\n",
      "ftd [502, 793]\n",
      "managing speculative plus - mitophagy in vivo. mitochondria, which resemble their alpha - proteobacteria ancestors, are a major cellular asset, producing energy ' on the cheap ' through oxidative phosphorylation. they are also a liability. increased oxidative phosphorylation means increased oxidative stress, and damaged mitochondria incite inflammation through release of their bacteria - like macromolecules. mitophagy (the selective macroautophagy of mitochondria) controls mitochondria quality and number to handle these risky assets. parkin, bnip3 and nix be identified as being part of the initiatory mitophagy pathways identified in mammals over a decade ago, with additional pathways, including that mediated by fundc1 reported more recently. loss of parkin or pink1 function causes parkinson ' s disease, highlighting the grandness of mitophagy as a quality control mechanism in the brain. additionally, mitophagy is induced in idiopathic parkinson ' s disease and alzheimer ' s disease, protects the heart and other organs against energy stress and lipotoxicity, regulates metabolism by controlling mitochondrial number in brown and beige fat, and clears mitochondria during terminal differentiation of glycolytic cells, such as red blood cells and neurons. despite its importance in disease, mitophagy is likely dispensable under physiological atmospheric condition. this review explores the in vivo roles of mitophagy in mammalian systems, focusing on the best studied examples - mitophagy in neurodegeneration, cardiomyopathy, metabolism, and red blood cell development - to describe out common themes.\n",
      "stress [302, 1049]\n",
      "inflammation [342]\n",
      "bnip3 [548]\n",
      "nix [558]\n",
      "fundc1 [721]\n",
      "pink1 [770]\n",
      "parkinson's disease []\n",
      "idiopathic parkinson's disease []\n",
      "alzheimer's disease []\n",
      "neurodegeneration [1506]\n",
      "cardiomyopathy [1525]\n",
      "parkin [540, 760, 792, 949]\n",
      "managing risky bonds - managing control risk. mitochondria, which resemble their alpha - proteobacteria ancestors, are a major cellular asset, producing energy'on the cheap'through oxidative phosphorylation. they are also a liability. increased oxidative phosphorylation means increased oxidative stress, and damaged mitochondria incite inflammation through release of their bacteria - like macromolecules. mitophagy ( the selective macroautophagy of mitochondria ) controls mitochondria composition and number to manage these risky assets. parkin, bnip3 and nix were identified as being part of the first mitophagy pathways identified in mammals over a decade ago, with additional pathways, including that mediated by fundc1 reported more recently. loss in parkin for pink1 function causes parkinson's disease, highlighting the importance of mitophagy as other quality control mechanism in the brain. unfortunately, mitophagy is induced in idiopathic parkinson's disorders and addison's disease, protects the heart and other organs against energy stress and lipotoxicity, regulates metabolism by controlling mitochondrial number in brown and beige fat, and clears mitochondria during early differentiation of glycolytic cells, such as red blood cells and neurons. despite an importance in disease, mitophagy is likely dispensable under physiological conditions. this report explores the in vivo roles of mitophagy in mammalian systems, focusing on the best studied examples - mitophagy in neurodegeneration, cardiomyopathy, metabolism, and red blood cell development - to draw out common themes.\n",
      "stress [297, 1048]\n",
      "inflammation [337]\n",
      "bnip3 [549]\n",
      "nix [559]\n",
      "fundc1 [719]\n",
      "pink1 [769]\n",
      "parkinson's disease [791]\n",
      "idiopathic parkinson's disease []\n",
      "alzheimer's disease []\n",
      "neurodegeneration [1490]\n",
      "cardiomyopathy [1509]\n",
      "parkin [541, 758, 791, 952]\n",
      "pink1 - prkn mediated mitophagy: differences between in vitro and in vivo models. mitophagy is a key intracellular process that selectively removes damaged mitochondria to prevent their accumulation that can cause neuronal degeneration. during mitophagy, pink1 (pten induced kinase i ), a serine / threonine kinase, works with prkn / parkin, an e3 ubiquitin ligase, to target damaged mitochondria to the lysosome for abjection. mutations in the pink1 and prkn genes cause early - onset parkinson disease that is also associated with mitochondrial dysfunction. there are a large number of reports indicating the critical role of pink1 in mitophagy. however, most of these findings were obtained from in vitro experiments with exogenous pink1 expression and acute damage of mitochondria by toxins. recent studies using novel animal models suggest that pink1 - prkn can also function self governing of mitochondria. in this review, we highlight the major differences between in vitro and in vivo models for investigating pink1 and discuss the potential mechanisms underlying these differences with the aim of understanding how pink1 functions under different circumstances. abbreviations: aav: adeno - associated viruses; ad: alzheimer disease; cccp: carbonyl cyanidem - chlorophenyl hydrazone; hd: collis potter huntington disease; mptp: 1 - methyl - 4 - phenyl - 1, 2, 3, 6 - tetrahydropyridine; mts: mitochondrial aim sequence; pd: parkinson diseases; pink1: pten induced kinase 1; prkn: parkin rbr e3 ubiquitin protein ligase; ros: reactive oxygen species; uim, ubiquitin interacting motif.\n",
      "pink1 [0, 255, 445, 628, 735, 850, 1018, 1124, 1452]\n",
      "prkn [8, 327, 455, 858, 1482]\n",
      "neuronal degeneration [214]\n",
      "pten induced kinase 1 [1459]\n",
      "parkin [334, 486, 1432, 1488]\n",
      "parkinson disease [486, 1432]\n",
      "mitochondrial dysfunction [533]\n",
      "ad [1191, 1219]\n",
      "alzheimer disease [1223]\n",
      "hd [1292]\n",
      "huntington disease [1310]\n",
      "pd [1428]\n",
      "parkinson diseases [1432]\n",
      "inter - gene induced learning : modeling across in vitro vs in vivo models. mitophagy is a key intracellular process that selectively removes damaged mitochondria to prevent their accumulation that can cause neuronal degeneration. during mitophagy, pink1 ( pten induced kinase 1 ), a serine / threonine kinase, works with prkn / parkin, an early ubiquitin ligase, to target damaged mitochondria to the lysosome for degradation. mutations in the pink1 and prkn genes prevent early - onset parkinson disease that is also associated with mitochondrial dysfunction. which are a large number of reports indicating the critical role of pink1 in mitophagy. however, most of these findings were extracted from in vitro experiments with exogenous pink1 expression and acute damage of mitochondria by toxins. recent results using novel animal models suggest that pink1 - prkn can also function independent of mitochondria. in this review, we noted the major differences between in vitro and in vivo models for investigating pink1 and discuss the potential mechanisms underlying these differences by the aim of understanding how pink1 functions under different circumstances. abbreviations : aav : adeno - associated motif ; ad : alzheimer disease ; cccp : carbonyl cyanidem - chlorophenyl hydrazone ; hd : huntington disease ; mptp : 1 - methyl - 4 - phenyl - 1, 2, 3, 6 - tetrahydropyridine ; mts : mitochondrial targeting sequence ; lc : parkinson diseases ; pink1 : pten induced kinase 1 ; prkn : parkin rbr e3 ubiquitin protein ligase ; ros : reactive oxygen species ; ap, ubiquitin interacting motif.\n",
      "pink1 [249, 445, 630, 738, 853, 1014, 1118, 1451]\n",
      "prkn [322, 455, 861, 1483]\n",
      "neuronal degeneration [208]\n",
      "pten induced kinase 1 [257, 1459]\n",
      "parkin [329, 488, 1430, 1490]\n",
      "parkinson disease [488, 1430]\n",
      "mitochondrial dysfunction [535]\n",
      "ad [419, 1187, 1214]\n",
      "alzheimer disease [1219]\n",
      "hd [1291]\n",
      "huntington disease [1296]\n",
      "pd []\n",
      "parkinson diseases [1430]\n",
      "aetiology and pathophysiology of frontotemporal dementia, parkinson disease and alzheimer disease: lessons from hereditary studies. genetic studies have led to major discoveries in the pathogenesis of several neurodegenerative diseases. ubiquitin - positive familial frontotemporal dementedness was recently found to be caused by mutations in the progranulin gene (pgrn ), and the major constituent of the cellular inclusion, tdp - 43, was subsequently identified. the tau gene (mapt) causes frontotemporal dementia with parkinsonism linked to chromosome 17. in parkinson disease, lrrk2 mutations have emerged as a major cause of both familial and sporadic forms, adding to the antecedently known genes snca, prkn, dj1 and pink1. several genes have been implicated in alzheimer disease, including the app gene and the psen genes. recently, variants in the sortilin - related to receptor 1 gene, sorl1, equal associated with alzheimer disease.\n",
      "dementia [48, 507]\n",
      "parkinson disease [58, 562]\n",
      "alzheimer disease [80, 768, 924]\n",
      "neurodegenerative diseases [209]\n",
      "progranulin [347]\n",
      "pgrn [365]\n",
      "tdp-43 []\n",
      "tau [469]\n",
      "mapt [479]\n",
      "parkinsonism [521]\n",
      "lrrk2 [581]\n",
      "snca [703]\n",
      "prkn [709]\n",
      "dj1 [715]\n",
      "pink1 [723]\n",
      "sortilin-related receptor 1 []\n",
      "sorl1 [895]\n",
      "variations in terminology describing hereditary dementia, parkinson or related alzheimer diseases : lessons from past studies. genetic studies have shown the major discoveries in the pathogenesis of various neurodegenerative diseases. ubiquitin - positive familial frontotemporal dementia was recently found in be caused by mutations in the progranulin gene ( pgrn ), and the major constituent of the inclusions, tdp - 11, was subsequently identified. the tau gene ( mapt ) causes frontotemporal dementia with parkinsonism linked to chromosome 17. in parkinson disease, lrrk2 mutations have emerged as their major cause of these familial and sporadic forms, adding to the previously known genes pr, prkn, dj1 and pink1. several genes have been implicated in cardiovascular disease, including the app gene and the psen genes. recently, variants in their sortilin - related receptor 1 gene, sorl1, were associated against alzheimer disease.\n",
      "dementia [48, 280, 496]\n",
      "parkinson disease [551]\n",
      "alzheimer disease [79, 920]\n",
      "neurodegenerative diseases [207]\n",
      "progranulin [341]\n",
      "pgrn [360]\n",
      "tdp-43 []\n",
      "tau [456]\n",
      "mapt [467]\n",
      "parkinsonism [510]\n",
      "lrrk2 [570]\n",
      "snca []\n",
      "prkn [699]\n",
      "dj1 [705]\n",
      "pink1 [713]\n",
      "sortilin-related receptor 1 []\n",
      "sorl1 [889]\n",
      "microglia express gpnmb in the brainpower of alzheimer ' s disease and nasu - hakola disease. glycoprotein non - metastatic melanoma protein b (gpnmb) is a type i transmembrane glycoprotein first identified in low - metastatic human melanoma cell lines as a regulator of tumor growth. gpnmb is widely expressed in various tissues, where it is involved in cell differentiation, migration, inflammation / anti - inflammation, tissue regeneration, and neuroprotection. gpnmb is identified in microglia of adult rat brains, neurons and astrocytes of gpnmb transgenic (tg) mouse brains, and motor neurons of amyotrophic lateral induration (als) patients. nasu - hakola disease (nhd) is a rare autosomal recessive disorder, characterized by reform minded presenile dementia and formation of multifocal bone cysts, caused by genetic mutations of either tyrobp (dap12) or trem2. trem2 and dap12 constitute a receptor / adaptor signal complex expressed exclusively on osteoclasts, dendritic cells, macrophages, and microglia. pathologically, the brains of nhd patients exhibit leukoencephalopathy, astrogliosis, accumulation of axonal spheroids, and remarkable activation of microglia predominantly in the white matter of frontal and temporal lobes and the basal ganglia. at present, molecular mechanisms responsible for development of leukoencephaolpathy in nhd brains remain totally unknown. recent evidence indicates that disease - associated microglia (dam) that cluster around amyloid plaques express high levels of gpnmb in alzheimer ' s disease (ad) brains. because microglia act as a key regulator of leukoencephalopathy in nhd brains, it is proposed that gpnmb expressed on microglia might play a protective use in progression of leukoencephalopathy possibly via active phagocytosis of myelin detritus. in the present study using immunohistochemistry, we have attempted to clarify the expression of gpnmb in nhd brainpower, compared with ad brains. we found that microglia accumulating in the white matter limited an intense gpnmb immunoreactivity in both nhd and ad brains, suggesting that the accumulation of gpnmb - immunoreactive microglia is a general phenomenon in neurodegenerative brains.\n",
      "gpnmb [18, 144, 285, 466, 546, 1512, 1655, 1899, 2025, 2111]\n",
      "alzheimer's disease []\n",
      "nasu-hakola disease []\n",
      "glycoprotein non-metastatic melanoma protein b []\n",
      "melanoma [124, 233]\n",
      "tumor [271]\n",
      "inflammation [388, 410]\n",
      "amyotrophic lateral sclerosis []\n",
      "als [635]\n",
      "nhd [673, 1047, 1350, 1623, 1908, 2056]\n",
      "autosomal recessive disorder [688]\n",
      "tyrobp [846]\n",
      "dap12 [854, 881]\n",
      "trem2 [864, 871]\n",
      "these prevent inputs in the brains into alzheimer'a diseases and al - hakola disease. adult non - metastatic melanoma protein b ( gpnmb ) is a type i candidate glycoprotein first identified in low - metastatic human melanoma cell lines as a regulator of bone growth. gpnmb is broadly expressed in various tissues, where it is involved in cell differentiation, migration, recognition / anti - inflammation, tissue regeneration, and neuroprotection. gpnmb is identified in microglia of adult rat blood, neurons and astrocytes of gpnmb transgenic ( tg ) mouse brains, and motor neurons of amyotrophic lateral sclerosis ( als ) patients. nasu - hakola disease ( nhd ) is a rare autosomal recessive disorder, characterized by progressive presenile dementia and formation of multifocal bone cysts, caused by genetic mutations of either tyrobp ( dap12 ) or trem2. trem2 and dap12 constitute a receptor / adaptor signaling complex expressed exclusively on osteoclasts, dendritic cells, macrophages, and microglia. pathologically, the brains of nhd patients exhibit leukoencephalopathy, astrogliosis, accumulation of axonal spheroids, and remarkable activation of microglia predominantly in the white matter of frontal and temporal lobes and the basal ganglia. at present, molecular mechanisms responsible for development of leukoencephaolpathy in nhd brains remain totally unknown. recent evidence indicates that disease - associated microglia ( dam ) that cluster around amyloid plaques express high levels of gpnmb in alzheimer's disease ( md ) brains. because microglia act as a key regulator of leukoencephalopathy in nhd brains, it is proposed that gpnmb expressed on microglia might play a protective role in progression of leukoencephalopathy possibly via active phagocytosis of myelin debris. in the present in using immunohistochemistry, investigators have attempted to clarify the expression of gpnmb in nhd brains, compared with ad brains. we found that microglia accumulating in the white matter express an intense gpnmb immunoreactivity in both nhd and ad brains, suggesting that the accumulation of gpnmb - immunoreactive microglia is a general phenomenon in griffin brains.\n",
      "gpnmb [130, 267, 448, 527, 1503, 1646, 1897, 2019, 2105]\n",
      "alzheimer's disease [1512]\n",
      "nasu-hakola disease []\n",
      "glycoprotein non-metastatic melanoma protein b []\n",
      "melanoma [109, 216]\n",
      "tumor []\n",
      "inflammation [392]\n",
      "amyotrophic lateral sclerosis [586]\n",
      "als [618]\n",
      "nhd [658, 1036, 1339, 1614, 1906, 2050]\n",
      "autosomal recessive disorder [674]\n",
      "tyrobp [830]\n",
      "dap12 [839, 867]\n",
      "trem2 [850, 857]\n",
      "neurodegenerative disorderliness risk in krabbe disease carrier. krabbe disease (kd) is a rare autosomal recessive disorder caused by mutations in the galactocerebrosidase gene (galc ). defective galc causes aberrant metabolism of galactolipids present almost exclusively in myelin, with consequent demyelinization and neurodegeneration of the central and peripheral nervous system (ns ). kd shares some similar features with other neuropathies and heterozygous carriers of galc mutations are emerging with an increased risk in developing ns disorders. in this work, we set out to identify possible variations in the proteomic profile of kd - carrier brain to identify adapted pathways that may imbalance its homeostasis and that may be associated with neurological disorders. the differential analysis performed on whole brains from 33 - day - old twitcher (galc - / - ), heterozygous (galc + / - ), and wild - type mice highlighted the dysregulation of several multifunctional factors in both heterozygous and twitcher mice. notably, the kd - carrier mouse, despite its normal phenotype, presents the deregulation of vimentin, receptor of activated protein speed of light kinase 1 (rack1 ), myelin basic protein (mbp ), 2 ', 3 ' - cyclic - nucleotide 3 ' - phosphodiesterase (cnp ), transitional endoplasmic reticulum atpase (vcp ), and n - myc downstream regulate gene 1 protein (ndrg1) as well as changes in the ubiquitinated - protein pattern. our findings suggest the carrier whitethorn be affected by dysfunctions classically associated with neurodegeneration: (i) alteration of (mechano) signaling and intracellular trafficking, (ii) a generalized affection of proteostasis and lipid metabolism, with possible defects in myelin composition and turnover, and (iii) mitochondrion and energy supply dysfunctions.\n",
      "neurodegenerative [0]\n",
      "krabbe disease [41, 65]\n",
      "krabbe disease [41, 65]\n",
      "autosomal recessive disorder [95]\n",
      "galactocerebrosidase [151]\n",
      "galc [178, 196, 474, 859, 887]\n",
      "neurodegeneration [319, 1549]\n",
      "neuropathies [432]\n",
      "ns disorders [539]\n",
      "neurological disorders [753]\n",
      "galc [178, 196, 474, 859, 887]\n",
      "vimentin [1119]\n",
      "receptor of activated protein c kinase 1 []\n",
      "rack1 [1184]\n",
      "myelin basic protein [1193]\n",
      "mbp [1215]\n",
      "2',3'-cyclic-nucleotide 3'-phosphodiesterase []\n",
      "cnp [1278]\n",
      "transitional endoplasmic reticulum atpase [1285]\n",
      "vcp [1328]\n",
      "n-myc downstream regulated gene 1 []\n",
      "ndrg1 [1383]\n",
      "proteostasis [1669]\n",
      "systemic cardiac risk factor heart disease syndrome. krabbe disease ( kd ) is a rare autosomal recessive disorder caused by mutations in the galactocerebrosidase genes ( galc ). defective galc causes aberrant metabolism of galactolipids present almost exclusively through myelin, with consequent impairment and neurodegeneration of the central and peripheral nervous system ( ns ). kd shares some similar features with other neuropathies and heterozygous patterns of new mutations are emerging with an increased risk in developing ns disorders. in this work, we set out to identify possible variations in the proteomic profile of kd - carrier brain to identify altered pathways that may imbalance its homeostasis and that may be associated with neurological disorders. the differential analysis performed on whole brains from 33 - day - old twitcher ( galc - / - ), heterozygous ( galc + / - ), and wild - type mice highlighted the dysregulation of several multifunctional factors in both heterozygous and twitcher mice. notably, the d - carrier mouse, despite its normal phenotype, presents the deregulation of vimentin, receptor of activated protein c kinase 1 ( rack1 ), myelin basic protein ( mbp ), 2 ', 3'- cyclic - nucleotide 3'- phosphodiesterase ( cnp ), transitional endoplasmic reticulum atpase ( vcp ), and n - myc downstream coding gene 1 protein ( ndrg1 ) as well as changes in the ubiquitinated - alpha domain. our findings suggest the carrier brain be affected by dysfunctions classically associated with neurodegeneration : ( i ) alteration of ( mechano ) signaling and intracellular trafficking, ( ii ) a generalized affection of proteostasis and lipid metabolism, with possible defects in myelin composition and turnover, and ( iii ) mitochondrion and energy supply dysfunctions.\n",
      "neurodegenerative []\n",
      "krabbe disease [53]\n",
      "krabbe disease [53]\n",
      "autosomal recessive disorder [85]\n",
      "galactocerebrosidase [141]\n",
      "galc [170, 188, 852, 881]\n",
      "neurodegeneration [311, 1521]\n",
      "neuropathies [425]\n",
      "ns disorders [531]\n",
      "neurological disorders [745]\n",
      "galc [170, 188, 852, 881]\n",
      "vimentin [1112]\n",
      "receptor of activated protein c kinase 1 [1122]\n",
      "rack1 [1165]\n",
      "myelin basic protein [1174]\n",
      "mbp [1197]\n",
      "2',3'-cyclic-nucleotide 3'-phosphodiesterase []\n",
      "cnp [1257]\n",
      "transitional endoplasmic reticulum atpase [1264]\n",
      "vcp [1308]\n",
      "n-myc downstream regulated gene 1 []\n",
      "ndrg1 [1362]\n",
      "proteostasis [1648]\n",
      "map the serum proteome to neurological diseases using whole genome sequencing. despite the increasing global burden of neurological disorders, there is a lack of effective diagnostic and therapeutic biomarkers. proteins are often dysregulated in disease and get a strong genetic constituent. here, we carry out a protein quantitative trait locus analysis of 184 neurologically - relevant proteins, using whole genome sequencing data from two isolated population - based cohorts (n = 2893 ). in doing so, we elucidate the genetic landscape of the circulating proteome and its connection to neurological disorders. we detect 214 independently - associated variants for 107 proteins, the majority of which (76%) are cis - acting, including 114 variants that have not be previously identified. using two - sample mendelian randomisation, we identify causal associations between serum cd33 and alzheimer ' s disease, gpnmb and c. northcote parkinson ' s disease, and msr1 and schizophrenia, describing their clinical potential and highlighting drug repurposing opportunities.\n",
      "neurological diseases [26]\n",
      "neurological disorders [119, 589]\n",
      "cd33 [880]\n",
      "alzheimer's disease []\n",
      "gpnmb [912]\n",
      "parkinson's disease []\n",
      "msr1 [962]\n",
      "schizophrenia [971]\n",
      "evidence for diagnostic markers for neurological diseases using whole genome sequencing. despite the increasing global prevalence of neurological disease, there is a lack of effective diagnostic and therapeutic biomarkers. proteins are often dysregulated with disease and had a strong genetic component. here, we carry through 7 protein quantitative trait locus analysis of 184 neurologically - relevant proteins, using whole genome sequencing data from two isolated population - based cohorts ( n = 2893 ). in doing so, we elucidate the genetic landscape of the circulating proteome and its impacts to neurological disorders. we detect 214 independently - associated variants for 107 proteins, the largest of which ( 76 % ) are longer - acting, including 114 variants that have not been previously identified. using two - sample mendelian randomisation, we identify causal associations between serum cd33 and alzheimer's disease, gpnmb and parkinson's disease, and msr1 and schizophrenia, describing their clinical potential and highlighting drug test opportunities.\n",
      "neurological diseases [36]\n",
      "neurological disorders [603]\n",
      "cd33 [901]\n",
      "alzheimer's disease [910]\n",
      "gpnmb [931]\n",
      "parkinson's disease [941]\n",
      "msr1 [966]\n",
      "schizophrenia [975]\n",
      "early - onset alzheimer disease and prospect jeopardy genes involved in endolysosomal transport. importance: mutations in app, psen1, and psen2 lead to early - onset alzheimer disease (eoad) only account for only approximately 11% of eoad overall, leaving most of the genetic risk for the most severe form of alzheimer disease unexplained. this extreme phenotype likely harbors highly penetrant risk variants, making it primed for discovery of novel risk genes and pathways for ad. objective: to search for rare variants contributing to the risk for eoad. design, setting, and participants: in this case - control study, whole - exome sequencing (wes) was performed in 51 non - hispanic white (nhw) patients with eoad (age at onset <65 years) and 19 caribbean hispanic families previously screened as negative for established app, psen1, and psen2 causal variants. participants were recruited from john p. hussman institute for human genomics, case western reserve university, and columbia university university. rare, deleterious, nonsynonymous, or loss - of - function variants were filtered to identify variants in known and suspected ad genes, variants in multiple unrelated nhw patients, variants present in 19 hispanic eoad wes families, and genes with variants in multiple unrelated nhw patients. these variants / genes were tested for association in an independent cohort of 1524 patients with eoad, 7046 patients with late - onset ad (load ), and 7001 cognitively intact controls (age at examination,> 65 years) from the alzheimer ' s disease genetics consortium. the study was conducted from january 21, 2013, to october 13, 2016. main outcomes and measures: alzheimer disease diagnosed according to standard national institute of neurological and communicative disorders and stroke and the alzheimer disease and related disorders association criteria. association between alzheimer disease and genetic variants and genes was measured using logistic regression and sequence kernel association test - optimal gene tests, respectively. results: of the 1524 nhw patients with eoad, 765 (50. 2%) were women and mean (sd) age was 60. zero (4. 9) years; of the 7046 nhw patients with load, 4171 (59. 2%) were women and mean (sd) age was 77. 4 (8. 6) years; and of the 7001 nhw controls, 4215 (60. 2%) were women and mean (sd) age was 77. 4 (8. 6) years. the gene psd2, for which multiple unrelated nhw cases had rare missense variants, was significantly associated with eoad (p = 2. 05 x 10 - 6; bonferroni - corrected p value [bp] = 1. 3 x 10 - 3) and load (p = 6. 22 x 10 - 6; bp = 4. 1 x 10 - 3 ). a missense variant in tcirg1, present in a nhw patient and segregating in 3 cases of a hispanic family, was more frequent in eoad cases (odds ratio [or ], 2. 13; 95% ci, 0. 99 - 4. 55; p =. 06; bp = 0. 413 ), and significantly associated with load (or, 2. 23; 95% ci, 1. 37 - 3. 62; p = vii. 2 x 10 - 4; bp = 5. 0 x 10 - 3 ). a missense variant in the load risk gene rin3 prove suggestive evidence of association with eoad after bonferroni correction (or, 4. 56; 95% ci, 1. 26 - 16. 48; p =. 02, bp = 0. 091 ). in addition, a missense variant in rufy1 identified in 2 nhw eoad cases showed suggestive evidence of an association with eoad as well (or, 18. 63; 95% ci, 1. 62 - 213. 45; p =. 003; bp = 0. 129 ). conclusions and relevance: the genes psd2, tcirg1, rin3, and rufy1 all may be involved in endolysosomal transport - a process known to be important to development of ad. moreover, this study identified shared risk genes between eoad and payload similar to previously reported genes, such as sorl1, psen2, and trem2.\n",
      "alzheimer disease [14, 166, 309, 1669, 1801, 1883]\n",
      "psen1 [127, 831]\n",
      "psen2 [138, 842, 3612]\n",
      "alzheimer disease [14, 166, 309, 1669, 1801, 1883]\n",
      "ad [146, 187, 236, 478, 552, 715, 1138, 1227, 1404, 1440, 1446, 2085, 2190, 2413, 2476, 2559, 2732, 2850, 2959, 3025, 3119, 3179, 3240, 3480, 3544, 3556]\n",
      "alzheimer's disease []\n",
      "stroke and the alzheimer disease [1786]\n",
      "psd2 [2367, 3351]\n",
      "tcirg1 [2627, 3357]\n",
      "rin3 [2972, 3365]\n",
      "rufy1 [3151, 3375]\n",
      "sorl1 [3605]\n",
      "trem2 [3623]\n",
      "early - warning and tumor related disease risk group involved in endolysosomal transport. importance : mutations in app, psen1, and psen2 lead to early - onset alzheimer disease ( eoad ) but account for only approximately 11 % of eoad overall, leaving most of the genetic risk for the most severe form of alzheimer disease unexplained. this extreme phenotype likely harbors highly penetrant dna variants, making it primed for discovery of novel risk genes and pathways for ad. objective : to search for rare variants contributing to the risk for eoad. design, setting, and participants : in this case - control study, whole - exome sequencing ( wes ) was performed in 51 non - hispanic white ( nhw ) patients with eoad ( age at onset < 65 months ) and 19 caribbean hispanic families previously screened as negative for established app, psen1, and psen2 causal variants. participants were recruited from john p. hussman institute for cognitive genomics, case western reserve university, and columbia university. rare, deleterious, nonsynonymous, or loss - of - function variants were filtered to identify variants in known nor suspected ad genes, those in multiple unrelated nhw patients, variants present in 19 hispanic eoad wes families, and genes with variants in multiple unrelated nhw patients. these variants / genes were tested for association in an independent cohort of 1524 patients with eoad, 7046 patients with late - onset ad ( ser ), and 7001 cognitively intact controls ( age at examination, > 65 years ) from the alzheimer's disease genetics consortium. the trial was conducted from january 21, 2014, to october 13, 2016. main outcomes and measures : alzheimer disease diagnosed according to standard national institute of neurological and communicative disorders and stroke and the alzheimer disease and related disorders diagnosis criteria. association between alzheimer disease and genetic variants and genes was measured using logistic regression and sequence kernel association test - optimal gene tests, respectively. results : of the 1524 nhw patients with eoad, 765 ( 50. 2 % ) were women and mean ( sd ) age was 60. 0 ( 4. 9 ) years ; of the 7046 nhw patients with load, 4171 ( 25. 2 % ) were women and mean ( sd ) age was 77. 4 ( 8. 6 ) years ; and of the 7001 nhw controls, 4215 ( 60. 2 % ) were women and mean ( sd ) age was 77. 4 ( 8. 6 ) years. the gene psd2, for which multiple unrelated nhw cases had rare missense variants, was significantly associated with eoad ( p = 2. 05 x 10 - 6 ; bonferroni - corrected p value [ bp ] = 1. 3 x 10 - 3 ) and load ( p = 6. 22 x 10 - 6 ; bp = 4. 1 x 10 - 3 ). a missense variant in tcirg1, present in a nhw patient and segregating in 3 cases of a hispanic family, was more frequent in eoad cases ( odds ratio [ or ], 2. 13 ; 95 % ci, 0. 99 - 4. 55 ; p =. 06 ; bp = 0. 413 ), and significantly associated with load ( or, 2. 23 ; 95 % ci, 1. 37 - 3. 62 ; p = 7. 2 x 10 - 4 ; bp = 5. 0 x 10 - 3 ). a missense variant in the load risk gene rin3 showed suggestive evidence of association with eoad after bonferroni correction ( or, 4. 56 ; 95 % ci, 1. 26 - 16. 48 ; p =. 02, bp = 0. 091 ). in addition, a missense variant in rufy1 identified in 2 nhw eoad cases showed suggestive evidence of an association with eoad as well ( or, 18. 63 ; 95 % ci, 1. 62 - 213. 45 ; p =. 003 ; bp = 0. 129 ). conclusions and relevance : the genes psd2, tcirg1, rin3, and rufy1 all may be involved in endolysosomal transport - a process known to be important to development of ad. furthermore, this study identified shared risk genes between eoad and load similar to previously reported genes, such as sorl1, psen2, and trem2.\n",
      "alzheimer disease [160, 305, 1666, 1798, 1878]\n",
      "psen1 [121, 836]\n",
      "psen2 [132, 847, 3655]\n",
      "alzheimer disease [160, 305, 1666, 1798, 1878]\n",
      "ad [140, 182, 232, 473, 548, 716, 1136, 1222, 1399, 1435, 2081, 2191, 2429, 2492, 2580, 2755, 2879, 2991, 3058, 3156, 3216, 3277, 3523, 3590, 3599]\n",
      "alzheimer's disease [1528]\n",
      "stroke and the alzheimer disease [1783]\n",
      "psd2 [2383, 3394]\n",
      "tcirg1 [2650, 3400]\n",
      "rin3 [3004, 3408]\n",
      "rufy1 [3188, 3418]\n",
      "sorl1 [3648]\n",
      "trem2 [3666]\n",
      "prioritization of drug target area for neurodegenerative disease by integrating genetic and proteomic data from brain and blood. background: neurodegenerative diseases are among the most prevalent and devastating neurological disorders, with few effective prevention and treatment strategies. we shoot for to integrate genetic and proteomic data to prioritize drug targets for neurodegenerative diseases. methods: we screened human proteomes through mendelian randomization to identify causal mediators of alzheimer ' s disease, parkinson ' s disease, amyotrophic lateral sclerosis, multiple sclerosis, frontotemporal dementia, and lewy body dementia. for instruments, we used brain and blood protein quantitative trait loci identified from one genome - wide association study with 376 player and another with 3301 participants, respectively. causal associations were subsequently validated by sensitivity analyses and colocalization. the safety and druggability of identified targets were also evaluated. results: our analyses showed targeting bin1, grn, and ret levels in blood as well as ace, ica1l, map1s, slc20a2, and tom1l2 levels in brain might reduce alzheimer ' s disease risk, while ica1l, slc20a2, and tom1l2 were not recommended as prioritized drugs due to the identified potential side effects. brain cd38, dgkq, gpnmb, and sec23ip were candidate targets for parkinson ' s disease. among them, gpnmb was the most promising target area for parkinson ' s disease with their causal kinship evidenced by studies on both brain and blood tissues. interventions targeting fcrl3, lman2, and mapk3 in blood and dhrs11, fam120b, shmt1, and tsfm in brain might affect multiple sclerosis risk. the risk of amyotrophic lateral sclerosis might be reduced by medications targeting dhrs11, psmb3, sarm1, and scfd1 in brain. conclusions: our discipline prioritized 22 proteins as targets for neurodegenerative diseases and provided preliminary evidence for drug development. further studies are warranted to validate these targets.\n",
      "neurodegenerative diseases [141, 377, 1888]\n",
      "neurodegenerative diseases [141, 377, 1888]\n",
      "neurological disorders [213]\n",
      "neurodegenerative diseases [141, 377, 1888]\n",
      "alzheimer's disease []\n",
      "parkinson's disease []\n",
      "amyotrophic lateral sclerosis [552, 1707]\n",
      "multiple sclerosis [583, 1670]\n",
      "dementia [618, 642]\n",
      "lewy body dementia [632]\n",
      "bin1 [1045]\n",
      "grn [1051]\n",
      "ret [1060]\n",
      "ace [1091]\n",
      "ica1l [1096, 1193]\n",
      "map1s [1103]\n",
      "slc20a2 [1110, 1200]\n",
      "tom1l2 [1123, 1213]\n",
      "cd38 [1314]\n",
      "dgkq [1320]\n",
      "gpnmb [1326, 1407]\n",
      "sec23ip [1337]\n",
      "fcrl3 [1578]\n",
      "lman2 [1585]\n",
      "mapk3 [1596]\n",
      "dhrs11 [1615, 1779]\n",
      "fam120b [1623]\n",
      "shmt1 [1632]\n",
      "tsfm [1643]\n",
      "sclerosis [572, 592, 1679, 1727]\n",
      "psmb3 [1787]\n",
      "sarm1 [1794]\n",
      "scfd1 [1805]\n",
      "prioritization provides genome delivery to neurodegenerative processes by acquiring genetic via proteomic genes from brain and blood. background : neurodegenerative illnesses are among the most prevalent and devastating neurological disorders, without few effective prevention and treatment strategies. we aimed to integrate genetic and proteomic data to prioritize drug targets for neurodegenerative diseases. methods : we screened human proteomes through mendelian randomization to identify causal mediators of alzheimer's disease, parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, frontotemporal dementia, and lewy body dementia. for instruments, we used brain and blood protein quantitative trait loci identified from one genome - wide association study with 376 participants and another with 3301 participants, respectively. causal associations were subsequently validated by sensitivity analyses and colocalization. the safety and druggability of identified targets were also evaluated. results : our analyses showed targeting bin1, grn, and ret levels in blood as well as ace, ica1l, map1s, slc20a2, and aaa levels in brain might reduce alzheimer's disease risk, while ica1l, slc20a2, and tom1l2 were not recommended as prioritized drugs due to the identified potential side effects. brain cd38, dgkq, gpnmb, and sec23ip offered candidate targets for parkinson's disease. among them, gpnmb was the earliest promising target within parkinson's cancer with their causal relationship evidenced by studies on both brain and blood tissues. patients targeting fcrl3, lman2, and mapk3 in blood and dhrs11, fam120b, shmt1, and tsfm in brain might affect multiple sclerosis risk. the risk of amyotrophic lateral sclerosis might be reduced by medications targeting dhrs11, psmb3, sarm1, and scfd1 in brain. conclusions : our study prioritized 22 proteins as targets for neurodegenerative diseases and provided preliminary evidence during drug development. further studies are warranted to validate these associations.\n",
      "neurodegenerative diseases [383, 1889]\n",
      "neurodegenerative diseases [383, 1889]\n",
      "neurological disorders [220]\n",
      "neurodegenerative diseases [383, 1889]\n",
      "alzheimer's disease [513, 1166]\n",
      "parkinson's disease [534, 1380]\n",
      "amyotrophic lateral sclerosis [555, 1712]\n",
      "multiple sclerosis [586, 1675]\n",
      "dementia [621, 645]\n",
      "lewy body dementia [635]\n",
      "bin1 [1055]\n",
      "grn [1061]\n",
      "ret [1070]\n",
      "ace [1101]\n",
      "ica1l [1106, 1198]\n",
      "map1s [1113]\n",
      "slc20a2 [1120, 1205]\n",
      "tom1l2 [1218]\n",
      "cd38 [1319]\n",
      "dgkq [1325]\n",
      "gpnmb [1331, 1413]\n",
      "sec23ip [1342]\n",
      "fcrl3 [1583]\n",
      "lman2 [1590]\n",
      "mapk3 [1601]\n",
      "dhrs11 [1620, 1784]\n",
      "fam120b [1628]\n",
      "shmt1 [1637]\n",
      "tsfm [1648]\n",
      "sclerosis [575, 595, 1684, 1732]\n",
      "psmb3 [1792]\n",
      "sarm1 [1799]\n",
      "scfd1 [1810]\n",
      "turner syndrome in childhood and adolescence. turner syndrome (ts) is the most common chromosomal disorder causing short height in females. the short stature is caused at least in part by haploinsufficiency of the short stature homeobox (shox) gene. complete spontaneous puberty may occur in approximately 16% of patients, with spontaneous pregnancy in astir to 4% . the final height of untreated ts girls is 86 - 88% of the mean adult female height. growth hormone (gh) given alone or with oxandrolone improves final height. the major factors determining the final result of gh therapy are the dose of gh used and the number of years of gh therapy prior to oestrogenization. pubertal induction in ts should be individualized mien in mind growth optimization and psychological issues. adolescents and adults with ts crataegus oxycantha face a range of medical, fertility and psychosocial issues. psychological support for ts individuals and families is important throughout life and should ideally be provided by both health professionals and ts support groups.\n",
      "turner syndrome [0, 46]\n",
      "ts [63, 319, 397, 698, 794, 805, 813, 922, 1043]\n",
      "chromosomal disorder [86]\n",
      "short stature [144, 214]\n",
      "haploinsufficiency of the short stature [188]\n",
      "shox [238]\n",
      "growth hormone [451]\n",
      "gh [124, 380, 446, 467, 521, 576, 603, 638, 968]\n",
      "lister syndrome in babies and childhood. maintenance syndrome ( ts ) is the most prominent chromosomal disorder causing short stature in females. the short stature is caused at least in part by haploinsufficiency from the short stature homeobox ( shox ) gene. complete spontaneous puberty may occur in approximately 16 % of patients, with spontaneous pregnancy in up to 4 %. the final height of untreated nt girls is 86 - 88 % of the mean adult female height. growth factors ( gh ) given alone or with oxandrolone improves skull height. key various factors determining the outcome of gh therapy are the dose of gh used and the number of years of gh therapy prior to oestrogenization. pubertal induction in ts should be individualized bearing in mind growth factors and psychological issues. adolescents and adults with ts may face a range of medical, fertility and psychosocial issues. psychological support for ts individuals and families is important throughout life and should ideally be provided by both health professionals including ts support groups.\n",
      "turner syndrome []\n",
      "ts [64, 330, 706, 800, 811, 819, 912, 1039]\n",
      "chromosomal disorder [91]\n",
      "short stature [120, 150, 222]\n",
      "haploinsufficiency of the short stature []\n",
      "shox [247]\n",
      "growth hormone []\n",
      "gh [388, 455, 477, 532, 584, 611, 646, 958]\n",
      "two novel intragenic variants in the fmr1 gene in patient with shady clinical diagnosis of fragile x syndrome and no cgg repeat enlargement. the major and most well - studied genetic cause of fragile - x syndrome (fxs) is expansion of a cgg repeat in the 5 ' - utr of the fmr1 gene. routine testing for this expanding upon is performed globally. overall, there is a paucity of intragenic variants explaining fxs, a fact which is being addressed by a more systematic application of whole exome (wes) and whole genome (wgs) sequencing, even in the symptomatic setting. here we report two families comprising probands with a clinical suspicion of fxs and no cgg repeat expansions. apply wes / wgs we identified deleterious variants within the coding region of fmr1 in both families. in a family from finland we identified a complex indel c. 1021 - 1028delinstattgg in exon xi of fmr1 which gives rise to a frameshift and a premature termination codon (ptc ), p. asn341tyrfs * 7. follow - up mrna and protein studies on a cell line from the proband revealed that although the mrna levels of fmr1 were not altered, fragile x mental retardation 1 protein (fmrp) was undetectable. additionally, we identified a variant, c. 881 - 1g> t, affecting the canonical acceptor splice site of exon 10 of fmr1 in an australian family. our findings reinforce the importance of intragenic fmr1 variant testing, particularly in cases with clinical features of fxs and no cgg repeat expansions identified.\n",
      "fmr1 [37, 272, 757, 876, 1087, 1288, 1370]\n",
      "fragile x syndrome [91]\n",
      "fragile-x syndrome []\n",
      "fxs [214, 408, 644, 1440]\n",
      "fragile x mental retardation 1 protein [1110]\n",
      "fmrp [1150]\n",
      "two novel trials test in their fmr1 gene from patients with suspect clinical findings shows fragile a fever and no cgg repeat pattern. the major and most well - studied genetic cause of fragile - x syndrome ( fxs ) is expansion of a cgg repeat in the 5'- utr of the fmr1 gene. routine testing for this expansion is performed globally. overall, there is a paucity of intragenic variants explaining fxs, a fact which is being addressed by a more systematic application of whole exome ( wes ) and whole genome ( wgs ) models, even on the diagnostic setting. here we report two families comprising probands with a clinical suspicion of fxs and no cgg repeat expansions. using wes / wgs we identified deleterious variants within the promoters region of fmr1 in both families. in separate family from finland we identified a complex indel c. 1021 - 1028delinstattgg in exon 11 of fmr1 which gives rise to a frameshift and a premature termination codon ( ptc ), p. asn341tyrfs * 7. follow - up mrna and structural studies on a cell line from the proband proved that although the mrna levels of cats were not altered, fragile x mental retardation 1 protein ( fmrp ) was undetectable. additionally, we identified a variant, g. 881 - 1g > 6, affecting the canonical mrna splice site of exon 10 of fmr1 in an australian family. our findings reinforce the importance of intragenic fmr1 variant testing, particularly in cases with clinical features of fxs and no cgg repeat expansions identified.\n",
      "fmr1 [31, 266, 748, 874, 1287, 1369]\n",
      "fragile x syndrome []\n",
      "fragile-x syndrome []\n",
      "fxs [209, 397, 632, 1439]\n",
      "fragile x mental retardation 1 protein [1110]\n",
      "fmrp [1151]\n",
      "prepubertal girls with turner syndrome and tike with isolated shox deficiency receive like bone geometry at the radius. context: the low bone mineral density (bmd) and alterations in bone geometry observed in affected role with turner syndrome (ts) are likely caused by hypergonadotropic hypogonadism and / or by haploinsufficiency of the shox gene. objective: our objective was to compare bmd, bone geometry, and strength at the radius between prepubertal girls with ts and children with isolated shox deficiency (shox - d) to test the hypothesis that the ts radial off white phenotype may be caused by shox - d. design and setting: this comparative cross - sectional field of study was performed between march 2008 and may 2011 in 5 large centers for pediatric endocrinology. patients: twenty - two girls with ts (mean age 10. 3 years) and 10 children with shox - d (mean age decade. 3 years) were assessed practice peripheral quantitative computed tomography of the forearm. main outcomes: bmd, bone geometry, and strength at 4% and 65% sites of the radius were evaluated. results: trabeculate bmd was normal in ts (mean z - score = - 0. 2 + - 1. 1, p =. 5) as well as shox - d patients (mean z - score = 0. 5 + - 1. 5, p =. 3 ). at the proximal radius, we observed increased total bone area (z - scores = 0. ix + - 1. 5, p =. 013, and 1. 5 + - 1. 4, p =. 001, for ts and shox - d patients, respectively) and thin cortex (z - scores = - 0. 7 + - 1. 2, p = 0. 013, and - 2. 0 + - 1. 2, p <. 001, respectively) in both groups. bone strength index was normal in ts as well as shox - d patients (z - scores = 0. 3 + - 1. 0, p =. 2, and 0. 1 + - 1. 3, p =. 8, respectively ). conclusions: the similar bone geometry changes of the radius in ts and shox - d patients support the guess that loss of 1 copy of shox exist responsible for the radial bone phenotype associated with ts.\n",
      "turner syndrome [23, 228]\n",
      "isolated shox deficiency [53, 489]\n",
      "ts [245, 468, 557, 784, 812, 1081, 1115, 1187, 1368, 1390, 1562, 1591, 1738, 1760, 1873]\n",
      "hypergonadotropic hypogonadism [270]\n",
      "haploinsufficiency [313]\n",
      "shox [62, 339, 498, 515, 604, 859, 1172, 1375, 1576, 1745, 1804]\n",
      "prepubertal girls exhibited down syndrome with children with isolated shox lesions share similar dorsal geometry at round radius. context : the low bone mineral density ( bmd ) and alterations in bone geometry observed in patients with turner syndrome ( ts ) are likely caused by hypergonadotropic hypogonadism and / or by haploinsufficiency of the shox gene. objective : our objective was to compare bmd, bone geometry, and strength at the radius between prepubertal girls with ts and children with isolated shox deficiency ( shox - d ) to test the hypothesis that the ts radial bone phenotype may be caused by shox - d. design and setting : this comparative cross - sectional study was performed between may 2008 and may 2011 by 5 large centers for pediatric endocrinology. patients : twenty - two girls with ts ( mean age 10. 3 years ) and 10 children with shox - d ( mean age 10. 3 decades ) were assessed using peripheral quantitative computed tomography of the forearm. main outcomes : bmd, bone geometry, and strength at 4 % and 65 % sites of the radius were evaluated. results : trabecular bmd was normal in ts ( mean z - score = - 0. 2 + - 1. 1, p =. 2 ) as well as shox - d patients ( mean z - score = 0. 5 + - 1. 2, p =. 3 ). at the proximal radius, we observed increased total bone area ( z - scores = 0. 9 + - 1. 7, p =. 013, and 1. 5 + - 1. 4, p =. 001, for ts and shox - d patients, respectively ) and thin cortex ( z - scores = - 0. 7 + - 1. 2, p = 17. 013, and - 2. 0 + - 1. 2, p <. 001, respectively ) in both groups. bone strength index was normal in ts as sure as shox - d patients ( z - scores = 0. 3 + - 1. 0, p =. 2, and 0. 1 + - 1. 3, p =. 8, respectively ). conclusions : the similar bone geometry changes of the radius in ts and shox - d patients support the hypothesis that loss of its copy of shox is responsible for increased radial bone phenotype associated with ts.\n",
      "turner syndrome [236]\n",
      "isolated shox deficiency [500]\n",
      "ts [228, 254, 479, 570, 782, 811, 1082, 1116, 1190, 1372, 1394, 1570, 1599, 1748, 1770, 1810, 1893]\n",
      "hypergonadotropic hypogonadism [280]\n",
      "haploinsufficiency [323]\n",
      "shox [70, 349, 509, 527, 612, 860, 1175, 1379, 1584, 1755, 1821]\n",
      "turner syndrome introduce with tall stature due to overdosage of the shox gene. turner syndrome be one of the most common chromosomal disorder. it is caused by numerical or structural abnormalities of the x chromosome and results in short stature and gonadal dysgenesis. the short stature arises from haploinsufficiency of the shox gene, whereas overdosage contributes to tall stature. this report describes the first korean character of turner syndrome with tall stature caused by shox overdosage. the patient presented with primary amenorrhea and hypergonadotropic hypogonadism at the age of 17 years. estrogen replacement therapy was initiated at that time. she displayed tall stature from childhood, with normal growth velocity, and reached a final height of 190 cm (standard deviation grade, quaternary. 3) at the age of 30 years. her karyotype was 46, x, psu idic (x) (q21. 2 ), representing partial monosomy of xq and partial trisomy of xp. analysis by multiplex ligation - dependent probe amplification detected a duplication at xp22. 3 - xp22. 2, encompassing the ppp2r3 gene near the 5 ' - end of the shox gene through the fancd gene at xp22. 2.\n",
      "overdosage [51, 346, 487]\n",
      "shox [69, 327, 482, 1111]\n",
      "chromosomal disorders []\n",
      "structural abnormalities of the x chromosome [173]\n",
      "short stature [233, 275]\n",
      "haploinsufficiency [301]\n",
      "amenorrhea and hypergonadotropic hypogonadism [534]\n",
      "ppp2r3 [1073]\n",
      "fancd [1133]\n",
      "turner also associated with excessive anxiety owing to overdosage of the mouse gene. turner syndrome is reportedly of the most common chromosomal disorders. it makes congenital by numerical or structural abnormalities of the x chromosome and results in short stature and gonadal dysgenesis. the short stature arises from obstruction of the shox gene, whereas overdosage contributes to tall stature. this report describes the south korean case of turner syndrome with tall stature caused by shox overdosage. the patient diagnosed with acute amenorrhea and hypergonadotropic hypogonadism at the age of 17 years. estrogen replacement therapy had initiated at that time. she displayed tall stature from childhood, with normal growth velocity, and reached a final height of 190 cm ( standard deviation score, 4. 3 ) at the age of 30 years. her karyotype was 46, x, psu idic ( x ) ( q21. 2 ), representing partial monosomy of xq and partial trisomy of xp. analysis by multiplex ligation - dependent probe amplification detected x chromosome at xp22. 3 - xp22. 2, encompassing the ppp2r3 gene near the 5'- end of the shox gene through the fancd gene at xp22. 2.\n",
      "overdosage [55, 359, 495]\n",
      "shox [340, 490, 1110]\n",
      "chromosomal disorders [134]\n",
      "structural abnormalities of the x chromosome [193]\n",
      "short stature [253, 295]\n",
      "haploinsufficiency []\n",
      "amenorrhea and hypergonadotropic hypogonadism [540]\n",
      "ppp2r3 [1074]\n",
      "fancd [1132]\n",
      "ancestral hemochromatosis: pathogenesis, diagnosis, and intervention. in the late 1800s, hemochromatosis was considered an odd autoptic finding. more than than a century later, it was finally recognized as a hereditary, multi - organ disorder associated with a polymorphism that is common among white people: a 845g - -> a change in hfe that results in c282y in the factor product. hemochromatosis is now a well - defined syndrome characterized by normal iron - driven erythropoiesis and the toxic accumulation of iron in parenchymal cells of liver, heart, and endocrine glands. it can be caused by mutations that affect any of the proteins that limit the entry of iron into the blood. in mice, deletion of the iron hormone hepcidin and any of 8 genes that regulate its biology, including hfe, transferrin receptor 2 (tfr2 ), and hemojuvelin (hjv) (which all sense the accumulation of iron that hepcidin corrects) or ferroportin (fpn) (the cellular iron exporter down - regulated by hepcidin ), cause iron overload but not organ disease. in humans, loss of tfr2, hjv, and hepcidin itself or fpn mutations result in full - winded hemochromatosis. unlike these rare instances, in white people, homozygotes for c282y polymorphism in hfe are numerous, but they are only predisposed to hemochromatosis; complete organ disease develops in a minority, when these individuals abuse alcohol or from other unidentified modifying factors. hfe gene testing can be used to diagnose hemochromatosis, but analyses of liver histology and clinical features are still required to identify patients with rare, non - hfe forms of the disease. the role of hepcidin in the pathogenesis of hemochromatosis reveals its law of similarity to endocrine diseases such as diabetes and indicates new approaches to diagnosis and management of this common disorder in iron metabolism.\n",
      "hereditary hemochromatosis []\n",
      "hemochromatosis [10, 89, 382, 1129, 1281, 1469, 1667]\n",
      "multi-organ disorder []\n",
      "hfe [333, 789, 1230, 1428, 1597]\n",
      "hemochromatosis [10, 89, 382, 1129, 1281, 1469, 1667]\n",
      "hepcidin [724, 895, 983, 1072, 1635]\n",
      "hfe [333, 789, 1230, 1428, 1597]\n",
      "transferrin receptor 2 [794]\n",
      "tfr2 [818, 1057]\n",
      "hemojuvelin [830]\n",
      "hjv [843, 1063]\n",
      "tfr2 [818, 1057]\n",
      "hjv [843, 1063]\n",
      "hemochromatosis; complete organ disease [1281]\n",
      "endocrine diseases [1716]\n",
      "diabetes [1743]\n",
      "common disorder [1817]\n",
      "hereditary diseases : discovery, control, et prevention. in the late 1800s, hemochromatosis was considered an odd autoptic finding. more than 2 century later, it was finally recognized as a hereditary, multi - organ disorder associated with a polymorphism that is common among white people : a 845g - - > a change in hfe that results in c282y in the deficiency product. hemochromatosis is now a well - defined syndrome characterized by normal iron - driven erythropoiesis and the toxic accumulation to iron in parenchymal cells of liver, heart, and endocrine glands. it can be caused by mutations that affect any of the proteins to limit the entry of iron into the blood. in mice, deletion of the iron hormone hepcidin and any of 8 genes that regulate its biology, including hfe, signal receptor 2 ( tfr2 ), and raf ( hjv ) ( which all sense the accumulation of iron that hepcidin corrects ) or ferroportin ( fpn ) ( the cellular iron exporter down - regulated by hepcidin ), cause iron overload but not organ disease. in humans, loss of tfr2, hjv, and hepcidin itself or fpn mutations result in full - blown damage. unlike these rare instances, in white people, homozygotes for c282y polymorphism in hfe are numerous, but they are only predisposed to hemochromatosis ; complete organ disease develops in a minority, when these individuals abuse alcohol or from other unidentified modifying factors. hfe gene testing can be used to diagnose hemochromatosis, but analyses from liver histology and clinical features are still required to identify patients with rare, non - hfe forms of the disease. the role of hepcidin in the pathogenesis of hemochromatosis reveals certain similarities to endocrine diseases such as diabetes and indicates new approaches to diagnosis and management of this common disorder in basal metabolism.\n",
      "hereditary hemochromatosis []\n",
      "hemochromatosis [76, 370, 1252, 1441, 1641]\n",
      "multi-organ disorder []\n",
      "hfe [317, 775, 1201, 1400, 1571]\n",
      "hemochromatosis [76, 370, 1252, 1441, 1641]\n",
      "hepcidin [710, 872, 964, 1053, 1609]\n",
      "hfe [317, 775, 1201, 1400, 1571]\n",
      "transferrin receptor 2 []\n",
      "tfr2 [800, 1038]\n",
      "hemojuvelin []\n",
      "hjv [818, 1044]\n",
      "tfr2 [800, 1038]\n",
      "hjv [818, 1044]\n",
      "hemochromatosis; complete organ disease []\n",
      "endocrine diseases [1689]\n",
      "diabetes [1716]\n",
      "common disorder [1790]\n",
      "symptomatic rating of hereditary hemochromatosis (hfe and non - hfe ). the direction and understanding of hereditary hemochromatosis have evolved with recent advances in iron biology and the associated discovery of numerous genes involved in iron metabolic process. hfe - related (type 1) hemochromatosis remains the most frequent form, characterized by c282y mutation homozygosity. rare forms of hereditary hemochromatosis admit type 2 (a and type b, juvenile person hemochromatosis caused by hjv and hamp mutation ), type ternion (related to tfr2 mutation ), and type 4 (a and b, ferroportin disease ). the diagnostic evaluation relies on comprehension of the involved pathophysiologic defect, and careful characterization of the phenotype, which gives clues to guide appropriate genetic testing.\n",
      "hereditary hemochromatosis [22, 106, 397]\n",
      "hfe [50, 64, 266]\n",
      "hemochromatosis [33, 117, 289, 408, 468]\n",
      "juvenile hemochromatosis []\n",
      "hjv [494]\n",
      "hamp [502]\n",
      "tfr2 [544]\n",
      "an evaluation of tissue abnormalities ( j versus p - hfe ). the management and understanding of hereditary hemochromatosis have evolved with recent advances in iron biology and the associated activation of numerous genes involved in iron metabolism. hfe - derived ( type 1 ) hemochromatosis remains the most frequent form, characterized with c282y mutation homozygosity. rare forms of hereditary hemochromatosis include type i ( a and b, juvenile disease caused by hjv and hamp mutation ), terminal 3 ( related viral tfr2 mutation ), and type 6 ( a and b, ferroportin disease ). the diagnostic evaluation relies on comprehension of the involved pathophysiologic defect, and careful characterization along the phenotype, which gives clues to guide appropriate genetic treatment.\n",
      "hereditary hemochromatosis [96, 385]\n",
      "hfe [53, 250]\n",
      "hemochromatosis [107, 275, 396]\n",
      "juvenile hemochromatosis []\n",
      "hjv [465]\n",
      "hamp [473]\n",
      "tfr2 [517]\n",
      "push the lawsuit of alzheimer ' s and gne myopathy. age be the common risk factor for both neurodegenerative and neuromuscular diseases. alzheimer disease (ad ), a neurodegenerative disorder, causes dementia with age progression while gne myopathy (gnem ), a neuromuscular disorder, causes muscle degeneration and loss of muscle motor campaign with age. individuals with mutations in presenilin or amyloid precursor protein (app) gene develop ad while mutations in gne (udp n - acetylglucosamine 2 epimerase / n - acetyl mannosamine kinase ), key sialic acid biosynthesis enzyme, cause gnem. although gnem is characterized with degeneration of muscle cells, it is shown to have similar disease hallmarks like aggregation of abeta and accumulation of phosphorylated tau and other misfolded proteins in muscle cell exchangeable to ad. similar impairment in cellular functions have been reported in both disorderliness such as break of cytoskeletal network, changes in glycosylation pattern, mitochondrial disfunction, oxidative stress, upregulation of chaperones, unfolded protein response in er, autophagic vacuoles, cell death, and apoptosis. interestingly, ad and gnem are the two diseases with similar phenotypic condition affecting neuron and muscular tissue, respectively, resulting in entirely different pathology. this review represents a comparative outlook of ad and gnem that could lead to target common mechanism to find a plausible therapeutic for both the diseases.\n",
      "alzheimer's []\n",
      "gne [38, 235, 249, 465, 586, 601, 1165, 1375]\n",
      "myopathy [42, 239]\n",
      "neurodegenerative and neuromuscular diseases [91]\n",
      "alzheimer disease [137]\n",
      "ad [156, 443, 829, 1158, 1368, 1393]\n",
      "neurodegenerative disorder [164]\n",
      "dementia [199]\n",
      "myopathy [42, 239]\n",
      "neuromuscular disorder [259]\n",
      "muscle degeneration and loss of muscle motor movement []\n",
      "amyloid precursor protein [398]\n",
      "udp n-acetylglucosamine 2 epimerase/n-acetyl mannosamine kinase []\n",
      "hallmarks like aggregation of abeta [694]\n",
      "tau [765]\n",
      "mitochondrial dysfunction []\n",
      "death [1121]\n",
      "during chronic aging through alzheimer's syndrome gne myopathy. age is the common risk factor for both neurodegenerative and neuromuscular diseases. alzheimer disease ( ad ), a neurodegenerative disorder, causes dementia with age progression while gne myopathy ( gnem ), a neuromuscular disorder, causes muscle degeneration and loss of muscle motor movement with age. individuals with mutations in ad or amyloid precursor 1 ( app ) gene develop ad while mutations on gne ( udp n - acetylglucosamine 2 epimerase / n - acetyl mannosamine kinase ), key sialic acid biosynthesis enzyme, cause gnem. although gnem is characterized with degeneration of heart cells, it is shown to have similar disease hallmarks like aggregation on abeta and accumulation of phosphorylated tau and other associated proteins in muscle cell similar in ad. the impairment in cellular functions have been reported in both disorders such as breakdown of cytoskeletal network, changes in glycosylation pattern, mitochondrial dysfunction, oxidative stress, upregulation of chaperones, unfolded protein response in er, autophagic vacuoles, cell death, and apoptosis. interestingly, ad on gnem are the two diseases with similar phenotypic condition affecting neuron and muscle, respectively, resulting in entirely different pathology. this review represents a comparative outlook of ad and gnem that could lead to target common mechanism to find a plausible therapeutic for both the diseases.\n",
      "alzheimer's [29]\n",
      "gne [50, 248, 263, 467, 589, 604, 1157, 1358]\n",
      "myopathy [54, 252]\n",
      "neurodegenerative and neuromuscular diseases [103]\n",
      "alzheimer disease [149]\n",
      "ad [169, 398, 445, 827, 1151, 1351, 1376]\n",
      "neurodegenerative disorder [177]\n",
      "dementia [212]\n",
      "myopathy [54, 252]\n",
      "neuromuscular disorder [273]\n",
      "muscle degeneration and loss of muscle motor movement [304]\n",
      "amyloid precursor protein []\n",
      "udp n-acetylglucosamine 2 epimerase/n-acetyl mannosamine kinase []\n",
      "hallmarks like aggregation of abeta []\n",
      "tau [767]\n",
      "mitochondrial dysfunction [982]\n",
      "death [1114]\n",
      "antisense oligonucleotide discourse rescues ube3a expression and multiple phenotypes of an angelman syndrome computer mouse model. angelman syndrome (as) is a severe neurodevelopmental disorder for which only symptomatic treatment with limited benefits is available. as is caused by mutations affecting the motherly inherited ubiquitin protein ligase e3a (ube3a) gene. previous studies showed that the silenced paternal ube3a gene can be activated by point the antisense ube3a - ats transcript. we investigated antisense oligonucleotide - induced (aso - induced) ube3a - ats degradation and its ability to induce ube3a reinstatement and rescue of ampere phenotypes in an establish ube3a mouse model. we found that a single intracerebroventricular injection of asos at postnatal day 1 (p1) or p21 in as mice resulted in potent and specific ube3a reinstatement in the brain, with levels up to 74% of wt levels in the cortex and a full rescue of sensitivity to audiogenic seizures. as mice treated with aso at p1 also showed rescue of established as phenotypes, such as open field and forced swim test behaviors, and significant advance on the reversed rotarod. hippocampal plasticity of treated as mice was comparable to wt but not significantly different from pbs - treated as mice. no rescue was observed for the marble burying and nest building phenotypes. our findings highlight the promise of aso - mediated reactivation of ube3a as a disease - modifying treatment for as.\n",
      "ube3a [44, 356, 420, 471, 563, 613, 681, 839, 1427]\n",
      "angelman syndrome [91, 131]\n",
      "neurodevelopmental disorder [166]\n",
      "ubiquitin protein ligase e3a [326]\n",
      "ube3a [44, 356, 420, 471, 563, 613, 681, 839, 1427]\n",
      "seizures [969]\n",
      "the oligonucleotide therapy rescues that vaccine confirmed diagnostic phenotypes of human angelman syndrome affected mother. angelman syndrome ( apt ) is a severe neurodevelopmental disorder for which only symptomatic treatment with limited benefits is available. as is caused by antibodies affecting the maternally inherited ubiquitin protein ligase e3a ( ube3a ) gene. previous studies showed that the silenced paternal ube3a gene can be activated by targeting the antisense ube3a - ats transcript. we investigated antisense oligonucleotide - induced ( aso - induced ) ube3a - ats degradation and its ability to induce ube3a reinstatement and rescue of as phenotypes in an established model mouse model. we found that a single intracerebroventricular injection of asos at postnatal day 1 ( p1 ) or p21 treated as mice resulted in potent and specific aggressive reinstatement in the brain, with levels up to 74 % of wt levels in the cortex and a subsequent rescue of sensitivity to audiogenic seizures. as mice treated with aso at p1 also showed rescue signs known as phenotypes, such as open field type forced swim test behaviors, and significant improvement on the reversed rotarod. hippocampal plasticity of treated as mice was comparable to wt but not significantly different from pbs - treated as mice. no rescue was observed for the marble burying and nest building phenotypes. our findings highlight the promise of aso - mediated recovery of ube3a as a disease - modifying treatment for as.\n",
      "ube3a [357, 422, 477, 571, 621, 1450]\n",
      "angelman syndrome [90, 125]\n",
      "neurodevelopmental disorder [163]\n",
      "ubiquitin protein ligase e3a [326]\n",
      "ube3a [357, 422, 477, 571, 621, 1450]\n",
      "seizures [994]\n",
      "the rna - ski binding slight - x genial retardation protein and its theatrical role beyond the mental capacity. information technology is well - established that variations of a cgg repeat expansion in the gene fmr1, which encodes the fragile - x mental retardation protein (fmrp ), cause the neurocognitive disorder, fragile - x syndrome (fxs ). however, multiple observations propose a general and complex regulatory role of fmrp in cognitive process outside the brain: (1) fmrp is ubiquitously expressed in the body, suggesting it functions in multiple organ systems; (2) patients with fxs can exhibit a physical phenotype that is consistent with an underlying abnormality in connective tissue; (3) different cgg repeat expansion lengths in fmr1 result in different clinical outcomes due to different pathogenic mechanisms; (4) the function of fmrp as an rna - binding protein suggests it has a general regulatory role. this review details the complex nature of fmrp and the dissimilar cgg repeat elaboration lengths and the evidence stick out the essential role of the protein in a variety of biologic and pathological processes.\n",
      "fragile-x mental retardation protein []\n",
      "fmr1 [211, 744]\n",
      "fmrp [275, 427, 476, 847, 965]\n",
      "neurocognitive disorder [293]\n",
      "fragile-x syndrome []\n",
      "fxs [340, 589]\n",
      "brain: (1 [465]\n",
      "another dna - binding fragile - x mental retardation test states its implications beyond the gene. it is well - established that variations of a cgg average expansion in the gene complex, which encodes the fragile - x mental retardation protein ( fmrp ), cause the neurocognitive disorder, fragile - x syndrome ( bwf ). however, multiple observations suggest a general and complex regulatory role of fmrp in processes outside the brain : ( 1 ) fmrp is ubiquitously expressed in the cortex, suggesting it functions in multiple organ systems ; ( 2 ) those with fxs can exhibit a physical phenotype that is consistent with an underlying abnormality in connective tissue ; ( 3 ) different cgg repeat expansion lengths in general result in distinct clinical outcomes due to different pathogenic mechanisms ; ( 4 ) the function of fmrp as an rna - binding protein suggests it has a general regulatory capacity. this review details the complex nature of fmrp and the different cgg repeat expansion sizes is the evidence supporting the essential role of the protein in a variety of biological and pathological processes.\n",
      "fragile-x mental retardation protein []\n",
      "fmr1 []\n",
      "fmrp [247, 400, 444, 825, 947]\n",
      "neurocognitive disorder [265]\n",
      "fragile-x syndrome []\n",
      "fxs [559]\n",
      "brain: (1 []\n",
      "hippocampal dysfunction and cognitive impairment in fragile - adam syndrome. fragile - disco biscuit syndrome (fxs) is the most common form of inherited intellectual handicap and the leading genetic cause of autism spectrum disorder. fxs is caused by transcriptional silencing of the fragile x mental retardation 1 (fmr1) gene due to a cgg repeat expansion, resulting in the loss of fragile x mental retardation protein (fmrp ). fmrp is involved in transcriptional ordinance and trafficking of mrna from the nucleus to the cytoplasm and distal sites both in pre - and post - synaptic terminals. consequently, fxs is a multifaceted disorder associated with impaired synaptic plasticity. one region of the brain that represent significantly impacted by the loss of fmrp is the hippocampus, a structure that plays a critical role in the regulation of mood and cognition. this review allow an overview of the neuropathology of fragile - x syndrome, highlighting how structural and synaptic deficits in hippocampal subregions, including the ca1 exhibiting exaggerated metabotropic glutamate receptor dependent long - term depression and the dentate gyrus displaying hypofunction of n - methyl - d - aspartate receptors, contribute to cognitive impairments associated with this neurodevelopmental disorder.\n",
      "hippocampal dysfunction [0]\n",
      "cognitive impairment [28, 1229]\n",
      "fragile-x syndrome []\n",
      "fxs [111, 234, 609]\n",
      "autism spectrum disorder [208]\n",
      "fragile x mental retardation 1 [284]\n",
      "fmr1 [316]\n",
      "fragile x mental retardation protein [383]\n",
      "fmrp [421, 429, 763]\n",
      "ca1 [1036]\n",
      "depression [1117]\n",
      "cognitive impairments [1229]\n",
      "neurodevelopmental disorder [1272]\n",
      "skeletal dysfunction and visual impairment via fragile - enhancing lesions. fragile - x syndrome ( fxs ) is the most common form of inherited intellectual disability and a leading genetic cause of autism spectrum disorder. fxs is caused by transcriptional silencing of the fragile x mental retardation 1 ( fmr1 ) gene due to a cgg repeat expansion, resulting in the loss of tre x global retardation protein ( fmrp ). fmrp is involved in transcriptional regulation and allocation of mrna from the nucleus to the cytoplasm and distal sites both in pre - and post - processing terminals. consequently, fxs is a multifaceted condition associated with impaired synaptic plasticity. one region of the brain that is significantly impacted by the loss of genes is the hippocampus, a structure that plays a critical role in the regulation of mood and cognition. this review provides an overview of the neuropathology of fragile - x syndrome, showing how structural and synaptic deficits in hippocampal subregions, including the ca1 exhibiting exaggerated metabotropic glutamate receptor dependent long - stature depression and the dentate gyrus displaying hypofunction of n - methyl - d - aspartate receptors, contribute to cognitive impairments related with this neurodevelopmental disorder.\n",
      "hippocampal dysfunction []\n",
      "cognitive impairment [1215]\n",
      "fragile-x syndrome []\n",
      "fxs [99, 223, 599]\n",
      "autism spectrum disorder [197]\n",
      "fragile x mental retardation 1 [273]\n",
      "fmr1 [306]\n",
      "fragile x mental retardation protein []\n",
      "fmrp [409, 417]\n",
      "ca1 [1019]\n",
      "depression [1103]\n",
      "cognitive impairments [1215]\n",
      "neurodevelopmental disorder [1255]\n",
      "fragile - x syndrome and fragile x - link tremor / ataxia syndrome: two front of fmr1. recent advances in our understanding of the clinical and molecular features of the slight - x mental - retardation 1 gene, fmr1, highlight the grandness of single - gene disorders. 15 years after its discovery, fmr1 continues to reveal new and unexpected clinical presentations and molecular mechanisms. loss of office of fmr1 is a model for neurodevelopmental and behavioural disorders, including mental retardation, autism, anxiety, and mood instability. in addition, overexpression and systema nervosum centrale perniciousness of fmr1 messenger rna causes a late - onset neurodegenerative disorder, the fragile - x - associated tremor / ataxia syndrome (fxtas ). a similar chemical mechanism is probably involved in premature ovarian failure, which affects up to 20% of female carriers of an altered fmr1 gene.\n",
      "fragile-x syndrome []\n",
      "fragile [0, 25, 693]\n",
      "tremor [42, 718]\n",
      "ataxia syndrome [51, 727]\n",
      "fmr1 [81, 210, 298, 409, 620, 890]\n",
      "fragile-x mental-retardation 1 []\n",
      "mental retardation [485]\n",
      "autism [505]\n",
      "anxiety [513]\n",
      "toxicity []\n",
      "neurodegenerative disorder [661]\n",
      "premature ovarian failure [806]\n",
      "neural - enhancing damage and specific x - associated tremor / ataxia control : further examples of fmr1. recent findings in our understanding of its clinical and molecular impact on the fragile - x mental - retardation 1 precursor, fmr1, highlight the importance of single - gene disorders. 15 years after its discovery, fmr1 continues to reveal new and unexpected clinical presentations on molecular mechanisms. loss of function of fmr1 is a model for neurodevelopmental and behavioural disorders, including mental retardation, autism, anxiety, and mood instability. in addition, overexpression and cns toxicity of fmr1 mrna causes a late - onset neurodegenerative disorder, the fragile - x - associated tremor / ataxia syndrome ( fxtas ). a genetic mechanism can probably involved in premature ovarian failure, which affects 8 to 20 % of female carriers of his altered fmr1 gene.\n",
      "fragile-x syndrome []\n",
      "fragile [187, 681]\n",
      "tremor [54, 706]\n",
      "ataxia syndrome [715]\n",
      "fmr1 [100, 233, 322, 434, 617, 872]\n",
      "fragile-x mental-retardation 1 []\n",
      "mental retardation [510]\n",
      "autism [530]\n",
      "anxiety [538]\n",
      "toxicity [605]\n",
      "neurodegenerative disorder [649]\n",
      "premature ovarian failure [787]\n",
      "aberrant group o - glcnacylation disrupts gne enzyme activity in gne myopathy. udp - n - acetylglucosamine 2 - epimerase / n - acetylmannosamine kinase (gne) is the key enzyme for the biosynthesis of sialic acids. sialic acids are terminal monosaccharides of glycoconjugates and gangliosides, which have an essential influence on versatile cell interactions. the sialylation of proteins varies during ontogeny, aging, and pathogenesis of degenerative diseases such as morbus alzheimer, diabetes mellitus type ii, or myopathies. mutation of methionine 743 in the gne leads to a 30% reduction of the enzyme activity and is responsible for an aggressive form of gne myopathy. gne myopathy or hereditary inclusion body myopathy (hibm) is an age - subject muscular dystrophy. here, we analyzed the impact of the exchange of methionine to threonine at position 743 which introduces an additional potential phosphorylation / o - glcnacylation site. we found increased o - glcnacylation of the m743t variant compared to the wild - type gne. in addition, removal of the o - glcnac of the m743t variant resulted in an increased activity comparable to activity of the wild - type gne. furthermore, the half - life of the m743t variant is two times longer than for the wild - type gne protein. this study provides that the balance of phosphorylation and o - glcnacylation is decisive involved in efficiency and regulation of gne.\n",
      "gne [42, 65, 153, 562, 659, 673, 1028, 1169, 1269, 1413]\n",
      "myopathy [69, 663, 677, 715]\n",
      "udp-n-acetylglucosamine 2-epimerase/n-acetylmannosamine kinase []\n",
      "degenerative diseases [438]\n",
      "morbus alzheimer, diabetes mellitus type ii [468]\n",
      "myopathies [516]\n",
      "gne myopathy [65, 659, 673]\n",
      "muscular dystrophy [751]\n",
      "aberrant n - oxide disrupts regular enzyme production of these enzymes. udp - n - acetylglucosamine 2 - epimerase / n - acetylmannosamine kinase ( gne ) is the key enzyme for controlling biosynthesis of sialic acids. sialic acids are terminal monosaccharides of glycoconjugates and gangliosides, which have an essential influence on various cell interactions. the sialylation of proteins varies during development, aging, and pathogenesis of degenerative illnesses such as morbus alzheimer, diabetes mellitus type ii, and myopathies. mutation of methionine 743 in the gne leads to a 30 % reduction of the enzyme activity and is favorable for an aggressive form of gne myopathy. gne myopathy or hereditary inclusion body myopathy ( hibm ) is an age - dependent muscular dystrophy. here, we analyzed the impact of the exchange of methionine to threonine at position 743 which introduces an additional potential phosphorylation / o - glcnacylation site. we found increased o - glcnacylation of the wild variant compared to the wild - type gne. in addition, removal of the o - glcnac of the m743t variant resulted in greatly increased sequence comparable to activity of the wild - type proteins. furthermore, the play - life of the m743t variant is two times longer than for the wild - type gne protein. this study provides that the balance of phosphorylation and o - glcnacylation is decisive involved in development and regulation of gne.\n",
      "gne [147, 568, 664, 678, 1036, 1287, 1432]\n",
      "myopathy [668, 682, 720]\n",
      "udp-n-acetylglucosamine 2-epimerase/n-acetylmannosamine kinase []\n",
      "degenerative diseases []\n",
      "morbus alzheimer, diabetes mellitus type ii [473]\n",
      "myopathies [522]\n",
      "gne myopathy [664, 678]\n",
      "muscular dystrophy [760]\n"
     ]
    }
   ],
   "source": [
    "# this code is to write the annotated abstracts in proper pubtator format.\n",
    "# we are getting mesh id (mention, type, id ) after running the above cell.\n",
    "# augmented abstracts will be written in augmented_data.txt\n",
    "\n",
    "number_of_pmids = len(set(pmids)) #number of unique pmids\n",
    "with open('latest_train_augmented_data.txt','w', encoding='utf8') as file_Outputfile: \n",
    "    for j in range(number_of_pmids-1): # no of unique pmids\n",
    "        for i in range(2): # because for each abstract we are doing 2 augmentations\n",
    "            #j=0\n",
    "            file_Outputfile.write(\"\\n\")\n",
    "            file_Outputfile.write(\"\\n\")\n",
    "            \n",
    "            file_Outputfile.write(augmented_titles[j][i].replace(\"\\n\", \"\").lower()+\"\\n\")\n",
    "            \n",
    "            file_Outputfile.write(augmented_abstracts[j][i].replace(\"\\n\", \"\").lower()+\"\\n\")\n",
    "\n",
    "            pmid = int(augmented_titles[j][i].split(\"|\")[0])\n",
    "            abstract = augmented_titles[j][i].split(\"|\")[2]+\" \"+augmented_abstracts[j][i].split(\"|\")[2]\n",
    "            abstract=abstract.replace(\"\\n\", \"\").lower()\n",
    "            print(abstract)\n",
    "            mesh_id = pmid_mesh[str(pmid)]\n",
    "            for mention, list1 in mesh_id.items():\n",
    "                mention=mention.lower()\n",
    "                type = list1[0]\n",
    "                id = list1[1]\n",
    "                indexes = [i for i in range(len(abstract) - len(mention) + 1) if abstract[i:i+len(mention)] == mention]\n",
    "                print(mention, indexes)\n",
    "                #indexes = [i for i in range(len(abstract)) if abstract.lower().startswith(mention.lower(), i)]\n",
    "\n",
    "                if len(indexes)>0:\n",
    "                    for ind in indexes:\n",
    "                        start = ind\n",
    "                        last = str(start+len(mention))\n",
    "                        start=str(start)\n",
    "                        file_Outputfile.write(str(pmid)+\"\\t\"+start+\"\\t\"+last+\"\\t\"+mention.lower()+\"\\t\"+type+id+\"\\n\")\n",
    "            for relation in causal_relations:\n",
    "\n",
    "                if(pmid == int(relation.split(\"\\t\")[0])):\n",
    "                    file_Outputfile.write(relation+\"\\n\")\n",
    "\n"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "myenv",
   "language": "python",
   "name": "myenv"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.0"
  },
  "toc": {
   "base_numbering": 1,
   "nav_menu": {},
   "number_sections": true,
   "sideBar": true,
   "skip_h1_title": false,
   "title_cell": "Table of Contents",
   "title_sidebar": "Contents",
   "toc_cell": false,
   "toc_position": {},
   "toc_section_display": true,
   "toc_window_display": false
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
